multi
Version: multiFiltratePRO
Instructions for Use

Software version: 5.0
Edition: 10A-2019
Date of issue: January 2019
Part no.: F40012013

CE 0123

FRESENIUS
MEDICAL CARE

Table of contents

1 Index

2 Important information

2.1 How to use the Instructions for Use ... 2-1

2.2 Significance of warnings ... 2-2

2.3 Significance of notes ... 2-2

2.4 Significance of tips ... 2-3

2.5 Brief description ... 2-3

2.6 Intended use ... 2-3
2.6.1 Intended purpose ... 2-3
2.6.2 Specification of use ... 2-4
2.6.3 Treatment therapies and fields of application ... 2-4
2.6.4 Anticoagulation of the extracorporeal blood circuit ... 2-4
2.6.5 Side effects ... 2-5
2.6.6 Contraindications ... 2-6
2.6.7 Interaction with other systems ... 2-7
2.6.8 Therapy restrictions ... 2-7
2.6.9 Target group ... 2-7

2.7 Please note the following when working on the device ... 2-7

2.8 Expected service life ... 2-8

2.9 Duties of the responsible organisation ... 2-8

2.10 Operator responsibility ... 2-8

2.11 Disclaimer of liability ... 2-9

2.12 Warnings ... 2-10
2.12.1 Warning about electrical safety ... 2-10
2.12.2 Warnings relating to consumables and accessories ... 2-11

2.13 SVHC (REACH) ... 2-12

2.14 Addresses ... 2-13

3 Design

3.1 Views of the device ... 3-1
3.1.1 Front view ... 3-1
3.1.2 Rear view ... 3-2
3.1.2.1 Connector strip ... 3-3
3.1.3 Left side view ... 3-4
3.1.4 Right side view ... 3-5

3.2 Controls and indicators ... 3-6

3.2.1 Monitor front ... 3-6
3.2.2 Monitor rear ... 3-7
3.2.3 Positioning the monitor ... 3-7
3.2.4 Using the card slot ... 3-8
3.2.5 Positioning the filter holder ... 3-8
3.2.6 Heparin pump ... 3-9
3.2.7 Heater ... 3-10
3.2.8 Extracorporeal Blood Circuit Module ... 3-11

3.3 User interface ... 3-12

3.4 General operating concept ... 3-13
3.4.1 Colour coding on the device and single-use articles ... 3-13
3.4.2 Screen colours ... 3-13
3.4.3 Context-specific information ... 3-14

3.5 Basic input procedures ... 3-15
3.5.1 Changing settings with the rocker switch buttons ... 3-15
3.5.2 Changing settings with the number buttons ... 3-16
3.5.3 Entering data with the keyboard ... 3-17
3.5.4 On/Off button ... 3-18
3.5.5 Viewing the ratio of the UF rate to the blood flow rate ... 3-19
3.5.6 Viewing the pressure values ... 3-19
3.5.7 Setting the pressure alarm limit values ... 3-21

4 Operation

4.1 Application principles ... 4-1

4.2 CRRT treatments ... 4-7
4.2.1 Switching on the device and starting the function test ... 4-7
4.2.2 Selecting the treatment option ... 4-8
4.2.3 Continuing the previous treatment ... 4-8
4.2.4 Start requirements ... 4-9
4.2.5 Mounting the cassette ... 4-9
4.2.5.1 Mounting the return system ... 4-10
4.2.5.2 Mounting the access system ... 4-11
4.2.5.3 Mounting the filtrate system ... 4-12
4.2.5.4 Loading the solution bags ... 4-12
4.2.5.5 Mounting the dialysate/substituate systems ... 4-13
4.2.5.6 Inserting the heparin syringe ... 4-14
4.2.5.7 Cassette mounting completed ... 4-15
4.2.6 Filling and rinsing the cassette ... 4-16
4.2.6.1 Filling the tubing system ... 4-16
4.2.6.2 Entering the Patient ID and Case ID ... 4-16
4.2.6.3 Entering treatment parameters ... 4-17
4.2.6.4 UF Rinse ... 4-18
4.2.7 Circulation ... 4-19
4.2.8 Connecting the patient ... 4-20
4.2.9 Treatment ... 4-21
4.2.9.1 Treatment screen ... 4-21
4.2.9.2 Menus ... 4-22
4.2.9.3 Histories ... 4-22
4.2.9.4 System Parameters ... 4-23
4.2.10 Changing the treatment mode ... 4-23
4.2.10.1 Changing the treatment mode from CVVHDF to CVVH ... 4-24

4.2.10.2 Changing the treatment mode from CVVHDF to CVVHD ... 4-25
4.2.11 End of treatment ... 4-26
4.2.11.1 Preparing the end of treatment ... 4-26
4.2.11.2 End of treatment with blood reinfusion ... 4-27
4.2.11.3 Starting blood reinfusion ... 4-27
4.2.11.4 NaCl solution detected ... 4-28
4.2.11.5 Disconnecting the patient ... 4-29
4.2.11.6 Dismantling the tubing system ... 4-29
4.3 CRRT Ci-Ca treatments ... 4-30
4.3.1 Switching on the device and starting the function test ... 4-30
4.3.2 Selecting the treatment option ... 4-31
4.3.3 Continuing the previous treatment ... 4-31
4.3.4 Start requirements ... 4-32
4.3.5 Mounting the cassette ... 4-32
4.3.5.1 Mounting the return system ... 4-33
4.3.5.2 Mounting the access system ... 4-34
4.3.5.3 Mounting the filtrate system ... 4-35
4.3.5.4 Loading the solution bags ... 4-35
4.3.5.5 Mounting the dialysate/substituate systems ... 4-37
4.3.5.6 Mounting the Ci-Ca system ... 4-38
4.3.5.7 Inserting the heparin syringe ... 4-40
4.3.5.8 Cassette mounting completed ... 4-41
4.3.6 Filling and rinsing the cassette ... 4-41
4.3.6.1 Filling the Ci-Ca system ... 4-41
4.3.6.2 Checking the Ci-Ca lines ... 4-42
4.3.6.3 Filling the tubing system ... 4-42
4.3.6.4 Entering the Patient ID and Case ID ... 4-43
4.3.6.5 Entering treatment parameters ... 4-44
4.3.6.6 UF Rinse ... 4-45
4.3.7 Circulation ... 4-46
4.3.8 Connecting the patient ... 4-47
4.3.9 Treatment ... 4-48
4.3.9.1 Treatment screen ... 4-49
4.3.9.2 Menus ... 4-50
4.3.9.3 Histories ... 4-51
4.3.9.4 System Parameters ... 4-51
4.3.10 End of treatment ... 4-52
4.3.10.1 Preparing the end of treatment ... 4-52
4.3.10.2 End of treatment with blood reinfusion ... 4-52
4.3.10.3 Starting blood reinfusion ... 4-53
4.3.10.4 NaCl solution detected ... 4-54
4.3.10.5 Disconnecting the patient ... 4-54
4.3.10.6 Dismantling the tubing system ... 4-55
4.4 TPE treatments ... 4-56
4.4.1 Switching on the device and starting the function test ... 4-56
4.4.2 Selecting the treatment option ... 4-57
4.4.3 Start requirements ... 4-57
4.4.4 Mounting the cassette ... 4-58
4.4.4.1 Mounting the return system ... 4-58
4.4.4.2 Mounting the access system ... 4-60
4.4.4.3 Mounting the filtrate system ... 4-60
4.4.4.4 Loading the solution bags ... 4-61
4.4.4.5 Mounting the plasma system ... 4-61
4.4.4.6 Inserting the heparin syringe ... 4-62
4.4.4.7 Cassette mounting completed ... 4-63

4.4.5 Filling and rinsing the cassette ... 4-63
4.4.5.1 Filling the tubing system ... 4-63
4.4.5.2 Entering the Patient ID and Case ID ... 4-64
4.4.5.3 Entering treatment parameters ... 4-65
4.4.5.4 UF Rinse ... 4-66
4.4.6 Circulation ... 4-67
4.4.7 Filling the plasma system ... 4-68
4.4.8 Patient connection ... 4-69
4.4.9 Preparing plasmafiltration ... 4-70
4.4.10 Treatment ... 4-71
4.4.10.1 Treatment screen ... 4-71
4.4.10.2 Menus ... 4-72
4.4.10.3 Histories ... 4-72
4.4.10.4 System Parameters ... 4-73
4.4.10.5 Performing a plasma bag change ... 4-73
4.4.10.6 Performing filtrate bag change (TPE) ... 4-75
4.4.11 End of treatment ... 4-75
4.4.11.1 Preparing the end of treatment ... 4-75
4.4.11.2 Exchanging residual plasma ... 4-76
4.4.11.3 Selecting blood reinfusion ... 4-77
4.4.11.4 End of treatment with blood reinfusion ... 4-78
4.4.11.5 Disconnecting the patient ... 4-80
4.4.11.6 Dismantling the tubing system ... 4-81

4.5 Treatment displays ... 4-82
4.5.1 Pressure / alarm history ... 4-82
4.5.2 Next operator action ... 4-82

4.6 Menus ... 4-83
4.6.1 Setting the level in the bubble catcher ... 4-83
4.6.2 Cancel preparation ... 4-83
4.6.3 Treatment pause ... 4-83
4.6.3.1 Treatment pause with blood reinfusion (CRRT only) ... 4-84
4.6.3.2 Treatment pause without blood reinfusion ... 4-88
4.6.4 Switching balancing off/on ... 4-93
4.6.5 Change syringe ... 4-94
4.6.6 Care mode is active ... 4-94
4.6.7 Switching between predilution and postdilution ... 4-95
4.6.8 Bag change (substituate/dialysate/filtrate) ... 4-96
4.6.9 Ci-Ca information ... 4-97
4.6.10 Ca bag change ... 4-98
4.6.11 Citrate bag change ... 4-99
4.6.12 Switching off Ci-Ca anticoagulation ... 4-99
4.6.13 Switching on Ci-Ca anticoagulation ... 4-100
4.6.14 Plasma volume calculation / Target volume input (TPE only) ... 4-102
4.6.15 Switching blood leak monitoring off (TPE only) ... 4-103

4.7 Histories ... 4-105
4.7.1 Balance data ... 4-105
4.7.1.1 CRRT ... 4-105
4.7.1.2 TPE ... 4-107
4.7.2 Balance history ... 4-108
4.7.3 Events ... 4-108

4.8 System Parameters ... 4-110
4.8.1 Access without UserCard ... 4-110
4.8.1.1 Pressure selection ... 4-111
4.8.1.2 Device information ... 4-111

4.8.1.3 Basic settings ... 4-112
4.8.2 Access with UserCard ... 4-113
4.8.2.1 Applications ... 4-113
4.8.3 User setup ... 4-115
4.8.3.1 Heparin ... 4-115
4.8.3.2 User interface ... 4-116
4.8.3.3 CRRT ... 4-117
4.8.3.4 TPE ... 4-121

4.9 Network ... 4-124
4.9.1 Observe before use ... 4-124
4.9.2 PDMS connection ... 4-125

5 Alarm processing

5.1 Repeated confirmation of a message ... 5-1

5.2 Alarm schemes ... 5-2
5.2.1 Alarm scheme one ... 5-2
5.2.2 Alarm scheme two ... 5-3

5.3 High-priority alarm conditions ... 5-4

5.4 Alarm system ... 5-5

5.5 Response of the alarm system ... 5-6

5.6 Messages ... 5-8

5.7 Messages during the functional test ... 5-9

5.8 UF/BF message ... 5-9

5.9 Ratio of calcium flow to filtrate flow ... 5-10

5.10 Ratio of citrate flow to blood flow ... 5-11

5.11 Ratio of plasma rate to blood flow ... 5-11

5.12 Pressure deviation messages ... 5-12
5.12.1 Resetting the alarm limit windows ... 5-12
5.12.2 Reducing the access pressure ... 5-13

5.13 Message "Air detected downstream of the bubble catcher" ... 5-14
5.13.1 Before beginning deaeration procedures ... 5-14
5.13.2 Air detected ... 5-15
5.13.3 Deaeration procedures ... 5-15

5.14 Message "Microbubbles detected downstream of bubble catcher" ... 5-18
5.14.1 Before removing the microbubbles ... 5-18
5.14.2 Microbubbles detected ... 5-19

5.15 Blood leak ... 5-20

5.16 Power failure (mains power failure) ... 5-21
5.16.1 During preparation ... 5-21
5.16.2 During treatment ... 5-21

5.17 Display failure ... 5-22

5.18 Manual blood reinfusion ... 5-22

5.19 Manually opening the pressure measurement units ... 5-23

6 Cleaning / disinfection

6.1 Surface cleaning / surface disinfection ... 6-1
6.1.1 Cleaning the display ... 6-2
6.1.2 Detachable device components ... 6-2

6.2 Disinfectants and cleaning agents ... 6-3

7 Functional description

7.1 Device functions ... 7-1

7.2 Description of therapies ... 7-1
7.2.1 Continuous renal replacement therapy ... 7-1
7.2.1.1 CVVH ... 7-2
7.2.1.2 CVVHD ... 7-6
7.2.1.3 CVVHDF ... 7-8
7.2.2 Therapeutic plasma exchange ... 7-11

7.3 Anticoagulation ... 7-14
7.3.1 Systemic anticoagulation ... 7-15
7.3.2 Regional citrate anticoagulation ... 7-15
7.3.2.1 Basic information on citrate anticoagulation ... 7-16
7.3.2.2 Adequate anticoagulation in the extracorporeal blood circuit ... 7-20
7.3.2.3 Control of systemic ionised calcium ... 7-21
7.3.2.4 Control of the systemic acid-base balance ... 7-23
7.3.2.5 Citrate accumulation ... 7-25
7.3.3 Solutions for citrate anticoagulation ... 7-26

8 Consumables, accessories, additional equipment

8.1 Consumables ... 8-2
8.1.1 multiFiltratePRO Treatment kits ... 8-2
8.1.2 Haemofilters/plasma filters ... 8-2
8.1.3 Isotonic NaCl solutions ... 8-3
8.1.4 Dialysate and haemofiltration solutions ... 8-3
8.1.5 Citrate solution ... 8-3
8.1.6 Disposable syringes ... 8-4
8.1.7 Other single-use items ... 8-4

8.2 Additional equipment ... 8-5

9 Installation

9.1 Connection requirements ... 9-1
9.1.1 Environment ... 9-1
9.1.2 Power supply network ... 9-1
9.1.3 Electrical installation ... 9-2

9.2 Installation / initial start-up requirements ... 9-2

9.3 Important information on initial start-up ... 9-3

10 Transport / storage

10.1 Relocation 10-1

10.2 Transport 10-3

10.3 Storage 10-3

10.4 Environmental compatibility / disposal 10-4

11 Technical Safety Checks / maintenance procedures

11.1 Important information on the Technical Safety Checks / maintenance procedures 11-1

12 Specifications

12.1 Dimensions and weight 12-1

12.2 Electrical safety 12-1

12.3 Electric power supply 12-1

12.4 Identification label (device marking) 12-2
12.4.1 Identification label of the device 12-2
12.4.2 Power label 12-3

12.5 Information on electromagnetic compatibility (IEC 60601-1-2:2014) 12-3
12.5.1 Minimum distances between radiation source and medical electrical equipment 12-3
12.5.2 Guidance and manufacturer's declaration on EMC 12-4

12.6 Operating conditions 12-6

12.7 Storage conditions 12-6

12.8 External connection options 12-6

12.9 Operating programs 12-9

12.10 Balancing/dialysate circuit and safety systems 12-9

12.11 Extracorporeal blood circuit and safety systems 12-12

12.12 Materials used 12-17

13 Definitions

13.1 Terms 13-1

13.2 Abbreviations 13-3

13.3 Symbols 13-4

13.4 Symbols on consumables 13-7

13.5 Certificates 13-7

14 Options

14.1 Chapter without content 14-1

15 Appendix

15.1 Instructions on the use of “free software” 15-1

1 Index

A

Abbreviations 13-3
Access pressure 12-12, 13-1
Access pressure measurement unit (red) 3-11
Access system 13-1
Accessories 8-5
Accessories case 3-2
Additional equipment 8-5
Air bubble detector 3-11, 12-14
Air detected 5-15
Alarm function check 13-1
Alarm limit 13-1
Alarm priorities 5-6
Alarm processing 5-1
Alarm scheme one 5-2
Alarm scheme two 5-3
Alarm schemes 5-2
Alarm system 5-5
Ambient temperature sensor 12-11
Anticoagulation 7-14
Appendix 15-1
Application principles 4-1
Audible tone 12-15
Audio paused 3-6

B

Bag change 4-96
Bag change (substituate/dialysate/filtrate) 4-96
Balance data 4-105
Balance history 4-108
Balancing 4-106, 7-1
Balancing error 4-106, 12-11
Basic input procedures 3-15
Battery 10-3, 13-1
Blood circuit module 3-11
Blood leak 5-20
Blood leak detector 13-1
Blood leak detector (yellow) 3-11
Blood leak/haemolysis detector 12-9
Blood pump 3-11, 12-13, 13-1
Blood reinfusion 5-22
Bubble catcher 4-83

C

Ca bag change 4-98
Calcium dose 7-22
Calcium drip counter (white) 3-11
Calcium fill level detector (white) 3-11
Calcium flow 13-1
Calcium pump (white) 3-11, 12-15, 13-1
Cancel preparation 4-11, 4-34, 4-60
Card for use by service engineers 13-3
Card slot 3-5, 3-7, 13-1
Care mode is active 4-94
Cassette detector 3-11, 12-15
Certificates 13-7
Change syringe 4-94
Changing settings with the number buttons 3-16
Changing settings with the rocker switch buttons 3-15
Ci-Ca drip counter 12-15
Ci-Ca fill level detector 12-15
Circulation 12-9
Citrate accumulation 7-25
Citrate bag change 4-99
Citrate dose 7-20, 7-21, 13-1
Citrate drip counter (green) 3-11
Citrate fill level detector (green) 3-11
Citrate flow 13-1
Citrate pump (green) 3-11, 12-15, 13-1
Citrate solution 8-3
Cleaning 6-1
Cleaning agents 6-3
Cleaning the display 6-2
Connection options 12-6
Connector strip 3-2, 3-3
Consumables 8-2
Context-specific information 3-14
Continuous renal replacement therapy 7-1
Contraindications 2-6
Controls and indicators 3-6
Convection 13-1
CRRT 7-1
CRRT Ci-Ca treatments 4-30
CRRT types 7-2
CVVHD 7-6

D

Deaeration procedures 5-15
Definitions 13-1
Device functions 7-1
Dialysate 8-3, 13-2
Dialysate pump 3-11
Diffusion 13-2
Dimensions 12-1
Disclaimer of liability 2-9
Disinfectants 6-3
Disinfection 6-1
Display failure 5-22
Disposable syringes 8-4
Duties of the responsible organisation 2-8

E

Electrical installation 9-2
Electrical safety 12-1
Electromagnetic emissions 12-4
Electromagnetic immunity 12-5
Electrostatic discharge 2-7
End of treatment / Blood reinfusion 12-9
Environmental compatibility / disposal 10-4
Equipotential bonding 3-3

Events 4-108
Exchange volume 13-2
Expected service life 2-8
External connection options 12-6
Extracorporeal blood circuit 7-1, 13-2
Extracorporeal blood circuit and safety systems 12-12
Extracorporeal Blood Circuit Module (CRRT) 3-11
Extracorporeal blood circuit, anticoagulation 2-4

F

Fill level detector 3-11, 12-14
Filling the tubing system 12-9
Filter holder 3-5
Filter life 4-106, 13-2
Filtrate bag 13-2
Filtrate pressure measurement unit (yellow) 3-11
Filtrate pump 3-11
Filtration 13-2
Flow rates 12-10
Free software 15-1
Front view of device 3-1
Functional description 7-1
Functional test 7-1, 12-9

G

General operating concept 3-13

H

Haemodialysis 13-2
Haemofilters/plasma filters 8-2
Haemofiltration 13-2
Haemofiltration solutions 8-3
Heater (green) 3-4
Heater (white) 3-4
Heater microswitch 12-11
Heparin pump 3-5, 3-9, 12-15, 13-2
High-priority alarm conditions 5-4
Histories 4-105
Hook-up test 13-2
How to use the Instructions for Use 2-1

I

Identification 3-2
Identification label 3-2
Important information 2-1
Important information on initial start-up 9-3
Important information on the Technical Safety Checks / maintenance procedures 11-1
Initial start-up 9-3
Initial start-up requirements 9-2
Insertion switch 13-3
Installation 9-1
IV pole (left and right) 3-1

K

Keyboard 3-17
Kit service life 13-3

L

LAN (local area network) network connection 3-3
Left side view of the device 3-4
Limit monitoring 3-19
Limit values 3-19
Line occlusion clamp (blue) 3-11
Line occlusion clamp (red) 3-11
Loudspeaker 3-7

M

Mains power failure (power failure) 5-21
Maintenance procedures 11-1
Manual blood reinfusion 5-22
Manually opening the pressure measurement units 5-23
Materials 12-17
Menu bar 3-12
Menu panel 3-13
Menus 4-83
Messages 5-8
Microbubbles 5-18
Microbubbles detected downstream of bubble catcher 5-18
Monitor 3-1, 3-6
Monitor arm 3-7
Monitor rear 3-7
Monitor/buttons 3-6

N

NaCl solutions 8-3
Net UF volume 13-3
Next operator action 4-82
Note symbol, significance 2-2
Nurse call port 3-3

O

On/Off button 3-18
Operating conditions 12-6
Operating programs 12-9
Operating status indicator (traffic light) 3-6
Operator responsibility 2-8
Optical detector 3-11, 12-14

P

Patient connection 12-9
Performing filtrate bag change (TPE) 4-75
Positioning the filter holder 3-8
Positioning the monitor 3-7
Post CVVH 7-2
Postdilution 4-14, 13-3
Post-filter calcium concentration 13-3
Power failure (mains power failure) 5-21
Power label 3-2
Power supply connection 3-3
Power switch 3-3
Pre CVVH 7-3
Predilution 4-13, 13-3
Predilution substituate pump 3-11
Pre-filter pressure 12-12
Pre-filter pressure measurement unit (red) 3-11
Preparation 12-9

Preparation time 13-3
Pressure / alarm history 4-82
Pressure alarm windows 3-21
Pressure displays 3-12
Pressure measurement units 3-3
Pressure values 3-19
Progress bar 3-12

R

Ratio of calcium flow to filtrate flow 5-10
Ratio of citrate flow to blood flow 5-11
Rear view of device 3-2
Recessed grip 3-7
Recommended separation distances 12-6
Regional citrate anticoagulation 2-5, 7-15
Relocation 10-1
Resetting the alarm limit windows 5-12
Return pressure 12-12, 13-3
Return pressure sensor (blue) 3-11
Return system 13-3
Right side view of the device 3-5
Rinsing 12-9
Rocker switch buttons 3-13
RS 232 port 3-3

S

Scale 1 (green) 3-2
Scale 2 (white) 3-2
Scale system 12-11
Scales 3-1
Screen colours 3-13
Screen failure sensor 3-6
Service port 3-3
ServiceCard 13-1, 13-3
Setting the level in the bubble catcher 4-83
Setting the pressure alarm limit values 3-21
Side effects 2-5
Specifications 12-1
Status bar 3-12
Storage 10-3
Storage conditions 10-4
Substituate 13-3
Substituate pump 3-11
Surface cleaning / surface disinfection 6-1
Switching balancing off/on 4-93
Switching off Ci-Ca anticoagulation 4-99
Switching on Ci-Ca anticoagulation 4-100
Symbols 13-4
System Parameters 4-110, 12-9
Systemic anticoagulation 2-4, 7-15
Systemic calcium concentration 13-3

T

Target group 2-7
Technical Safety Checks / maintenance procedures 11-1
Temperature 4-18, 4-45, 4-66
Terms 13-1
Therapies, description 7-1
Therapy restrictions 2-7
Tip symbol, significance 2-3
TMP 12-13
Touchscreen panel 3-6
Transport 10-3
Treatment 12-9
Treatment data, CVVH 7-4
Treatment data, CVVHD 7-8
Treatment data, CVVHDF 7-11
Treatment data, Pre-Post CVVH 7-6
Treatment data, TPE 7-14
Treatment displays 4-82
Treatment pause 12-9
Treatment pause (circulation with NaCl solution) 4-89
Treatment pause (circulation with recirculation connector) 4-90
Treatment pause without blood reinfusion 4-88
Treatment therapies and fields of application 2-4
Treatment time 4-106, 13-3
Trolley with brakes 3-1

U

UF rate 3-19
UF/BF 5-9
Ultrafiltration 12-10
User interface 3-12
UserCard 13-1, 13-3
Using the card slot 3-8

V

Vascular access 7-1

W

Warning about electrical safety 2-10
Warning symbol, significance 2-2
Warnings relating to consumables and accessories 2-11
Warnings, electrical 2-10
Weight 12-1
Wheels with brakes 3-4

2 Important information

2.1 How to use the Instructions for Use

Device type

In this document, unless otherwise stated, the word "device" on its own always refers to the multiFiltratePRO device.

Identification

The document can be identified by the following information on the title page and on the labels, if any:
- Software version of the device
- Edition of the document
- Date of issue of the document
- Part number of the document

Footer

The footer contains the following information:
- Company name
- Device type
- The English abbreviation for the document type and the international abbreviation for the document language, e.g., IFU-EN means Instructions for Use in English.
- The edition identification, for example, 4A-2013 refers to edition 4A released in 2013.
- The page identification, for example, 1-3 refers to chapter 1, page 3.

Organisation of the chapters

To facilitate the use of documents from Fresenius Medical Care, the organisation of the chapters has been standardised in all manuals. There may therefore be chapters within this document without any content. Chapters without content are marked accordingly.

Styles used in the document

The following text styles may be used in the document:

Style	Description
Keys and buttons	Keys and buttons on the device are shown in **bold type**. Example: **Example** button
Message text	Device messages are shown in *italic type*. Example: Message: *Example message*
➢ Instructions	Instructions are indicated by an arrow ➢. Instructions must be followed. Example: ➢ Carry out instruction.
1. Numbered Instructions 2. ... 3. ...	Long passages containing instructions can be shown as numbered lists. Instructions must be followed. Example: 1. Carry out instruction.

Illustrations

The illustrations used in the documents may differ from the original if this does not have any influence on the function.

Importance of the instructions

The Instructions for Use are part of the accompanying documents and are an essential part of the device. They include all the necessary information for operating the device.

The Instructions for Use must be carefully studied before attempting to operate the device.

Changes

Changes to documents will be released as new editions or supplements. In general, this manual is subject to change without notice.

Reproduction

Reproduction, even in part, is only permitted with written approval.

2.2 Significance of warnings

Advises the operator of hazards that carry the risk of serious to potentially life-threatening bodily injury to persons, unless the measures for avoiding the risk described are followed.

Warning

Type of hazard and risk

Possible consequences of exposure to the risk.

➢ Measures for avoiding the risk.

Warnings can deviate from the above template in the following cases:
– If a warning describes several risks
– If no specific risks can be detailed in the warning

2.3 Significance of notes

Note

Advises the operator that the following effects can be expected in the event of failure to observe this information:
– Damage to the device.
– Required functions failing to run at all or running incorrectly.

2.4 Significance of tips

Tip

Information providing useful tips for easy handling.

2.5 Brief description

The device enables extracorporeal blood purification procedures to be performed. It controls and monitors the extracorporeal blood circuit.

There are four operating buttons on the monitor. Input of treatment parameters and operator control is effected mostly by way of a high-resolution touchscreen. While treatment is in progress, the treatment parameters are displayed.

Tube pumps are used to convey the blood, filtrate, dialysate, substituate or blood plasma, as well as the citrate and calcium solutions if citrate anticoagulation is used, depending on the procedure. For volume replacement therapies, balancing is gravity-controlled using scales, while integrated heaters can be used to heat the dialysate, substituate or replacement plasma as necessary, depending on the treatment mode.

In the extracorporeal blood circuit, the blood is passed through a filter or an adsorber. The blood can be continuously anticoagulated. An air bubble detector prevents the infusion of air to the patient. Any dangerous loss of blood is prevented by a blood leak detector and by monitoring the return pressure. The access pressure monitoring unit can detect an occlusion of the needle or catheter, e.g. due to suction to the vessel wall.

The device is classified as class IIb equipment (MDD).

2.6 Intended use

2.6.1 Intended purpose

The device is intended for use in continuous renal replacement therapy, haemoperfusion procedures and therapeutic plasma exchange.

2.6.2 Specification of use

The device has been specified by the manufacturer for the following purposes:

– The treatment of patients with a body weight of 40 kg and more, irrespective of their age, under consideration of the specified technical data of the device and the single-use items used (e.g., delivery rates, fill volumes) (see chapter 12.11 on page 12-12).
– Operation in suitable rooms in professional health care facilities. Normative and local regulations must be observed.

Consumables with a service life adapted to the duration of therapy have to be used for the treatment; see specification in the instructions for use of the consumables.

2.6.3 Treatment therapies and fields of application

CRRT treatment mode	**Field of application**
Pre CVVH, Post CVVH	– Acute renal insufficiency
Pre-Post CVVH, CVVHD	– Removal of toxic metabolic products
Pre CVVHDF, Post CVVHDF	– Treatment of life-threatening electrolyte imbalance, e.g., hyperkalaemia
	– Correction of the acid-base balance, e.g., metabolic acidosis
	– Diuretic-resistant fluid retention, especially in the event of cardiac insufficiency or pulmonary oedema
CytoSorb in CRRT	– See above plus increased cytokine levels in the blood

Therapeutic apheresis procedures	**Field of application**
TPE	– Removal of plasma, e.g. for the removal of pathological immunoglobulins, for the removal of protein-bound toxins or for the administration of sufficient quantities of physiological proteins contained in donor plasma.

2.6.4 Anticoagulation of the extracorporeal blood circuit

Most patients need anticoagulation to prevent their blood from clotting in the extracorporeal blood circuit. This can be performed systemically, i.e. also in the patient's body, or regionally limited to the extracorporeal blood circuit.

Systemic anticoagulation

The integrated heparin pump can be used for the continuous anticoagulation of the blood.

Regional citrate anticoagulation

The Ci-Ca function integrated in the system permits regional anticoagulation in the extracorporeal blood circuit with citrate. It can be used on most patients with CRRT indication. Exceptions (see chapter 2.6.6 on page 2-6). This function is intended to be used for adults and can be indicated particularly in the following cases:

– Patients with a bleeding risk, that is, patients on whom systemic anticoagulation cannot be used at all or only to a degree that is inadequate for continuous renal replacement therapy.

– Patients with whom the haemofilter rapidly and repeatedly becomes clogged when different anticoagulation methods are used.

– Heparin intolerance.

If citrate anticoagulation is used, attention must be paid to risks regarding the acid-base balance and the electrolyte concentrations. Further information (see chapter 7.3.2 on page 7-15).

2.6.5 Side effects

Extracorporeal therapies occasionally cause hypotension, nausea, vomiting and cramps in some patients. In rare cases, allergic reactions can occur. Pay particular attention to the package inserts enclosed with the solutions, filters, etc. used.

During extracorporeal treatments, particularly during CRRT treatments, the concentrations of different electrolytes (sodium, potassium, calcium, magnesium, phosphate) can become too high or too low and an acid-base imbalance can occur. Such situations can be prevented and treated by selecting adequate CRRT solutions and by an additional substitution of electrolytes, if necessary.

The operating conditions in the extracorporeal blood circuit may lead to patient heat loss.

Among other things, this depends on the room temperature and the treatment parameters, particularly with low flow rates or if a heater is intentionally switched off.

The heaters of the device have been designed to heat dialysate, haemofiltration solution, FFP (Fresh Frozen Plasma) and plasma replacement solution and thus counteract heat loss. As the heating must be limited for safety reasons, heat loss cannot always be fully compensated. For this reason, the patient's body temperature must always be monitored.

Note

Electrolyte imbalances (especially hypokalaemia, hypophosphataemia) are more likely to occur with high CRRT doses, as an unbalanced composition of the CRRT solution can have a more pronounced effect.

Systematic anticoagulation with heparin

Systemic anticoagulation increases the risk of bleeding. There is also the risk of heparin-induced thrombocytopaenia, particularly when using unfractionated heparin. The patient information leaflet for the anticoagulants used must be observed.

Regional citrate anticoagulation

– Metabolic acid-base disorders (acidosis, alkalosis)
– Systemic hypocalcemia or hypercalcemia
– Hypomagnesaemia
– Hypernatraemia
– Side effects caused by a disordered citrate metabolism

For more detailed information on situations in which these risks might occur and on the options for reducing the occurrence of these risks (see chapter 7.3.2 on page 7-15).

2.6.6 Contraindications

– The contraindications of all the tubing systems, filters, dialysers and solutions intended for use in a therapy must be observed.
– Inadequate vascular access to the venous blood circuit, e.g., with a double-lumen central venous catheter, so that the blood flow necessary for treatment cannot be achieved.

Systemic anticoagulation

Systemic anticoagulation is often contraindicated for patients with bleeding or a high risk of bleeding. Here, measures should be taken within the treatment regimen which permit a renal replacement treatment with little or no anticoagulation. A regional citrate anticoagulation can be applied where appropriate.

Regional citrate anticoagulation

An established disordered citrate metabolism is an absolute contraindication.

In case of a disordered citrate metabolism, CRRT treatment should be considered with a bicarbonate-containing HF solution. Here, anticoagulation of the extracorporeal blood circuit might not be necessary under certain circumstances.

If, for example, a disordered citrate metabolism is suspected because of a restricted liver function, citrate anticoagulation can still be started, but only under particularly intensive monitoring. In this case, the signs of systemic citrate accumulation must be observed closely. This applies especially to a decrease in the systemic ionised calcium, high calcium substitution requirements for stabilising the ionised calcium and to an increase in systemic total calcium (see chapter 7.3.2.3 on page 7-21).

With regional citrate anticoagulation, a quantity of citrate is unavoidably infused systemically and must be metabolised by the patient by consuming oxygen. A case of poisoning that adversely influences this oxidative metabolism therefore presents a contraindication for citrate anticoagulation. Evidence suggests that this is the case for poisoning with paracetamol and metformin.

If hypocalcaemia already exists before beginning the treatment, this should always be balanced by calcium substitution, for example, unless there is a clinical indication to suggest otherwise.

Note

Treatment in connection with citrate anticoagulation must only be performed in an intensive care unit or under similar conditions with close medical supervision and continuous monitoring.

2.6.7 Interaction with other systems

The use of line roller pumps may lead to minimal electrostatic discharge into the tubing system due to friction on the pump segment. As the charge is very low, these discharges do not represent a direct hazard to patients or operators. If ECG units are used at the same time, these discharges may, in rare cases, cause periodic interferences of the ECG signal.

In order to minimise this interference, it is advisable to observe the recommendations of the ECG device manufacturer, e.g.:

– correct positioning of the electrodes.
– use of specific electrodes with low contact impedance.

2.6.8 Therapy restrictions

Regional citrate anticoagulation

Citrate anticoagulation is available for adult patients for CVVHD and CVVHDF.

2.6.9 Target group

The device must only be installed, operated and used by individuals with the appropriate training, knowledge and experience, and who are certified to have been trained.

2.7 Please note the following when working on the device

Warning

Risk of injury for the patient and operator as a result of improper servicing performed on the device

Improper servicing can impair the safe functioning of the device.

➢ Make sure that start-up, extensions, adjustments, calibrations, maintenance procedures, modifications or repairs are only carried out by the manufacturer or persons authorised by the manufacturer.

More information on installation (see chapter 9 on page 9-1).

More information on Technical Safety Checks and maintenance procedures (see chapter 11 on page 11-1).

Use only spare parts approved by the manufacturer.

For identifying and ordering spare parts, test equipment and tools, always use the electronic spare parts catalogue.

For additional information about transportation and storage, (see chapter 10 on page 10-1).

2.8 Expected service life

If the Technical Safety Checks are performed to the full extent specified and at the prescribed intervals, the safe operation of the device in the time between them is guaranteed.
In addition, the manufacturer recommends that maintenance procedures be performed at the same time intervals to avoid device malfunctions caused by wear and tear.
With each Technical Safety Check, the "expected service life" according to IEC 60601-1 will therefore be prolonged until the next prescribed Technical Safety Check.

2.9 Duties of the responsible organisation

Specification

The responsible organisation is responsible for ensuring that the following specifications are met:
– Compliance with the national or local regulations concerning the installation, operation, use, and maintenance of the device.
– Compliance with the accident prevention regulations.
– Ensuring the proper and safe condition of the device.
– Ensuring the permanent availability of the Instructions for Use.
– The device may only be operated under the operating conditions specified by the manufacturer.

To enhance treatment quality and patient safety, the manufacturer recommends following IEC/TR 62653 "Guideline for safe operation of medical devices used for haemodialysis treatment". The guideline describes the requirements for using haemodialysis systems safely and for their intended purpose.

Training and instruction

Before the responsible organisation may begin operating the device, the individual responsible for operation must have been instructed by the manufacturer on how to use the device, with certification of their instruction, and must be thoroughly familiar with the contents of the Instructions for Use.
The device must only be operated by individuals who have been trained and certified in the proper operation and handling of the device.

The manufacturer provides training for this device.

The local service support organisation is available to answer any further questions (see chapter 2.14 on page 2-13).

2.10 Operator responsibility

The addresses given herein must be used to notify the manufacturer of any unexpected operation behavior or other incidents
(see chapter 2.14 on page 2-13).

Warning

Risk of injury as a result of a device defect

Treatment cannot be performed properly and safely with a defective device.

➢ Do not perform a treatment with a defective device.

➢ Take the device out of service and disconnect it from the power supply.

➢ If a treatment is in progress, start a blood reinfusion and terminate the treatment. Perform a manual blood reinfusion, if necessary (see chapter 5.18 on page 5-22).

➢ Notify the responsible organisation or service support.

➢ Replace any damaged accessories.

The device can be considered defective in any of the following cases:
– The device has mechanical defects
– The power cable is damaged
– The device does not react as expected
– The performance characteristics of the device deteriorate

The following must be observed when entering parameters:
– The parameters entered must be verified by the operator, i.e., the operator must check that the values entered are correct.
– If this check reveals a deviation between the desired parameters and the parameters displayed on the device, the setting must be corrected before activating the function.
– The actual values displayed must be compared with the prescribed target values.

2.11 Disclaimer of liability

Warning

Chapter 8 (see chapter 8 on page 8-1) contains a list of consumables and accessories that are suitable for use with this device and can be used safely with it.

The manufacturer cannot guarantee that other consumables and accessories than those listed in this chapter are suitable for use with this device. The manufacturer cannot guarantee that the safety and performance of the device will remain unimpaired if consumables and accessories other than those listed in this chapter are used.

If other consumables and accessories are used, their suitability must be verified beforehand. This can be done with the aid of the information in the instructions accompanying such consumables and accessories.

The manufacturer accepts no liability for damage to the device resulting from the use of unsuitable consumables or accessories.

2.12 Warnings

2.12.1 Warning about electrical safety

Warning

Risk of injury as a result of an electric shock

Without a protective earth connection, there is a risk of electric shock.

➢ Always connect the device to a power supply network with a protective earth.

Warning

Risk of injury as a result of an electric shock

There is a risk of electric shock if the patient comes into contact with the pins or contacts of the device's connectors, whether directly or indirectly through the operator.

➢ Avoid touching connector pins or contacts during treatment.

Warning

Risk of injury as a result of an electric shock

For treatments using a central venous catheter, if the tip is positioned in the patient's right atrium, the following precautions must be observed:

➢ Make sure the device (multiFiltratePRO) is connected to the grounded equipotential zone of the installation.

➢ Move all non-medical and medical electrical equipment with touch currents or patient leakage currents in excess of the limits for type CF applied parts out of reach of the patient (more than 1.5 metres away in every direction).

The touch current or patient leakage current of non-medical or medical electrical equipment can be conducted to ground over the patient's central venous catheter and over the type B or BF applied part of the device (multiFiltratePRO).



Patient leakage current limits for type CF applied parts:
– 10 µA AC / DC (normal condition, i.e., no fault condition)
– 50 µA AC / DC (single fault condition)

Please address any queries to the local service support organisation.

2.12.2 Warnings relating to consumables and accessories

Warning

Risk of contamination as a result of improper handling of connection sites

Pathogens can enter the extracorporeal blood circuit.

➢ Use aseptic technique for all blood system connections and all the connections of the sterile solutions to be used.

Warning

Risk of cross-contamination as a result of contaminated consumables

There is a risk of spreading germs.

➢ Consumables must be discarded after a treatment in compliance with the regulations for the disposal of potentially contaminated materials.

2.13 SVHC (REACH)

For information on the topic of SVHC in accordance with Article 33 of Regulation (EC) 1907/2006 ("REACH"), visit the following website:

www.freseniusmedicalcare.com/en/svhc

2.14 Addresses

Manufacturer

Fresenius Medical Care AG & Co. KGaA
D-61346 Bad Homburg
Germany
Phone: +49 (0) 6172 609-0
www.fmc-ag.com

Service support, international

Fresenius Medical Care
Deutschland GmbH
Technical Operations
Technical Coordination Office (TCO)
Hafenstrasse 9
D-97424 Schweinfurt
Germany

Service support, local

3 Design

3.1 Views of the device

3.1.1 Front view



Legend

1	Left IV pole	**4**	Scales 3 and 4
2	Monitor	**5**	Trolley with brakes
3	Extracorporeal Blood Circuit Module	**6**	Right IV pole

3.1.2 Rear view



Legend

1 Scale 2 (white)
2 Push handle
3 Connector strip
4 Accessories case
5 Power label
6 Identification label
7 Scale 1 (green)

3.1.2.1 Connector strip



Legend

1 Equipotential bonding connection
2 Power supply connection
3 Luer lock connection for manually opening the pressure measurement units
4 LAN (local area network) network connection
5 Nurse call port
6 1st RS 232 serial port with 5 V power supply
7 2nd RS 232 serial port
8 Service port (only for service engineers)
9 Power switch

3.1.3 Left side view



Legend

1 Heater (green)
2 Wheels with brakes
3 Heater (white)
4 Push handles

3.1.4 Right side view



Legend

1 Card slot
2 Filter holder
3 Heparin pump

3.2 Controls and indicators

3.2.1 Monitor front



Legend

1 Screen failure sensor (hidden)

2 LED/button **Audio paused** (red)
- **LED flashes** – Message/alarm with audible tone is being signalled
- **LED is lit** – Audible tone of current message/alarm has been suppressed by pressing the **Audio paused** button
- **LED off** – No message/alarm

3 LED/button **Stop pumps** (red)
- **LED is lit** – Blood pump has been stopped
- **LED off** – Blood pump is running

4 LED/button **Start pumps** (green)
- **LED flashes** – Blood pump has been stopped with the **Stop pumps** button
- **LED is lit** – Blood pump is running
- **LED off** – Blood pump has been stopped by device

5 LED/button **On/Off** (green)
- **LED flashes slowly** – Device off, battery is being charged
- **LED flashes rapidly** – Device on/off, battery is not being charged
- **LED is lit** – Device on, battery is being charged
- **LED off** – Device off, battery is not being charged

6 Touchscreen panel

7 Operating status indicator (traffic light)
Further information: (see chapter 5.2 on page 5-2)

3.2.2 Monitor rear



Legend

1 Card slot
2 Recessed grip
3 Monitor arm
4 Loudspeaker

3.2.3 Positioning the monitor



Position the monitor with the aid of the recessed grips **(a)** on either side.

The monitor can be swivelled **(b)** and tilted **(c)** for positioning.

3.2.4 Using the card slot

Insert the card into the card slot (**b**).

3.2.5 Positioning the filter holder



Open the lever (**a**) towards the left and insert the filter.

Turn the filter holder until the filter is in the required position (**b**).

Insert the tubing systems into the line holders intended for them (**c**).

3.2.6 Heparin pump



Legend

1 Barrel holders with syringe detector
2 Bracket
3 Jaws of the spring clip
4 Stock
5 Spring clip

3.2.7 Heater



Legend

1 Label Warning: Hot surface
2 Microswitch
Detects a distended heater bag in the event of an error to ensure that the heater is switched off and treatment is stopped.
3 Temperature sensors
4 Heating element
5 Line holder (green or white)

3.2.8 Extracorporeal Blood Circuit Module



Legend

1 Return pressure sensor (blue)
2 Dialysate pump/Predilution substituate pump (depends on treatment mode)
3 Citrate pump (green)
4 Citrate drip counter/Citrate fill level detector (green)
5 Fill level detector
6 Substituate pump
7 Air bubble detector/Optical detector
8 Calcium pump (white)
9 Calcium drip counter/Calcium fill level detector (white)
10 Blood leak detector (yellow)
11 Line occlusion clamp (red)
12 Filtrate pressure measurement unit (yellow)
13 Line occlusion clamp (blue)
14 Filtrate pump
15 Access pressure measurement unit (red)
16 Blood pump
17 Cassette detector
18 Pre-filter pressure measurement unit (red)

3.3 User interface



Legend

A **Status bar**
1 Treatment mode
2 Anticoagulation method
3 Current menu
4 Balancing status/plasma treatment status indicator
green: Balancing/plasma treatment on
yellow: Balancing/plasma treatment off
5 Progress bar:
Time remaining before next operator action/
time remaining for processes in progress

B **Pressure displays**
6 Access pressure
7 Return pressure
8 Pre-filter pressure

C **Menu bar**
During operation, each menu will open automatically as needed. Alternatively, you can press on any of the available menu buttons to open the menu concerned.
Monitor symbol in menu button PREPARATION (deactivates/reactivates the monitor for cleaning during operation).

D **Menu panel**
The main part of the screen shows the appropriate data fields of the active menu.
9 Display/input field
10 Rocker switch buttons
11 Information area
Shows messages and graphs
12 Quick access buttons
For menu options

3.4 General operating concept

3.4.1 Colour coding on the device and single-use articles

Mistake proofing

The colour coding on the device and on the single-use articles helps you identify connections correctly and insert items in their proper place.

3.4.2 Screen colours



Legend

1 BLUE means: can be selected
Examples: **Heparin** field and **MENUS** button
2 GREEN means: active
Examples: Information tab Pressure / alarm history and **TREATMENT** button

3 GREY means: not active/cannot be selected
Example: **PREPARATION** button

3.4.3 Context-specific information

In the input windows of the display/input fields, additional, important information is shown on the left of the number buttons.

➢ Press the **Ca dose** field.
The input window opens.
On the left of the number buttons, additional, context-specific information is displayed.

➢ Press the **Ca** button in the context-specific information area.
The calcium dosage target range and adjustment steps are displayed.

3.5 Basic input procedures

3.5.1 Changing settings with the rocker switch buttons



➢ Use the **+ / –** rocker switch buttons (A) to set the required flow.

3.5.2 Changing settings with the number buttons

➢ Press the relevant display/input field.
The input window opens.

➢ Enter the new value with the aid of the number buttons.
Grey buttons prevent invalid entries.

➢ Check the new value against the target value.

➢ To correct your entry, press the **C** button.
The last active value will be displayed.

➢ Press the **OK** button to apply the displayed value.
The input window is closed.

➢ The applied value is checked.

3.5.3 Entering data with the keyboard



➢ Press the relevant display/input field.
The input window opens.

➢ Use the keyboard to enter the required data.
(A) Shift between upper case and lower case letters using the **arrow (up/down)** buttons.
(B) Press the **Pos1** button to move the cursor to the beginning of the line.
(C) Move the cursor to a different position in the line using the **arrow (left/right)** buttons.
(D) Press the **Ins** button to switch between overtype mode and insert mode.

➢ Check the entered data.

➢ To correct your entry, press the **C** button.

➢ Press the **OK** button to apply the displayed data.
The input window is closed.

3.5.4 On/Off button

➢ Press the **Heparin** field.
The input window opens.

➢ Press the **I/O** button.
This activates the input window (number buttons).

➢ Enter the required heparin flow with the aid of the number buttons.
Grey buttons prevent invalid entries.

➢ Check the new value against the target value.

➢ To correct your entry, press the **C** button.
The last active value will be displayed.

➢ Press the **OK** button to apply the displayed value.
The input window is closed.

➢ The applied value is checked.

3.5.5 Viewing the ratio of the UF rate to the blood flow rate

The UF/BF ratio is shown in the field between the rocker switch buttons of the blood pump, and also in the input windows of the following fields, as context-specific information:

Substituate (in postdilution mode)
Net UF rate
Blood flow

3.5.6 Viewing the pressure values

The device incorporates an automatic limit monitoring system. This helps avoid superfluous error messages that could otherwise occur, for example, when a patient shifts position.

The asymmetric return pressure limit values are set by default to ensure a rapid reaction to a loss of pressure.



The pressure values are always shown on the left of the screen and depend on the treatment type.

(A) Access pressure (red arrow)
(B) Return pressure (blue arrow)
(C) Pre-filter pressure (Pre-F)
(D) Transmembrane pressure (TMP)

The actual values are shown as numerical values and indicated by the green line over the pressure alarm window in each case.

The pressure alarm window is shown in the form of a rectangular tile in each case.

3.5.7 Setting the pressure alarm limit values



➢ Press on the required pressure display field.
The input window opens.

➢ Select the type of change you wish to make.
(A) Change the pressure alarm window size
(B) Move the pressure alarm window position

➢ Use the **+ / –** rocker switch buttons to change the limit parameter values accordingly.

➢ Check the limit parameters you have set.

➢ Press the **OK** button to apply the new limit parameters.
The input window is closed.

➢ To correct your entry, press the **C** button.
The last active pressure alarm window will be applied.

By pressing the **Auto** button, you can reset the pressure alarm windows for all the pressure types automatically around the current values.
This does not change the size of the pressure alarm windows.

4 Operation

Note

The screens shown in the Instructions for Use may differ from those displayed on the device.

On the device, the current treatment mode is always displayed in the upper left-hand corner of the screen in the status bar. For technical reasons, the screens figuring in the Instructions for Use do not always represent the selected treatment mode.

The values shown in the screenshots are for illustrative purposes only. All treatment parameters must be entered as specified by the physician.

The device must be operated according to the instructions on the screen.

4.1 Application principles

Warning

Danger in case of excessive load on the IV pole (observe the maximum load)

An excessively heavy load on the IV poles can overturn the device.

➢ Do not exceed the maximum permitted load of 5.5 kg on the IV pole.

Warning

Risk of embolism as a result of particle reinfusion

➢ Use the dialysate and substituate in accordance with the manufacturer's instructions.

Warning

Risk of contamination as a result of unsuitable infusion solutions

➢ For the treatment modes CVVHDF and CVVH, only solutions that are suitable for infusion must be used.

Warning

Risk for the patient as a result of a disorder of the electrolyte balance due to incorrect selection of dialysate and substituate

➢ After changing the treatment mode, change the solutions if necessary.

➢ Adjust the flow ratios of the solutions in relation to each other and in relation to the blood flow.

Warning

Risk of cross-contamination as a result of tubing systems without hydrophobic filters

There is a risk of spreading germs.

➢ Only use tubing systems with hydrophobic filters in the pressure lines.

Warning

Risk of cross-contamination as a result of a wrong proceeding in case of a wet or defective hydrophobic filter

There is a risk of spreading germs.

➢ Never force back any fluid with a syringe (damages the hydrophobic filter).

➢ Make sure the pressure line is tightly sealed.

➢ Replace the affected tubing system. In the case of a pressure line with a wetted hydrophobic filter, use a replacement pressure line (accessory available from manufacturer).

If you cannot exclude the possibility that the device may have become contaminated:

➢ Take the device out of service after completing treatment.

➢ Have the device tested for contamination by service support.

If the device is contaminated, all affected parts must be disinfected or replaced by service support.

Warning

Risk of injury as a result of hot surfaces

Touching the inside of the heaters can result in burns.

➢ Do not touch the inside of the heaters during treatment.

Warning

Risk of crush injury from pressure measurement unit when closing

➢ Keep fingers clear of open pressure measurement units.

Warning

Risk of crush injury when closing line occlusion clamp

➢ Keep fingers clear of open line occlusion clamps.

Warning

Risk for the patient as a result of corrupted data

Objects placed on top of the tilted monitor can inadvertently change treatment data.

➢ Do not place any objects on top of the monitor.

Warning

Risk of contamination as a result of improper handling of single-use items and consumables

Single-use items and consumables can come into contact with germs when removed from their outer packaging.

➢ Do not unpack and insert single-use items and consumables until immediately before beginning treatment.

Warning

Risk of blood loss as a result of damaged tubing systems

Risk of circulatory disturbance as a result of fluid loss

There is a risk of blood and plasma loss.

➢ In long treatments, replace tubing systems before the end of their service life as specified by the manufacturer or when a warning message is displayed by the device.

Preparation times also count as part of the service life. The service life information is printed on the packaging of the tubing systems. Any specified limit values or warning messages of the device are ignored at the operator's own risk.

Warning

Risk of blood loss as a result of an undetectable dislocation

Risk of blood loss as a result of an undetectable leakage

A leak in the tubing system and/or a dislocation of the return line can result in the patient suffering a serious loss of blood.

➢ The lower return pressure limit value must be set as close as possible to the actual return pressure value.

Warning

Risk for the patient as a result of improper use of consumables

Treatment cannot be performed properly and safely if consumables are used incorrectly.

➢ Follow the instructions that come with the consumables used.

Warning

Risk of contamination as a result of damaged tubing systems

Risk of air embolism as a result of air in the tubing system

Risk of blood loss as a result of damaged tubing systems

Risk of blood loss as a result of connection sites not closed correctly

Risk of haemolysis as a result of a kinked and crushed tubing system

Risk of circulatory disturbance as a result of fluid loss

➢ When inserting the tubing system, observe the following:

– Only use the tubing system specified for the selected treatment mode.
– Consumables must only be used if the packaging and the consumable itself, including any protective caps or plugs, are undamaged. Protective caps and plugs must be in place and must not have fallen off.
– Before connecting the patient, make sure the tubing system is free of air.
– Insert tubing systems cleanly, without kinks, line tension or twisting. Use the line holders provided.
– Make sure the tubing systems cannot become crushed or pinched.
– Make sure all screw-lock joints are properly tightened, particularly those of the patient connections, the dialyser connections, and the device connections. Take the appropriate corrective measures (e.g., tighten the Luer lock connections, or replace the tubing system if necessary).
– Always check the solution bags for visible leaks before connecting them to the tubing system.

Warning

Risk of air embolism as a result of air in the tubing system

Risk of haemolysis as a result of a kinked and crushed tubing system

Risk of blood loss as a result of connection sites not closed correctly

Risk of circulatory disturbance as a result of fluid loss

➢ Before starting a treatment, check the following:

– All the joints of the tubing system are securely connected
– There are no apparent leaks in the tubing system, either during or after filling
– Tighten connections as needed, or, if necessary, replace the entire tubing system
– The tubing system is free of air, is inserted cleanly without kinks, line tension or twisting, and all fluid levels are correct

Warning

Risk of air embolism as a result of air in the tubing system

Risk of haemolysis as a result of a kinked and crushed tubing system

Risk of blood loss as a result of connection sites not closed correctly

Risk of circulatory disturbance as a result of fluid loss

➢ During treatment, check the following at appropriate intervals:

– The condition of the patient.
– The volume balancing and fluid removal monitoring systems.
– The correct function of the device and the extracorporeal blood circuit. To protect the patient from dangerous blood loss, return pressure monitoring of the extracorporeal blood circuit is used as a safety system against external blood leaks. However, pressure monitoring cannot detect an external blood leak in all cases. Particularly critical occurrences are dislocations of the return line or small leaks in the high pressure components of the extracorporeal blood circuit. For this reason, the extracorporeal blood circuit must be checked regularly for leaks while treatment is in progress, paying particular attention to all the joints of the tubing system and the connections to the catheters.
– The tubing system, watching out for possible leaks, air ingress, or loosened joints. Particularly at the joints downstream of the air detector, negative pressure can permit air to enter into the extracorporeal blood circuit. This can be a problem when using central venous catheters.
– Check that the tubing system is not kinked, under tension, or twisted.
– The filtrate and dialysate circuits, watching out for leaks.
– Discolouration in the filtrate bag caused by blood loss.

Warning

Risk of contamination as a result of improper handling of connection sites

Pathogens can enter the extracorporeal blood circuit.

➢ Use aseptic technique for all blood system connections and all the connections of the sterile solutions to be used.

Note

If clotting occurs despite citrate anticoagulation, this can be an indication of severe HIT (type 2) in the patient. Sufficiently large filters must always be used!

Note

Scales:
The maximum load capacity of 12 kg per scale must not be exceeded. The weighing cell can even be permanently damaged by a short-term overload (e.g., pulling or lifting the device by the scales), in which case the device can no longer be used.

Note

Blood pump rotor:
The blood pump rotor has red markings, including the arrow showing the direction of rotation, and must only be installed in the blood pump, which is marked by a matching red dot.

Note

Blood leak/haemolysis monitoring:
The filtrate line must remain in the blood leak detector (yellow) for the entire duration of the treatment.

Note

When administering drugs or connecting infusions via the access line, make sure the substances used will survive the dialyser.
The effectiveness of the intended treatment may depend on this.

When working on the tubing system during a treatment, observe the following:

If you need to move any part of the tubing system out of position, make sure the correct layout of the entire tubing system is restored before continuing treatment, paying special attention to the correct placement of the positioners.

4.2 CRRT treatments

General description of the CVVH, CVVHD, CVVHDF and Pre-Post CVVH procedures with information on the differences between the individual therapies.

4.2.1 Switching on the device and starting the function test

There must be no load on any of the scales.

➢ Switch on the device with the **On/Off** button.

The software version, date and time will be displayed.



➢ Press the **Start** button to start the function test.

4.2.2 Selecting the treatment option



➢ Select the treatment option.

Press the **Continue** button to continue the previous treatment.

4.2.3 Continuing the previous treatment



➢ Press the **Retain** button to confirm the previous balance data.

Or

➢ Press the **Delete** button to reset the previous balance data to 0.

The Patient ID and Case ID will not be deleted.

➢ Then press the **OK** button to confirm your previous selection ("Retain" or "Delete").

4.2.4 Start requirements

➢ Check the contents of the solution bags against the information shown on the screen.

➢ Press **OK** to confirm that you have the correct solutions available.

Press the **Back** button to return to the treatment options screen.

4.2.5 Mounting the cassette



You can use the following buttons for mounting the cassette:

Press ▶ to go to the next step.

Press ▶| to jump to the end of the setup instructions.

Press ◀ to return to the previous step.

Press |◀ to jump back to the beginning of the setup instructions.

Note

For the CVVH, CVVHD, CVVHDF and Pre-Post CVVH procedures, the multiFiltratePRO Kit HDF is used. For all these treatment modes, the substituate system and the dialysate system need to be mounted and filled. During the CVVHD procedure, the substituate pump is stopped. During the CVVH procedure, the dialysate pump is stopped.

➢ Hang up the cassette according to the instructions.

➢ Fix the filter in the filter holder.

➢ Press to go to the next step.

4.2.5.1 Mounting the return system

Warning

Risk of air embolism due to loss of function of the air detector

Blood clots (coagula) in the tubing system, contaminations and/or moisture on the air bubble detector can impair the correct function of the air bubble detector.

➢ Make sure that the air bubble detector is clean and dry.

➢ Do not use any ultrasound-conducting objects or media on the air bubble detector.

Warning

Risk of air embolism as a result of air in the tubing system

If the tubing system is not inserted properly, this can prevent the air detection system from working.

➢ When the tubing system is inserted into the air bubble detector/optical detector, the tube must lie along the full length of the tube holder.

Warning

Risk of air embolism as a result of air in the tubing system

➢ Insert the tubing system correctly into the line occlusion clamp.

➢ Do not remove the tubing system from the line occlusion clamp during treatment.



➢ Mount the return system according to the instructions.

➢ Press to go to the next step.

4.2.5.2 Mounting the access system



➢ Mount the access system according to the instructions.

Check that the correct cassette has been mounted for the selected treatment option.

➢ Press to go to the next step.

Note

Once the first positioner has been inserted, the cassette system can only be dismantled and changed by cancelling the preparation (**Menus** / **Cancel preparation**).

4.2.5.3 Mounting the filtrate system

Warning

Risk of contamination as a result of damaged bags

Bags can burst when dropped.

➢ Push filtrate bags as far back as possible onto the hooks of the lower scales.



➢ Mount the filtrate system according to the instructions.

Filtrate bag monitoring can be set in the System Parameters, from 5 l to 20 l.
If set to more than 10 l, two 10-litre bags must be connected with a Y adapter.

➢ Press to go to the next step.

4.2.5.4 Loading the solution bags

Note

When loading the solution bags onto the scales, make sure the connectors face inwards and to the rear.



➢ Load the solution bags onto the scales according to the instructions.

Maximum load per scale is 12 kg.
Observe the colour coding of the connectors.

➢ Press ▶ to go to the next step.

4.2.5.5 Mounting the dialysate/substituate systems

Note

When inserting the heater bags, observe the correct colour coding.

● **Predilution (CVVHDF / CVVH)**



➢ Mount the dialysate/substituate systems according to the instructions.

➢ Press ▶ to go to the next step.

- **Postdilution (CVVHDF / CVVH / CVVHD)**



➢ Mount the dialysate/substitute systems according to the instructions.

➢ Press ● to go to the next step.

- **Predilution/postdilution substitute system (Pre-Post CVVH)**



➢ Mount the predilution/postdilution substitute system according to the instructions.

➢ Connect the Pre-Post CVVH adapter with the filter connection (green) of the dialysate system and the predilution port (red).

➢ Press ● to go to the next step.

4.2.5.6 Inserting the heparin syringe

Note

Only use the syringe type selected in the Setup and shown on the screen.

Note

When inserting the heparin syringe, observe the following:
– The syringe wings must be positioned between the barrel holders and the bracket.
– The thumb rest of the syringe plunger must be positioned between the jaws of the spring clip on the stock.

Tip

The heparin syringe can be inserted any time after starting treatment by choosing **MENUS/Change syringe** (only if heparin pump is activated).



➢ Insert the heparin syringe according to the instructions.

➢ Press ▶ to go to the next step.

4.2.5.7 Cassette mounting completed



➢ Insert complete cassette.

If the **OK** button cannot be selected (greyed out), check the mounted tubing system according to the instructions on the screen.

➢ Press the **OK** button to confirm that the tubing system is fully mounted.

If heparin anticoagulation has been selected, the heparin line will be filled automatically after confirmation.

4.2.6 Filling and rinsing the cassette

4.2.6.1 Filling the tubing system

Tip

The default rinse flow of 100 ml/min ensures the best possible deaeration of the filter and tubing system.

➢ Press the **Start** button to start filling the tubing system.

Rinsing starts automatically as soon as the correct fill level in the bubble catcher is detected.

The rinse flow can be changed with the **+/–** rocker switch buttons.

4.2.6.2 Entering the Patient ID and Case ID

Requirements

The **Patient** menu opens automatically when filling is started, if **Jump to Patient menu** is activated. Otherwise, the **Treatment parameters** menu will open automatically when filling is started (see chapter 4.2.6.3 on page 4-17).



➢ Check the **Patient ID** and **Case ID** shown.
The fields will be empty if no data has yet been entered.



➢ To change or enter the **Patient ID** and **Case ID**, press the relevant field.

➢ Use the keyboard to enter the required **Patient ID** and **Case ID**.

➢ Press the **OK** button to apply the displayed value.

➢ Check the **Patient ID** and **Case ID** entered.

4.2.6.3 Entering treatment parameters

Note

The bolus function can be used if an initial heparin bolus needs to be administered.

The infusion of anticoagulation fluids is corrected automatically in the overall balance.



➢ Check the preset treatment parameters. If necessary, adjust the treatment parameters.

– Temperature:
Enter the temperature of the dialysate and the substituate (°C). The **Temperature** button can be used to switch the heater on and off.

4.2.6.4 UF Rinse

Note

When using NaCl bags with only one connector, make sure there is enough NaCl solution.



If using an NaCl bag with two connectors:

➢ Remove return line from empty bag and connect to NaCl solution.

➢ Press the **Start** button to start the UF rinse.

If using an NaCl bag with one connector:

➢ Leave the existing connections as they are.

➢ Press the **Start** button to start the UF rinse.

The level in the bubble catcher will be set automatically when the UF rinse is finished.

4.2.7 Circulation

Warning

Risk of contamination as a result of non-compliance with hygienic conditions

➢ Keep preparation and circulation times before the treatment as short as possible.

Note

If the patient connection must be delayed, the extracorporeal circuit can be kept in circulation for a certain time after preparation.

To avoid stressing the tubing system for too long, the circulation time is also taken into account when monitoring the kit service life.

Note

In the Setup, circulation can be set to start automatically or to be confirmed by the user.

The factory setting is **Confirm**, since an automatic changeover into circulation mode is only possible if an NaCl solution bag with two connections is used.

- **Stop before circulation**



After the rinse is completed, the blood pump will stop.

An audible tone is emitted.

➢ Connect the access and return lines to the recirculation connector.

➢ Press the **Start** button to start the circulation.

Or

➢ Press the **Preparation** button to begin patient connection.

- **Automatic circulation**

After the rinse is completed, the circulation will start automatically.

➢ Prepare to connect the patient.

➢ Press the **Preparation** button to stop the blood pump.

4.2.8 Connecting the patient



The blood pump is stopped.

➢ Press the **Start** button to start the blood pump.

The blood pump will continue operating until the optical detector has detected blood.
If necessary, administer a heparin bolus.

Press the **Continue** button to continue the circulation.



The optical detector has detected blood.

The blood pump is stopped.

➢ Press the **Start** button to start the treatment.

4.2.9 Treatment

4.2.9.1 Treatment screen

The treatment screen is displayed throughout the entire treatment.

The information area shows important treatment data:

Pressure / alarm history

Next operator action

4.2.9.2 Menus

The following menu options can be selected:

– Rocker switch buttons for setting the level in the bubble catcher:
  For raising or lowering the level in the bubble catcher.
– Cancel preparation:
  For dismantling (user) / ejecting (device) the tubing system during preparation.
– Treatment interrupted:
  For pausing treatment.
– Switch off balancing / Switch balancing on:
  For switching balancing off and back on.
– Change syringe:
  For changing the heparin syringe.
– Care:
  For starting Care mode.
– Switch to predilution/postdilution:
  For changing between predilution and postdilution methods.
– Bag change:
  For changing the substituate and dialysate bags and emptying the filtrate bag.

Detailed description of menu options shown (see chapter 4.6 on page 4-83).

4.2.9.3 Histories



The following tabs can be selected:

– Balance data
– Balance history
– Events

(see chapter 4.7 on page 4-105)

Pressing the **Reset balance data** button will reset all the cumulative volume information recorded so far to "zero". The treatment time and the filter life will not be reset.

4.2.9.4 System Parameters



In the **System Parameters** screen, only the blue (activated) buttons can be used to open the appropriate options (see chapter 4.8 on page 4-110).

To activate any grey buttons, you will need a ServiceCard or UserCard.

4.2.10 Changing the treatment mode

Warning

Risk of contamination as a result of unsuitable infusion solutions

➢ For the treatment modes CVVHDF and CVVH, only solutions that are suitable for infusion must be used.

Warning

Risk for the patient as a result of a disorder of the electrolyte balance due to incorrect selection of dialysate and substituate

➢ After changing the treatment mode, change the solutions if necessary.

➢ Adjust the flow ratios of the solutions in relation to each other and in relation to the blood flow.

Warning

Risk of contamination as a result of non-compliance with hygienic conditions

There is a risk of spreading germs.

➢ Observe service life of opened bags as specified by the manufacturer.

➢ If the service life is exceeded, leave substitute or dialysate deactivated or initiate end of treatment.

Note

Changing the treatment mode is always possible by switching the substituate flow or dialysate flow off/on.

A change of the treatment mode effected in this way can be undone. A change of the treatment mode is shown in the status bar by the greyed-out letters.

Depending on the treatment option you change over to, the various flows, ratios, and connections may need to be adapted. Observe and follow the instructions on the screen.

Note

From the pre-post CVVH treatment mode, it is only possible to change to pre CVVH or post CVVH.

4.2.10.1 Changing the treatment mode from CVVHDF to CVVH

➢ Select **Dialysate** and switch off the flow with the **I/O** button.

➢ Press the **OK** button to apply the change.

A change of the treatment mode is shown in the status bar

To undo this change, simply switch the dialysate flow back on with the **I/O** button.

4.2.10.2 Changing the treatment mode from CVVHDF to CVVHD

Note

A substitute bolus is not possible in the CVVHD treatment mode.

➢ Select **Substituate** and switch off the flow with the **I/O** button.

➢ Press the **OK** button to apply the change.

A change of the treatment mode is shown in the status bar

To undo this change, simply switch the substituate flow back on with the **I/O** button.

4.2.11 End of treatment

4.2.11.1 Preparing the end of treatment



➢ Select **End of treatment** from the menu bar.

➢ Press the **Confirm** button to select blood reinfusion.

Press the **Continue** button to continue the treatment.

Press the **Confirm** button under **Without blood reinfusion** and **Blood pump Stop** in the screen that follows to go straight to the **Disconnect the patient!** screen (see chapter 4.2.11.5 on page 4-29).

4.2.11.2 End of treatment with blood reinfusion

➢ Press the **Stop** button to stop the blood pump.

Balancing is switched off.

Press the **Back** button to return to the Prepare end of treatment screen.

4.2.11.3 Starting blood reinfusion



➢ Disconnect the access line from the patient and connect it to an NaCl solution bag.

➢ Press the **Start** button to start blood reinfusion.

The blood flow is limited to 100 ml/min.



Blood reinfusion ends automatically as soon as the optical detector detects the NaCl solution.

Press the **Pause** button to stop the blood reinfusion.

Press the **Exit** button to terminate blood reinfusion.

4.2.11.4 NaCl solution detected



➢ Press the **Exit** button to terminate blood reinfusion.

Press the **Continue** button to reinfuse a further 100 ml of NaCl solution.

This can be repeated as needed.

4.2.11.5 Disconnecting the patient

➢ Disconnect the patient.

➢ Press the **Eject** button to start ejecting the tubing system.

4.2.11.6 Dismantling the tubing system

Warning

Risk of cross-contamination as a result of contaminated consumables

There is a risk of spreading germs.

➢ Consumables must be discarded after a treatment in compliance with the regulations for the disposal of potentially contaminated materials.



➢ Dismantle the tubing system.

In the **HISTORIES** menu, you can view the treatment data and events.

➢ Switch the device off with the **Switch off** button.

4.3 CRRT Ci-Ca treatments

General description of the Ci-Ca CVVHD and Ci-Ca postCVVHDF procedures with information on the differences between the individual therapies.

4.3.1 Switching on the device and starting the function test



There must be no load on any of the scales. There must be no tubing systems inserted in the Ci-Ca pumps.

➢ Switch on the device with the **On/Off** button.

The software version, date and time will be displayed.



➢ Press the **Start** button to start the function test.

4.3.2 Selecting the treatment option

➢ Select the treatment option.

Press the **Continue** button to continue the previous treatment.

4.3.3 Continuing the previous treatment



➢ Press the **Retain** button to confirm the previous balance data.

Or

➢ Press the **Delete** button to reset the previous balance data to 0.

The Patient ID and Case ID will not be deleted.

➢ Then press the **OK** button to confirm your previous selection ("Retain" or "Delete").

4.3.4 Start requirements



➢ Check the contents of the solution bags against the information shown on the screen.

➢ Press **OK** to confirm that you have the correct solutions available.

Press the **Back** button to return to the treatment options screen.

4.3.5 Mounting the cassette



You can use the following buttons for mounting the cassette:

Press ▶ to go to the next step.

Press ▶| to jump to the end of the setup instructions.

Press ◀ to return to the previous step.

Press |◀ to jump back to the beginning of the setup instructions.

➢ Hang up the cassette according to the instructions.

➢ Fix the filter in the filter holder.

➢ Press to go to the next step.

4.3.5.1 Mounting the return system

Warning

Risk of air embolism due to loss of function of the air detector

Blood clots (coagula) in the tubing system, contaminations and/or moisture on the air bubble detector can impair the correct function of the air bubble detector.

➢ Make sure that the air bubble detector is clean and dry.

➢ Do not use any ultrasound-conducting objects or media on the air bubble detector.

Warning

Risk of air embolism as a result of air in the tubing system

If the tubing system is not inserted properly, this can prevent the air detection system from working.

➢ When the tubing system is inserted into the air bubble detector/optical detector, the tube must lie along the full length of the tube holder.

Warning

Risk of air embolism as a result of air in the tubing system

➢ Insert the tubing system correctly into the line occlusion clamp.

➢ Do not remove the tubing system from the line occlusion clamp during treatment.



➢ Mount the return system according to the instructions.

➢ Press ▶ to go to the next step.

4.3.5.2 Mounting the access system



➢ Mount the access system according to the instructions.

Check that the correct cassette has been mounted for the selected treatment option.

➢ Press ▶ to go to the next step.

Note

Once the first positioner has been inserted, the cassette system can only be dismantled and changed by cancelling the preparation (**Menus** / **Cancel preparation**).

4.3.5.3 Mounting the filtrate system

Warning

Risk of contamination as a result of damaged bags

Bags can burst when dropped.

➢ Push filtrate bags as far back as possible onto the hooks of the lower scales.



➢ Mount the filtrate system according to the instructions.

Filtrate bag monitoring can be set in the System Parameters, from 5 l to 20 l.
If set to more than 10 l, two 10-litre bags must be connected with a Y adapter.

➢ Press to go to the next step.

4.3.5.4 Loading the solution bags

Note

When loading the solution bags onto the scales, make sure the connectors face inwards and to the rear.

- **CVVHDF**

Warning

Risk of blood loss as a result of clotting

Risk for the patient as a result of a disorder of the electrolyte balance due to incorrect selection of dialysate

The use of calcium-containing dialysate for a Ci-Ca treatment can lead to blood clotting and/or hypercalcaemia.

➢ Only use calcium-free dialysate for treatments with citrate anticoagulation.

Warning

Risk for the patient as a result of a disorder of the electrolyte balance due to incorrect selection of substituate

The use of substituate with the wrong calcium level for a Ci-Ca treatment can lead to an electrolyte imbalance in the patient.

➢ Only use calcium-containing substituate for treatments with citrate anticoagulation.

➢ Check that the calcium solution used corresponds to the type selected in the Setup and shown on the screen.



➢ Load the solution bags onto the scales according to the instructions.

Maximum load per scale is 12 kg.
Make sure you load the solutions onto the correct scales.
Observe the colour coding of the connectors.

➢ Press to go to the next step.

- **CVVHD**

Warning

Risk of blood loss as a result of clotting

Risk for the patient as a result of a disorder of the electrolyte balance due to incorrect selection of dialysate

The use of calcium-containing dialysate for a Ci-Ca treatment can lead to blood clotting and/or hypercalcaemia.

➢ Only use calcium-free dialysate for treatments with citrate anticoagulation.



➢ Load the solution bags onto the scales according to the instructions.

Maximum load per scale is 12 kg.
Observe the colour coding of the connectors.

➢ Press ▶ to go to the next step.

4.3.5.5 Mounting the dialysate/substituate systems

Note

When inserting the heater bags, observe the correct colour coding.

- **CVVHDF**

Note

For a Ci-Ca postCVVHDF treatment, the substituate line must always be connected to the postdilution port.



➢ Mount the dialysate/substituate systems according to the instructions.

➢ Press ▶ to go to the next step.

- **CVVHD**



➢ Mount the dialysate system according to the instructions.

➢ Press ● to go to the next step.

4.3.5.6 Mounting the Ci-Ca system

Warning

Risk for the patient as a result of incorrect Ci-Ca anticoagulation and changes in the patient's acid-base balance

Risk for the patient as a result of a disorder of the electrolyte balance

➢ Check that the citrate and calcium solutions used correspond to the types selected in the Setup and shown on the screen.

Warning

Risk for the patient as a result of incorrect Ci-Ca anticoagulation and changes in the patient's acid-base balance

Risk for the patient as a result of a disorder of the electrolyte balance

➢ When mounting the Ci-Ca system, make sure the pump segments are correctly fixed and observe the correct colour coding of the Ci-Ca lines.

➢ Make sure you connect the lines of the citrate and calcium solutions correctly.

Warning

Risk for the patient as a result of a reduction in body temperature

If the temperature of the citrate and calcium solutions is too low, this can lead to hypothermia in the patient.

➢ The solutions must be at room temperature when used.

➢ Either select a suitable storage temperature or heat the bags to the required temperature before use.



➢ Mount the Ci-Ca system according to the instructions.

➢ Press ▶ to go to the next step.



➢ Check the Ci-Ca system.

➢ Press the **Start** button to start inserting the Ci-Ca pump segments.

4.3.5.7 Inserting the heparin syringe

If heparinisation is needed in addition to the Ci-Ca anticoagulation, a heparin syringe can be inserted.

Note

Only use the syringe type selected in the Setup and shown on the screen.

Note

When inserting the heparin syringe, observe the following:
– The syringe wings must be positioned between the barrel holders and the bracket.
– The thumb rest of the syringe plunger must be positioned between the jaws of the spring clip on the stock.

Tip

The heparin syringe can be inserted any time after starting treatment by choosing **MENUS/Change syringe** (only if heparin pump is activated).



➢ Insert the heparin syringe according to the instructions.

➢ Press ▶ to go to the next step.

4.3.5.8 Cassette mounting completed



➢ Insert complete cassette.

If the **OK** button cannot be selected (greyed out), check the mounted tubing system according to the instructions on the screen.

➢ Press the **OK** button to confirm that the tubing system is fully mounted.

If heparin anticoagulation has been selected, the heparin line will be filled automatically after confirmation.

4.3.6 Filling and rinsing the cassette

4.3.6.1 Filling the Ci-Ca system



➢ Press the **Start** button to start filling the Ci-Ca system.

The level in the Ci-Ca fill level detectors is checked.

➢ If necessary, adjust the levels in the level detectors manually until they are between the markings.

4.3.6.2 Checking the Ci-Ca lines



➢ Visually check that the Ci-Ca lines are free of air.

➢ Press the **OK** button to confirm that you have checked the Ci-Ca lines.

If there is still air in the Ci-Ca lines:

➢ Press the **Citrate** button to continue filling the citrate line.

➢ Press the **Ca** button to continue filling the calcium line.

4.3.6.3 Filling the tubing system

Tip

The default rinse flow of 100 ml/min ensures the best possible deaeration of the filter and tubing system.



➢ Press the **Start** button to start filling the tubing system.

Rinsing starts automatically as soon as the correct fill level in the bubble catcher is detected.

The rinse flow can be changed with the **+/–** rocker switch buttons.

4.3.6.4 Entering the Patient ID and Case ID

Requirements

The **Patient** menu opens automatically when filling is started, if **Jump to Patient menu** is activated. Otherwise, the **Treatment parameters** menu will open automatically when filling is started
(see chapter 4.3.6.5 on page 4-44).



➢ Check the **Patient ID** and **Case ID** shown.
The fields will be empty if no data has yet been entered.



➢ To change or enter the **Patient ID** and **Case ID**, press the relevant field.

➢ Use the keyboard to enter the required **Patient ID** and **Case ID**.

➢ Press the **OK** button to apply the displayed value.



➢ Check the **Patient ID** and **Case ID** entered.

4.3.6.5 Entering treatment parameters

Note

Setting the treatment parameters (citrate dose, calcium dose, blood flow, and dialysate flow) is described in a separate chapter (see chapter 7.3.2 on page 7-15).

The correct ratio of the blood flow to the dialysate flow / substituate flow is important.

Note

Anticoagulation must be set as prescribed by the physician!
The bolus function can be used if an initial heparin bolus needs to be administered.

The infusion of anticoagulation fluids is corrected automatically in the overall balance.



➢ Check the preset treatment parameters. If necessary, adjust the treatment parameters.

– Temperature:
Enter the temperature of the dialysate and the substituate (°C). The **Temperature** button can be used to switch the heater on and off.

– Calcium dose, Citrate dose:
Enter the calcium and citrate dosage.

4.3.6.6 UF Rinse

Note

When using NaCl bags with only one connector, make sure there is enough NaCl solution.



If using an NaCl bag with two connectors:

➢ Remove return line from empty bag and connect to NaCl solution.

➢ Press the **Start** button to start the UF rinse.

If using an NaCl bag with one connector:

➢ Leave the existing connections as they are.

➢ Press the **Start** button to start the UF rinse.

The level in the bubble catcher will be set automatically when the UF rinse is finished.

4.3.7 Circulation

Warning

Risk of contamination as a result of non-compliance with hygienic conditions

➢ Keep preparation and circulation times before the treatment as short as possible.

Note

If the patient connection must be delayed, the extracorporeal circuit can be kept in circulation for a certain time after preparation.

To avoid stressing the tubing system for too long, the circulation time is also taken into account when monitoring the kit service life.

Note

In the Setup, circulation can be set to start automatically or to be confirmed by the user.

The factory setting is **Confirm**, since an automatic changeover into circulation mode is only possible if an NaCl solution bag with two connections is used.

- **Stop before circulation**



After the rinse is completed, the blood pump will stop.

An audible tone is emitted.

➢ Connect the access and return lines to the recirculation connector.

➢ Press the **Start** button to start the circulation.

Or

➢ Press the **Preparation** button to begin patient connection.

- **Automatic circulation**



After the rinse is completed, the circulation will start automatically.

➢ Prepare to connect the patient.

➢ Press the **Preparation** button to stop the blood pump.

4.3.8 Connecting the patient

Note

Pressing the **Start** button under Blood pump also starts the citrate anticoagulation. If the blood pump delivers 300 ml without any blood being detected, a message is output and all pumps are stopped. If the patient detection runs for more than 10 minutes without any blood being detected, the Ci-Ca pumps will stop. The calcium pump starts after the start of treatment and balancing.



The blood pump is stopped.

➢ Press the **Start** button to start the blood pump.

The blood pump will continue operating until the optical detector has detected blood.
If necessary, administer a heparin bolus.

Press the **Continue** button to continue the circulation.



The optical detector has detected blood.
The blood pump is stopped.

➢ Press the **Start** button to start the treatment.

4.3.9 Treatment

Warning

Risk of blood loss as a result of clotting

➢ The post-filter calcium concentration must be checked 5 minutes after switching on the Ci-Ca anticoagulation and at regular intervals afterwards.

Warning

Risk for the patient as a result of incorrect Ci-Ca anticoagulation and changes in the patient's acid-base balance

Risk for the patient as a result of a disorder of the electrolyte balance

➢ Observe the instructions for taking a sample in chapter 7.

➢ In the event of widely varying measurement values of the electrolytes and the acid-base balance, consult a physician.

Note

The use of a calcium-containing substituate for the Ci-Ca postCVVHDF treatment means that a calcium substitution is performed. If the concentrations have been entered correctly in the **User Setup** menu option, this is automatically taken into account in the calcium dose.

After the treatment has been started, a message is displayed prompting the operator to check the post-filter calcium concentration after 5 minutes.

4.3.9.1 Treatment screen

The treatment screen is displayed throughout the entire treatment.

The information area shows important treatment data:

Pressure / alarm history
Next operator action

4.3.9.2 Menus

The following menu options can be selected:

– Rocker switch buttons for setting the level in the bubble catcher:
  For raising or lowering the level in the bubble catcher.
– Cancel preparation:
  For dismantling (user) / ejecting (device) the tubing system during preparation.
– Treatment interrupted:
  For pausing treatment.
– Switch off balancing / Switch balancing on:
  For switching balancing off and back on.
– Change syringe:
  For changing the heparin syringe.
– Care:
  For starting Care mode.
– Bag change:
  For changing the dialysate bag and emptying the filtrate bag.
– Ci-Ca information:
  For viewing additional information on Ci-Ca anticoagulation.
– Ca bag change:
  For changing the calcium bag.
– Citrate bag change:
  For changing the citrate bag.
– Switch off/on Ci-Ca anticoagulation:
  For switching citrate anticoagulation off and back on.

Detailed description of menu options shown (see chapter 4.6 on page 4-83).

4.3.9.3 Histories

The following tabs can be selected:
– Balance data
– Balance history
– Events

(see chapter 4.7 on page 4-105)

Pressing the **Reset balance data** button will reset all the cumulative volume information recorded so far to "zero". The treatment time and the filter life will not be reset.

4.3.9.4 System Parameters



In the **System Parameters** screen, only the blue (activated) buttons can be used to open the appropriate options (see chapter 4.8 on page 4-110).

To activate any grey buttons, you will need a ServiceCard or UserCard.

4.3.10 End of treatment

4.3.10.1 Preparing the end of treatment



➢ Select **End of treatment** from the menu bar.

➢ Press the **Confirm** button to select blood reinfusion.

Press the **Continue** button to continue the treatment.

Press the **Confirm** button under **Without blood reinfusion** and **Blood pump Stop** in the screen that follows to go straight to the **Disconnect the patient!** screen (see chapter 4.3.10.5 on page 4-54).

4.3.10.2 End of treatment with blood reinfusion

➢ Press the **Stop** button to stop the blood pump.

Balancing is switched off.

Press the **Back** button to return to the Prepare end of treatment screen.

4.3.10.3 Starting blood reinfusion



➢ Disconnect the access line from the patient and connect it to an NaCl solution bag.

➢ Press the **Start** button to start blood reinfusion.

The blood flow is limited to 100 ml/min. Ci-Ca anticoagulation is stopped.



Blood reinfusion ends automatically as soon as the optical detector detects the NaCl solution.

Press the **Pause** button to stop the blood reinfusion.

Press the **Exit** button to terminate blood reinfusion.

4.3.10.4 NaCl solution detected



➢ Press the **Exit** button to terminate blood reinfusion.

Press the **Continue** button to reinfuse a further 100 ml of NaCl solution.

This can be repeated as needed.

4.3.10.5 Disconnecting the patient

Warning

Risk of blood loss as a result of connection sites not closed correctly

Risk for the patient as a result of a disorder of the electrolyte balance

If pump segments of the Ci-Ca system are not inserted, there is a risk of blood loss or hypercalcaemia.

➢ It is forbidden to remove the Ci-Ca tubing system manually before the patient is disconnected.



➢ Disconnect the patient.

➢ Press the **Eject** button to start ejecting the tubing system.

4.3.10.6 Dismantling the tubing system

Warning

Risk of cross-contamination as a result of contaminated consumables

There is a risk of spreading germs.

➢ Consumables must be discarded after a treatment in compliance with the regulations for the disposal of potentially contaminated materials.

Note

Use the positioner to remove the tubing from the stators of the Ci-Ca pumps in each case. The pump rotor will then begin to eject the pump segments. You can help the ejection of the pump segments by lightly pulling on the positioners.



➢ Dismantle the tubing system.

In the **HISTORIES** menu, you can view the treatment data and events.

➢ Switch the device off with the **Switch off** button.

4.4 TPE treatments

4.4.1 Switching on the device and starting the function test

There must be no load on any of the scales.

➢ Switch on the device with the **On/Off** button.

The software version, date and time will be displayed.



➢ Press the **Start** button to start the function test.

4.4.2 Selecting the treatment option



➢ Select the **TPE** tab.

➢ Select the treatment option **TPE**.

4.4.3 Start requirements



➢ Check heparin syringe type, number of filtrate bags and filtrate bag size against the information on the screen.

➢ Press the **OK** button to confirm the consumables used.

Press the **Back** button to return to the treatment options screen.

4.4.4 Mounting the cassette



You can use the following buttons for mounting the cassette:

Press to go to the next step.

Press to jump to the end of the setup instructions.

Press to return to the previous step.

Press to jump back to the beginning of the setup instructions.



➢ Hang up the cassette according to the instructions.

➢ Fix the plasma filter in the filter holder.

➢ Press to go to the next step.

4.4.4.1 Mounting the return system

Warning

Risk of air embolism as a result of air in the tubing system

Blood clots (coagula) in the tubing system, contaminations and/or moisture on the air bubble detector can impair the correct function of the air bubble detector.

➢ The air bubble detector must be clean and dry.

➢ Do not use any ultrasound-conducting objects or media.

Warning

Risk of air embolism as a result of air in the tubing system

If the tubing system is not inserted properly, this can prevent the air detection system from working.

➢ When the tubing system is inserted into the air bubble detector/optical detector, the tube must lie along the full length of the tube holder.

Warning

Risk of air embolism as a result of air in the tubing system

➢ Insert the tubing system correctly into the line occlusion clamp.

➢ Do not remove the tubing system from the line occlusion clamp during treatment.



➢ Mount the return system according to the instructions.

➢ Press to go to the next step.

4.4.4.2 Mounting the access system



➢ Mount the access system according to the instructions.

Check that the correct cassette has been mounted for the selected treatment option.

➢ Press to go to the next step.

Note

Once the first positioner has been inserted, the cassette system can only be dismantled and changed by cancelling the preparation (**Menus** / **Cancel preparation**).

4.4.4.3 Mounting the filtrate system

Warning

Risk of contamination as a result of damaged bags

Bags can burst when dropped.

➢ Push filtrate bags as far back as possible onto the hooks of the lower scales.



➢ Mount the filtrate system according to the instructions.

Filtrate bag monitoring can be set in the System Parameters, from 5 L to 20 L. If set to more than 10 L, two 10-litre bags must be connected with a Y adapter.

➢ Press ▶ to go to the next step.

4.4.4.4 Loading the solution bags

Note

When loading the solution bags onto the scales, make sure the connectors face inwards and to the rear.



➢ Load the NaCl solution onto scale 1 according to the instructions.

➢ If necessary, place the plasma bag holder on scale 2.

Maximum load per scale is 12 kg

➢ Press ▶ to go to the next step.

4.4.4.5 Mounting the plasma system

Note

When inserting the heater bags, observe the correct colour coding.



➢ Mount the plasma system according to the instructions.

➢ Press ▶ to go to the next step.

4.4.4.6 Inserting the heparin syringe

Note

Only use the syringe type selected in the Setup and shown on the screen.

Note

When inserting the heparin syringe, observe the following:
– The syringe wings must be positioned between the barrel holders and the bracket.
– The thumb rest of the syringe plunger must be positioned between the jaws of the spring clip on the stock.

Tip

If a treatment has been started without heparin, a heparin syringe can be inserted any time by choosing **Menus / Change syringe** (only if heparin pump is activated).



➢ Insert the heparin syringe according to the instructions.

➢ Press to go to the next step.

4.4.4.7 Cassette mounting completed



➢ Insert complete cassette.

If the **OK** button cannot be selected (greyed out), check the mounted tubing system according to the instructions on the screen.

➢ Press the **OK** button to confirm that the tubing system is fully mounted.

If heparin anticoagulation has been selected, the heparin line will be filled automatically after confirmation.

4.4.5 Filling and rinsing the cassette

4.4.5.1 Filling the tubing system

Tip

The default rinse flow of 100 ml/min ensures the best possible deaeration of the plasma filter and tubing system.



➢ Press the **Start** button to start filling the tubing system.

Rinsing starts automatically as soon as the correct fill level in the bubble catcher is detected.

The rinse flow can be changed with the **+/–** rocker switch buttons.

4.4.5.2 Entering the Patient ID and Case ID

Requirements

The **Patient** menu opens automatically when filling is started, if **Jump to Patient menu** is activated. Otherwise, the **Treatment parameters** menu will open automatically when filling is started (see chapter 4.3.6.5 on page 4-44)



➢ Check the **Patient ID/Case ID** shown.

The fields will be empty if no data has yet been entered.



➢ To change or enter the **Patient ID/Case ID**, press the relevant field.

➢ Use the keyboard to enter the required Patient ID/Case ID.

➢ Press the **OK** button to apply the displayed value.



➢ Check the **Patient ID / Case ID** entered.

4.4.5.3 Entering treatment parameters

Note

The bolus function can be used if an initial heparin bolus needs to be administered.

The infusion of anticoagulation fluids is corrected automatically in the overall balance.



➢ Check the preset treatment parameters. If necessary, adjust the treatment parameters.

➢ Temperature:
Switch on the substituate or plasma heater.

Warning

Risk for the patient due to heat loss via the extracorporeal blood circuit if the temperature of the plasma replacement solution is too low

Haemodynamic instability due to the reduction in core body temperature

➢ Preheat plasma replacement solution to at least 20 °C before treatment.

➢ Conduct treatment at a room temperature of at least 20 °C.

➢ Switch on heater.

➢ Avoid drafts during treatment.

➢ Regular monitoring of patient temperature.

➢ If necessary, take measures to maintain patient temperature, such as use of electric blankets.

Note

In order to avoid damage to the proteins in donor plasma, the heating power in TPE treatments has been reduced. The temperature at the insertion site depends among other things on the ambient temperature (see chapter 12 on page 12-1).

4.4.5.4 UF Rinse

Note

When using NaCl bags with only one connector, make sure there is enough NaCl solution.



If using an NaCl bag with two connectors:

➢ Remove return line from empty bag and connect to NaCl solution.

➢ Press the **Start** button to start the UF rinse.

If using an NaCl bag with one connector:

➢ Leave the existing connections as they are.

➢ Press the **Start** button to start the UF rinse.

The level in the bubble catcher will be set automatically when the UF rinse is finished.

4.4.6 Circulation

Warning

Risk of contamination as a result of non-compliance with hygienic conditions

There is a risk of spreading germs.

➢ Only insert single-use items and consumables immediately before beginning treatment.

➢ Keep preparation and circulation times before the treatment as short as possible.

Note

If the patient connection must be delayed, the extracorporeal circuit can be kept in circulation for a certain time after preparation.

To avoid stressing the tubing system for too long, the circulation time is also taken into account when monitoring the kit service life.

Note

In the Setup, circulation can be set to start automatically (without recirculation connector) or to be confirmed by the user (with recirculation connector).

The factory setting is **Confirm**, since an automatic changeover into circulation mode is only possible if an NaCl solution bag with two connections is used.

- **Stop before circulation**



After the rinse is completed, the blood pump will stop.

An audible tone is emitted.

➢ Connect the access and return lines to the recirculation connector.

➢ Press the **Start** button to start the circulation.

Or

➢ Press the **Preparation** button to prepare the filling of the plasma system.

- **Automatic circulation**



After the rinse is completed, the circulation will start automatically.

➢ Press the **Preparation** button to prepare the filling of the plasma system.

The blood pump is stopped.

4.4.7 Filling the plasma system

Note

After pressing the **Fill plasma Start** button, it is not possible to return to circulation. Plasma filling is completed after the blood pump stops, and this is followed by the **Patient connection**.



The blood pump is stopped.

➢ Close the clamp (white) on the line to the NaCl bag on scale 1.

➢ Load the plasma bag onto scale 2, or hang it on the plasma bag holder, and connect the plasma line.

➢ Enter the volume of the opened plasma bags (see second screen).

➢ Press the **Start** button to start filling the plasma system.

The substituate pump delivers 270 ml

Press the **Continue** button to continue the circulation.

4.4.8 Patient connection



The blood pump is stopped.

➢ Press the **Start** button to start the blood pump.

The blood pump will continue operating until the optical detector has detected blood.
If necessary, administer a heparin bolus.



The optical detector has detected blood.

The blood pump is stopped.

➢ Press the **Start** button to start preparing plasmafiltration.

4.4.9 Preparing plasmafiltration



Filter conditioning with blood

The substituate pump and filtrate pump are stopped.

The transition to filter conditioning with plasma takes place automatically.



Filter conditioning with plasma

The substituate pump is controlled automatically until the target rate is reached.

4.4.10 Treatment

4.4.10.1 Treatment screen

The treatment screen is displayed throughout the entire treatment.

The information area shows important treatment data:

Pressure / alarm history
Next operator action

4.4.10.2 Menus



The following menu options can be selected:

– Rocker switch buttons for setting the level in the bubble catcher:
  For raising or lowering the level in the bubble catcher.
– Cancel preparation:
  For dismantling (user) / ejecting (device) the tubing system during preparation.
– Treatment interrupted:
  For pausing treatment.
– Switch off balancing / Switch balancing on:
  For switching balancing off and back on.
– Change syringe:
  For changing the heparin syringe.
– Bag change:
  For changing the plasma bag.
– Plasma calculator:
  For calculating the plasma to be exchanged.
– Switch blood leak monitoring off/on:
  For switching blood leak monitoring off and back on.

Detailed description of menu options shown (see chapter 4.6 on page 4-83).

4.4.10.3 Histories

The following tabs can be selected:

– Balance data
– Balance history
– Events

(see chapter 4.7 on page 4-105)

4.4.10.4 System Parameters



In the **System Parameters** screen, only the blue (activated) buttons can be used to open the appropriate options (see chapter 4.8 on page 4-110).

To activate any grey buttons, you will need a ServiceCard or UserCard.

4.4.10.5 Performing a plasma bag change



The **Next operator action** tab indicates if the plasma bag needs to be changed in under 3 minutes.

➢ Select the **Bag change** menu option (see chapter 4.6.8 on page 4-96).

Or

➢ Wait until the **Plasma bag empty** message appears.



A message appears on the screen when the plasma bag is empty.

➢ Press the **Start** button to open the bag change menu.



➢ Change bags according to the instructions.

Balancing is switched off.
Make sure you load the solutions onto the correct scales.

➢ Enter the new volume of the opened plasma bags.

➢ Press the **Confirm** button to return to the treatment screen.

Balancing is started automatically.

Press the **Cancel** button to cancel the plasma bag change.

The entered plasma volume is not applied.

4.4.10.6 Performing filtrate bag change (TPE)

A filtrate bag change is displayed.

➢ Change bags according to the instructions.

Balancing is switched off.

➢ Wait until the **Filtrate bag is full** message appears.

➢ Press the **Confirm** button to return to the treatment screen.

Treatment is continued with the current weight of each changed bag. Balancing is started automatically.

4.4.11 End of treatment

4.4.11.1 Preparing the end of treatment



➢ Select **End of treatment** from the menu bar.

➢ Select **Exchange** to end the treatment with a residual plasma exchange.

Press the **Continue** button to continue the treatment.

Press the **Discard** button to switch directly to the **Treatment ended without exchanging residual plasma** menu
(see chapter 4.4.11.3 on page 4-77).

Note

Residual plasma exchange is disabled under certain conditions.

4.4.11.2 Exchanging residual plasma



➢ Press the **Stop** button to stop the substituate pump.

Balancing is switched off.

Press the **Back** button to return to the **Prepare end of treatment** screen.



➢ Load and connect the NaCl bag on scale 1.

➢ Close the clamp (white) on the plasma line to the plasma bag on scale 2.

➢ Press the **Start** button to start the residual plasma exchange.



The remaining volume is displayed.

The substituate pump delivers 270 ml

Press the **Exit** button to terminate the residual plasma exchange.

4.4.11.3 Selecting blood reinfusion



➢ Press the **Confirm** button to select blood reinfusion.

Press the **Confirm** button under **Without blood reinfusion** and **Blood pump Stop** in the screen that follows to go straight to the **Disconnect the patient!** screen (see chapter 4.4.11.5 on page 4-80).

- **End of treatment without exchanging residual plasma**

➢ Press the **Confirm** button to select blood reinfusion.

Press the **Back** button to return to the Prepare end of treatment screen.

Press the **Confirm** button under **Without blood reinfusion** and **Blood pump Stop** in the screen that follows to go straight to the **Disconnect the patient!** screen (see chapter 4.4.11.5 on page 4-80).

4.4.11.4 End of treatment with blood reinfusion



➢ Press the **Stop** button to stop the blood pump.

Press the **Back** button to return to the blood reinfusion selection screen.



➢ Disconnect the access line from the patient and connect it to an NaCl solution bag.

➢ Press the **Start** button to start the reinfusion.

The blood flow is limited to 100 ml/min.



Blood reinfusion ends automatically as soon as the optical detector detects the NaCl solution.

Press the **Pause** button to stop the blood reinfusion.

Press the **Exit** button to terminate blood reinfusion.



➢ Press the **Exit** button to terminate blood reinfusion.

Press the **Continue** button to reinfuse a further 100 ml of NaCl solution.

This can be repeated as needed.

4.4.11.5 Disconnecting the patient

➢ Disconnect the patient.

➢ Press the **Eject** button to start ejecting the tubing system.

4.4.11.6 Dismantling the tubing system

Warning

Risk of cross-contamination as a result of contaminated consumables

There is a risk of spreading germs.

➢ Consumables must be discarded after a treatment in compliance with the regulations for the disposal of potentially contaminated materials.



➢ Dismantle the tubing system.

In the **HISTORIES** menu, you can view the treatment data and events.

➢ Switch the device off with the **Switch off** button.

4.5 Treatment displays

4.5.1 Pressure / alarm history

The **Pressure / alarm history** tab shows the different pressures recorded over time. The Pressure / alarm history display can be configured in the System Parameters menu option.

Use the buttons to shift the time frame shown.

4.5.2 Next operator action

The **Next operator action** tab lists the tasks that remain to be performed during the treatment in chronological order.

If the time for performing the next task is less than 15 minutes away, the **Next operator action** tab will jump to the foreground (of the treatment display).

4.6 Menus

4.6.1 Setting the level in the bubble catcher



➢ Use the **Level** rocker switch buttons to set the level in the bubble catcher manually.

4.6.2 Cancel preparation

➢ Select the **Cancel preparation** menu option.

➢ Press the **Start** button to start ejecting the tubing system.

Press the **Back** button to carry on mounting the tubing system.

4.6.3 Treatment pause

The **Treatment pause** function allows the patient to be disconnected from the device for a short time during treatment.

Warning

Risk for the patient as a result of cross-contamination / immune response

Reconnecting a patient to the wrong device after a treatment pause can lead to cross-contamination and elicit an immune response.

➢ After a treatment pause, make absolutely certain that you only reconnect the same patient to the device.

Warning

Risk of contamination as a result of improper handling of connection sites

Pathogens can enter the extracorporeal blood circuit.

➢ Use aseptic technique for all blood system connections and all the connections of the sterile solutions to be used.

➢ Select the **Treatment interrupted** menu option.

➢ Press the **With blood reinfusion** button to pause the treatment with a blood reinfusion (cannot be selected with TPE).

Or

➢ Press the **W/o blood reinfusion** button to pause the treatment without a blood reinfusion.

Press the **Continue** button to continue the treatment.

4.6.3.1 Treatment pause with blood reinfusion (CRRT only)

Warning

Risk of contamination as a result of long dwell time of fluids in the tubing system

➢ For reasons of hygiene, and taking local rules and regulations into account, a treatment pause should be kept as short as possible.

Note

Treatment pause with blood reinfusion can also be accessed directly, if the optical detector no longer detects blood during treatment and the Treatment pause with blood reinfusion is started.

➢ Press the **Stop** button to stop the blood pump.
The treatment pause **must now be completed**!

The blood pump is stopped.
Balancing is switched off.
Anticoagulation is switched off.
The upper limits of the pressures are monitored.

Press the **Back** button to return to the Prepare for treatment pause screen.



➢ Connect the access line to an NaCl solution bag.

➢ Press the **Start** button to start blood reinfusion.

The blood flow is automatically limited to 100 ml/min if it was set to more than 100 ml/min for treatment.
Balancing remains switched off.
Anticoagulation remains switched off.



Blood reinfusion ends automatically as soon as the optical detector detects the NaCl solution.

Press the **Pause** button to interrupt the blood reinfusion.



➢ Connect the return line to an NaCl solution bag.

➢ Press the **Start** button to start the treatment pause.

The blood flow is automatically limited to 100 ml/min if it was set to more than 100 ml/min for treatment.
Balancing remains switched off.
Anticoagulation remains switched off.

The treatment pause is running.

The elapsed time is displayed.

➢ Press the **Preparation** button to begin patient connection.

● **Prepare to connect the patient**

➢ Press the **Confirm** button to confirm the correct identity of the patient.

Press the **Continue** button to continue the treatment pause.



➢ Connect the access line to the patient.

➢ Press the **Start** button to start the patient connection.

The blood pump will continue operating until the optical detector has detected blood.

Press the **Continue** button to continue the treatment pause.



The optical detector has detected blood.

The blood pump is stopped.

➢ Connect the return line to the patient.

➢ Press the **Start** button to start the treatment.

Balancing is switched on.
Anticoagulation is switched on.

4.6.3.2 Treatment pause without blood reinfusion

Warning

Risk of contamination as a result of long dwell time of blood in the tubing system

Risk of haemolysis as a result of a crushed tubing system

Risk of blood loss as a result of clotting

➢ Taking local rules and regulations into account, a treatment pause without blood reinfusion should be kept as short as possible.

A short treatment pause is defined as lasting no more than 10 minutes. The treatment pause can be extended for a further 10 minutes, but only after confirmation by the operator.
If the treatment pause is expected to last longer, a treatment pause with blood reinfusion must be selected instead.



➢ Press the **NaCl solution** button to start a treatment pause using NaCl solution.

Or

➢ Press the **Recirc. connector** button to start a treatment pause using the recirculation connector.

Press the **Back** button to return to the Prepare for treatment pause screen.

● Circulation with NaCl solution



➢ Press the **Stop** button to stop the blood pump.

The blood pump is stopped.
Balancing is switched off.
Anticoagulation is switched off.

Press the **Back** button to return to the Prepare for treatment pause without blood reinfusion screen.



➢ Connect the access and return lines to an NaCl solution bag.

➢ Press the **Start** button to start the treatment pause.

The blood flow is automatically limited to 100 ml/min if it was set to more than 100 ml/min for treatment.
Balancing remains switched off.
Anticoagulation remains switched off.

● **Circulation with recirculation connector**



➢ Press the **Stop** button to stop the blood pump.

The blood pump is stopped.
Balancing is switched off.
Anticoagulation is switched off.

Press the **Back** button to return to the Prepare for treatment pause without blood reinfusion screen.



➢ Connect the access and return lines to the recirculation connector.

➢ Press the **Start** button to start the treatment pause.

The blood flow is automatically limited to 100 ml/min if it was set to more than 100 ml/min for treatment.
Balancing remains switched off.
Anticoagulation remains switched off.

The pressure test for testing the connections of the recirculation connector will start automatically.

If the pressure test is completed successfully, the treatment pause will start automatically.



The treatment pause is running.

The elapsed time is displayed.

➢ Press the **Preparation** button to begin patient connection.

- **Prepare to connect the patient**

➢ Press the **Confirm** button to confirm the correct identity of the patient.

Press the **Continue** button to continue the treatment pause.



➢ Connect the access and return lines to the patient.

➢ Press the **Start** button to start the treatment.

Balancing is switched on.
Anticoagulation is switched on.

Press the **Continue** button to continue the treatment pause.

4.6.4 Switching balancing off/on

Note

A substituate bolus is not possible if balancing is switched off.

If balancing remains switched off for more than 10 minutes, a warning is issued.

Note

If balancing is switched off during a treatment with Ci-Ca anticoagulation, the calcium substitution is stopped. The citrate supply continues running until the message "Balancing switched off" is displayed.

If balancing remains switched off, the citrate supply will be stopped after a further 6 minutes.

When balancing is switched on, Ci-Ca anticoagulation starts automatically.

➢ To switch balancing off, select the **Switch off balancing** menu option.

The balancing scales in the status bar will turn yellow.

➢ To switch balancing on, select the **Switch on balancing** menu option.

The balancing scales in the status bar will turn green.

4.6.5 Change syringe

Note

If the syringe change takes longer than 5 minutes, a message will be displayed.



➢ Select the **Change syringe** menu option.

➢ Change the syringe according to the instructions.

Balancing is switched off.

➢ Press the **Exit** button to return to the treatment screen.

Treatment will be continued with the heparin rate set. Balancing is started automatically.

4.6.6 Care mode is active

The Care mode temporarily reduces the blood flow and extends the alarm limit windows to allow patient care procedures to be performed.

➢ Select the **Care** menu option.

The blood flow is reduced to 40 ml/min.
Balancing is switched off.
Anticoagulation is switched on.
The upper limits of the pressures are monitored.

➢ To continue with the treatment, press **Continue**.

Treatment is continued, with the blood flow rate previously set for treatment.

After a blood volume of 200 ml has been delivered, a screen prompt appears.

➢ To repeat the Care mode, press **Repeat**.

➢ To continue with the treatment, press **Continue**.

Treatment is continued, with the blood flow rate previously set for treatment.

4.6.7 Switching between predilution and postdilution

Note

The Ci-Ca postCVVHDF treatment option is a pure postdilution treatment. Switching to predilution is not permitted during a Ci-Ca postCVVHDF treatment. For this treatment option, switching to predilution is only possible if the citrate anticoagulation is switched off first. However, citrate anticoagulation cannot be reactivated in this case, except if the treatment mode is switched from predilution back to postdilution first.

➢ Select the **Switch to predilution/postdilution** menu option.

➢ Reconnect the substituate line according to the instructions.

Balancing is stopped.

➢ Press the **Confirm** button to confirm the switchover.

Press the **Cancel** button to cancel the process.

4.6.8 Bag change (substituate/dialysate/filtrate)

Warning

Risk of circulatory disturbance as a result of excessive fluid removal

➢ After emptying the filtrate bag, make sure the drain valve is closed tight and not dripping.

Note

Bags must only be changed after selecting the **Bag change** menu option.

If the bag change takes longer than 10 minutes, a message will be displayed.



➢ Select the **Bag change** menu option.

➢ Change bags according to the instructions.

Balancing is switched off.
Make sure you load the solutions onto the correct scales.
Observe the colour coding of the connectors.

➢ Visually check that the tubing systems are free of air.

If there is still air in any of the tubing systems:

➢ Press the appropriate **Deaerate** button for the tubing systems concerned.

➢ Press the **Exit** button to return to the treatment screen.

Treatment is continued with the current weight of each changed bag. Balancing is started automatically.

4.6.9 Ci-Ca information

➢ Select the **Ci-Ca information** menu option.

The following tabs can be selected:
– Solutions
– Acid-base status

The **Solutions** tab contains information on the required solutions.

➢ Press the **Back** button to return to the **Menus** screen.



The **Acid-base status** tab contains information on the effects on the acid-base balance.

➢ Press the **Back** button to return to the **Menus** screen.

4.6.10 Ca bag change

Note

If the bag change takes longer than 2 minutes, a message will be displayed.



➢ Select the **Ca bag change** menu option.

➢ Change bags according to the instructions.

Balancing is stopped automatically.
The calcium pump is stopped.
The citrate pump continues running.

➢ Press the **Exit** button to return to the treatment screen.

Treatment is continued with the new volume of the changed bag.

Press the **Back** button to cancel the bag change.

As soon as the screen is closed, balancing is automatically switched on and the calcium pump starts.

4.6.11 Citrate bag change

Note

If the bag change takes longer than 2 minutes, a message will be displayed.



➢ Select the **Citrate bag change** menu option.

➢ Change bags according to the instructions.

Balancing is stopped automatically. The Ci-Ca pumps are stopped.

➢ Press the **Exit** button to return to the treatment screen.

Treatment is continued with the new volume of the changed bag.

Press the **Back** button to cancel the bag change.

As soon as the screen is closed, balancing is automatically switched on and the Ci-Ca pumps start.

4.6.12 Switching off Ci-Ca anticoagulation

Warning

Risk for the patient as a result of wrong composition of the solutions

There is a risk of hypocalcaemia.

➢ If Ci-Ca anticoagulation is switched off, CVVHD or CVVHDF treatment must only be continued or performed with a calcium-containing solution.

The following must be observed when Ci-Ca anticoagulation is switched off:

– It is mandatory that the solution bags be changed
– An alternative anticoagulation method must be selected by the operator
– The Ci-Ca lines must not be removed from the pumps until the treatment has ended and the patient has been completely disconnected



➢ Select the **Switch off Ci-Ca anticoagulation** menu option.

➢ Press **Yes** to switch off the citrate anticoagulation.

Press **No** to continue the treatment.



➢ Press the **Confirm** button to go to the **Bag change** menu screen.

➢ Change bags according to the instructions and exit.

4.6.13 Switching on Ci-Ca anticoagulation

Warning

Risk for the patient as a result of wrong composition of the solutions

There is a risk of hypercalcaemia.

➢ If Ci-Ca anticoagulation is switched on, CVVHD treatment must only be continued or performed with a calcium-free solution.

➢ If Ci-Ca anticoagulation is switched on, CVVHDF treatment must only be continued or performed with a calcium-free dialysate and a calcium-containing substituate.

Warning

Risk for the patient as a result of a disorder of the electrolyte balance

There is a risk of hypocalcaemia or hypercalcaemia.

➢ The post-filter calcium concentration must be checked 5 minutes after switching on the Ci-Ca anticoagulation and at regular intervals afterwards.

Note

Check that the citrate and calcium solutions have the correct concentration in each case.

Make sure the levels in the citrate and calcium drip chambers are between the markings.

➢ Select the **Switch on Ci-Ca anticoagulation** menu option.

➢ Press **Yes** to switch on the citrate anticoagulation.

Press **No** to continue the treatment.



➢ Press the **Confirm** button to go to the **Bag change** menu screen.

➢ Change bags according to the instructions and exit.

4.6.14 Plasma volume calculation / Target volume input (TPE only)

➢ Select the **Plasma volume** menu option.

➢ Enter the patient data for calculating the plasma volume (PV).

The plasma volume for treatment (PV factor) is calculated and displayed.

The calculated plasma volume is displayed in the context-specific information when entering the target volume.

➢ Press the **Back** button to return to the **Menus** screen.

4.6.15 Switching blood leak monitoring off (TPE only)

Warning

Risk for the patient due to haemolysis or blood loss / risk of blood loss due to bypassed blood leak detector

When the blood leak safety system is bypassed, monitoring for haemolysis or blood loss is deactivated temporarily or for the entire treatment.

➢ In this case, the operator is responsible for the patient's safety.

➢ Especially when treating permanently haemolytic plasma, look for additional dark colouration in the plasma circuit in the event of a blood leak.

Note

If the message **Blood leak detected** is pending, the treatment option TPE allows you to deactivate the safety system. This means that monitoring for haemolysis and blood leaks is cancelled for the duration of the current treatment. The safety system is reactivated when the device is switched on again.

Note

If during the observation phase with the blood leak detector deactivated it is noted there is no more haemolysis, it is strongly recommended to switch on the blood leak monitoring again.

Note

If a blood leak is detected during treatment with the safety system deactivated, the message **Blood leak detected** still has to be acknowledged.



A blood leak message is pending:

➢ In the menu, select **Switch blood leak monitoring off**.

➢ Press **Confirm** to switch the blood leak monitoring off.

The deactivation of the blood leak monitoring is indicated in the treatment screen.

Look for additional dark colouration in the plasma line in the event of a blood leak.

Monitoring can be reactivated at any time in the Treatment menu.

4.7 Histories

The following tabs can be selected:
– Balance data
– Balance history
– Events

The **Balance data** tab shows the current treatment duration and the treatment option selected at the start of treatment.

4.7.1 Balance data

The balance data shown by the device is based on the values measured by the scales, and is subject to the tolerance and error margins specified in the technical data.

4.7.1.1 CRRT



The **Balance data** tab shows detailed treatment parameters. It also shows:
Start date of treatment
Start time of treatment option
Elapsed time since the start of treatment or last balance data reset

Pressing the **Reset balance data** button will reset all the cumulative volume information recorded so far to "zero". The treatment time and the filter life will not be reset.

Balancing

Balancing = (substituate bolus volume) + (net UF volume)
Example: -2.20 l = (0.20 l) + (-2.40 l)

- If no substituate bolus was administered, the balancing value corresponds to the net UF volume.
- If a substituate bolus is administered, the corresponding amount remains in the patient, i.e., the substituate bolus volume is not extracted by the filter. This is why the balancing value needs to be adjusted accordingly.
- The administered heparin volume is extracted by the filter (both bolus and continuous volumes). This means that the total administered heparin volume does not affect the balance.
- The total administered citrate and calcium solution volume is extracted by the filter. The citrate and calcium volumes therefore do not affect the balance.
- If treatment is performed without a net UF rate, and no substituate bolus was administered, the balancing value will read "0.00 l".
- If fluid is removed from the patient without being returned, the balancing value will be negative (preceded by a minus sign).
- The balancing value can turn positive if the fluid removal is compensated by administering one or more substituate boluses. As a rule, the balancing value will either be negative or neutral.
- The calculation period of the balance data is shown under **Entire period**.
- Pressing the **Reset balance data** button will reset all the balance data to zero, and the calculation period will restart.

Treatment time

This is the effective treatment duration so far, not including messages and periods during which balancing is switched off. Pressing the **Reset balance data** button will not reset the treatment time.

Filter life

This is the total time that has elapsed since blood began flowing through the tubing system. This is normally more than the treatment time shown, since it includes periods during which the treatment time was stopped in response to messages. The filter life is not affected by a balance data reset.

Balancing error

If the total balancing error detected by the device exceeds 500 g, the treatment must be terminated. Balancing stops and cannot be continued.

4.7.1.2 TPE

The **Balance data** tab displays detailed treatment parameters. It also shows:
– Start date of treatment
– Start time of treatment option
– Time since start of treatment

Pressing the **Reset balance data** button will reset all the cumulative volume information recorded so far to "zero". The treatment time and the filter life will not be reset.

Exchanged plasma

The exchanged plasma is the plasma volume filtered off from the patient's blood and substituted by the plasma replacement solution.

The administered heparin volume is extracted by the filtrate pump (both bolus and continuous volumes). This means that the total administered heparin volume does not affect the balance.

The calculation period of the balance data is shown under "Period".

Treatment time

This is the effective treatment duration so far, not including messages during which balancing is switched off.

Filter life

The filter life is the parameter that is used to monitor how long blood has been flowing through the tubing system. This is basically the same as the treatment time, but will normally be higher, because, while the treatment time count is suspended when balancing is interrupted, the filter life count continues.

Balancing error

If the total balancing error detected by the device exceeds 500 g, the treatment must be terminated. Balancing stops and cannot be continued.

4.7.2 Balance history



The **Balance history** tab shows the balance data during a particular period of the current treatment, depending on the treatment mode.

You can enter the Date, End, and Duration to view a calculation period of your choice.

The balance data in the Balance history tab is updated every 15 minutes.

4.7.3 Events

Warning

Risk for the patient as a result of misinterpreting data

Errors in the patient-specific treatment parameters can result from misinterpreting the data shown in the Events tab if the treatment parameters are determined on this basis.

➢ The data listed under Events must not be used as a basis for diagnosis and/or therapy-related decisions.

➢ Any irregularities indicated by this data must always be verified by an independent diagnosis.

The event log lists messages and parameter settings in chronological order. The messages are colour-coded according to priority.

The list of messages shows every single occurrence of an alarm condition, with the time of occurrence, message number, and message title (the alarm system cannot be switched off).

The maximum event log capacity cannot be exhausted even by the maximum possible treatment duration. The event log contents are automatically deleted if the device starts a new patient connection.

A power failure will have no effect on the event log, provided the battery is working. In the event of a complete power failure (mains power failure and device voltage supply failure), all the entries in the event log will be lost.

Use the buttons to scroll back and forth between the individual pages of the list.

Use the buttons to jump to the beginning or end of the list.

The **Events** field allows you to filter the event list.



The **Events** field offers the following filters for the events list:
– All
– Messages
– Parameters

Press **OK** to apply your selected filter and return to the events list.

4.8 System Parameters

Note

The responsible organisation should define the most important configurable parameter settings itself (or confirm the default values) and have these set by service support as required.

The **System Parameters** menu allows you to choose device and treatment settings.

Grey menu fields can only be selected with the appropriate access authorisation (e.g. UserCard).

The access authorisation level shown in the screens in this document can differ from the level you actually have (whether unrestricted access or defined by your UserCard).

System parameters that can be edited with unrestricted access or a UserCard are listed in tables, showing the default value, the possible value range, and the required access authorisation level.

4.8.1 Access without UserCard



Menu fields that can be selected without a UserCard are:
- Pressure selection
- Device information
- Basic settings

➢ Select the menu option required.

4.8.1.1 Pressure selection



The **Pressure selection** menu option allows you to select the pressures you wish to have displayed in the Pressure / alarm history tab of the **Treatment** screen.

➢ Select the required pressures.

➢ Press the **OK** button to apply your selection.

4.8.1.2 Device information

The **Device information** menu option displays general information on the device.

For example: serial number, software version, operating hours, etc.

4.8.1.3 Basic settings

Note

After changing the date or time, the memory contents will no longer be in the correct chronological sequence, which may lead to problems in displaying the error logs, histories and event logs.

Switching the device off and back on again is recommended after changing the date or time.

After changing the language, the device must be restarted before the new language is applied.

The minimum possible value of the Sound volume range ensures that sounds emitted by the device remain audible. The sound volume adjustment only applies until the device is next switched off. When the device is switched back on, the sound volume will automatically return to the default value. The responsible organisation can only set the minimum sound volume and standard sound volume with a ServiceCard.

Tip

Local summer/winter time can be set in **Basic settings**.

The setup parameters shown in the table below can be set in the **Basic settings** menu.

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **System Parameters** screen.

Basic settings	Default value	Value range	Access level
Date	–	01.01.1999 to 31.12.2037	Unrestricted
Time	–	00:00:00 to 23:59:59	Unrestricted
Sound volume	6	Minimum sound volume up to 9	Unrestricted
Pressure history period	60 min	10 to 180 min	Unrestricted

Basic settings	Default value	Value range	Access level
Brightness	5	1 to 5	Unrestricted
Ca concentration of substituate	1.5 mmol/l	1 to 2 mmol/l	UserCard
Language	German	Depends on language package	UserCard

4.8.2 Access with UserCard



Menu fields that can be selected with a UserCard are:
– Applications
– User setup

➢ Insert the UserCard into the card slot.

➢ Select the menu option required.

4.8.2.1 Applications



The **Applications** menu can be used for entering and viewing parameters for operator training and for the patient data management system (PDMS).

➢ Press the **Back** button to return to the **System Parameters** screen.

● Training



The **Training** menu can be used to activate the OD simulation, change the alarm scheme, and create test messages.

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **Applications** screen.

Training	Default value	Value range
OD simulation	inactive	Active, Inactive
Alarm scheme	2	1 to 2
Create test message	No test message	**For alarm scheme 1:** No test message Alarm/system error Warning Advisory **For alarm scheme 2:** No test message System error High-priority alarm Medium-priority alarm Low-priority alarm High-priority advisory

- **PDMS**

The **PDMS** menu can be used to view the parameters for the patient data management system (PDMS).

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **Applications** screen.

4.8.3 User setup



The main configurable parameter values can be set in the **User setup** menu.
– Heparin
– User interface
– CRRT

➢ Press the **Back** button to return to the **System Parameters** screen.

4.8.3.1 Heparin

Note

Changes to the syringe type or the heparin bolus need to be made before the functional test is completed, so that the changes apply to the treatment that is to follow.

The **Heparin** menu can be used to set the parameters for heparin anticoagulation shown in the table below.

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **User setup** screen.

Heparin	Default value	Value range
Syringe type	0 (invalid)	Fresenius Medical Care 30 ml B. Braun Omnifix 30 ml BD Perfusion 50 ml Fresenius Injectomat 50 ml B. Braun Perfusor 50 ml B. Braun Omnifix 50 ml BD Plastipak 50 ml
Heparin OFF alarm time	1 min	0 to 10 min
Heparin bolus	1 ml	0.1 to 5.0 ml

4.8.3.2 User interface

The system parameters of the user interface shown in the table below can be set in the **User interface** menu.

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **User setup** screen.

User interface	Default value	Value range
Return delay	11 min	11 to 30 min
Button sounds	Active	Inactive, Active
Alarm scheme	2	1, 2

4.8.3.3 CRRT



The **CRRT** screen allows you to set treatment-specific parameters.
– Pressure alarm limits
– Ci-Ca anticoagulation
– General parameters
– Treatment parameters

➢ Press the **Back** button to return to the **User setup** screen.

- **CRRT pressure alarm limits**

Note

Changes to the pressure alarm limits need to be made before the first pump segment is inserted, so that the changes apply to the treatment that is to follow.



The **CRRT pressure alarm limits** menu can be used to set the pressure parameters shown in the table below.

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **CRRT** screen.

CRRT pressure alarm limits	Default value	Value range
Access pressure limit value	Symmetrical	Asymmetrical, Symmetrical
Access pressure alarm window size	200 mmHg	40 to 200 mmHg
Return pressure limit value	Asymmetrical	Asymmetrical, Symmetrical
Return pressure alarm window size	100 mmHg	40 to 200 mmHg
Pre-filter pressure limit value	Symmetrical	Asymmetrical, Symmetrical
Pre-filter pressure alarm window size	200 mmHg	40 to 200 mmHg

- **Ci-Ca anticoagulation**

Pressing **Ci-Ca anticoagulation** allows you to view the parameters for Ci-Ca anticoagulation.

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **CRRT** screen.

● General parameters, adult

Note

Changes to the "General parameters, adult" need to be made before the start of filling, so that the changes apply to the treatment that is to follow.

The **General parameters, adult** menu can be used for setting the general parameters shown in the table below that are to apply for all CRRT procedures.

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **CRRT** screen.

General parameters, adult	Default value	Value range
Rinse volume	300 ml	300 to 5000 ml
UF rinse volume	300 ml	300 to 2000 ml
Max. patient connection blood flow	100 ml/min	10 to 100 ml/min
Blood flow	100 ml/min	10 to 200 ml/min
Max. blood reinfusion flow	100 ml/min	10 to 100 ml/min
Temperature	38 °C	35 to 39 °C
Substituate bolus	100 ml	100 to 200 ml

● Treatment parameters, adult

Note

Changes to the "Treatment parameters, adult" need to be made before the start of filling, so that the changes apply to the treatment that is to follow.



The **Treatment parameters, adult** menu can be used for setting the specific treatment parameters shown in the table below for the different CRRT procedures.

Treatment options without Ci-Ca anticoagulation.
- CVVHDF
- CVVHD
- CVVH
- Pre-Post CVVH

Treatment options with Ci-Ca anticoagulation
- Ci-Ca postCVVHDF
- Ci-Ca CVVHD

➢ Press the **Back** button to return to the **CRRT** screen.

CVVHDF	Default value	Value range
Predilution substituate	1000 ml/h	600 to 4800 ml/h
Postdilution substituate	1000 ml/h	600 to 4800 ml/h
Dialysate	1000 ml/h	600 to 4800 ml/h

CVVHD	Default value	Value range
Dialysate	2000 ml/h	600 to 4800 ml/h

CVVH	Default value	Value range
Predilution substituate	1000 ml/h	600 to 4800 ml/h
Postdilution substituate	1000 ml/h	600 to 4800 ml/h

Pre-Post CVVH	Default value	Value range
Predilution substituate	1000 ml/h	600 to 4800 ml/h
Postdilution substituate	1000 ml/h	600 to 4800 ml/h

Ci-Ca postCVVHDF	Default value	Value range
Postdilution substituate	1000 ml/h	600 to 2400 ml/h
Dialysate	2000 ml/h	600 to 4800 ml/h

Ci-Ca postCVVHDF	Default value	Value range
Citrate dose	5 mmol/l	2 to 6 mmol/l
Calcium dose	1.7 mmol/l	0.1 to 3.0 mmol/l
Ca concentration of substituate	1.5 mmol/l	1 to 2 mmol/l

Ci-Ca CVVHD	Default value	Value range
Dialysate	2000 ml/h	600 to 4800 ml/h
Citrate dose	4 mmol/l	2 to 6 mmol/l
Calcium dose	1.7 mmol/l	0.0 to 3.0 mmol/l

4.8.3.4 TPE



The **TPE** menu allows you to set treatment-specific parameters:
– Pressure alarm limits
– Treatment parameters TPE

➢ Press the **Back** button to return to the **User setup** screen.

- **TPE pressure alarm limits**

Note

Changes to the pressure alarm limits need to be made before the first pump segment is inserted, so that the changes apply to the treatment that is to follow.

The **TPE pressure alarm limits** menu can be used to set the pressure parameters.

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **TPE** menu.

TPE pressure alarm limits	Default value	Value range
Access pressure limit value	Symmetrical	Asymmetrical, Symmetrical
Access pressure alarm window size	200 mmHg	40 to 200 mmHg
Return pressure limit value	Asymmetrical	Asymmetrical, Symmetrical
Return pressure alarm window size	100 mmHg	40 to 200 mmHg

- **Treatment parameters TPE**

Note

Changes to the treatment parameters TPE need to be made before the first pump segment is inserted, so that the changes apply to the treatment that is to follow.



The **Treatment parameters TPE** menu can be used for setting TPE-specific parameters.

Pressing the **Information** button will show you the changed parameters and when the changes will be applied.

➢ Press the **Back** button to return to the **TPE** menu.

Treatment parameters TPE	Default value	Value range
Rinse volume	300 ml	300 to 5000 ml
UF rinse volume	300 ml	300 to 2000 ml
Max. patient connection blood flow	100 ml/min	10 to 100 ml/min
Blood flow	100 ml/min	40 to 300 ml/min
Max. reinfusion blood flow	100 ml/min	10 to 100 ml/min
Pre-filter pressure limit value	Symmetrical	Asymmetrical, Symmetrical
Pre-filter pressure alarm window size	200 mmHg	40 to 200 mmHg

4.9 Network

4.9.1 Observe before use

Warning

Risk for the patient as a result of corrupted data

Data corruption or data loss caused by the network and the server software cannot be detected by the device. This can lead to malfunctions.

➢ The system installer must ensure that device data is processed securely, e.g., in PC software applications.

➢ The network operator must ensure that any data transferred without encryption is protected.

Note

There are special requirements for further processing of the data.

The network operator is responsible for ensuring that the network is available for the required data transfer.

Data corruption affecting the correctness, plausibility and completeness of the data that is caused by the network and the server software is not detected by the device.

Note

Only devices complying with the regulations of (DIN) EN 60950-1:2006 or IEC 60950-1:2006 must be connected to the LAN ports.

When connecting the device to Ethernet, connect the cable first to the device, then to the external network. Only the shielded Cat 5 Ethernet cable listed under Additional equipment must be used for this purpose (see chapter 8.2 on page 8-5).

Note

The network operator is responsible for the protection of data transferred without encryption.

The data transfer of alarm states via the network must not be used for the purpose of external alerts (nurse call).

Note

In normal condition, the enclosure leakage current from or between components of the system must not exceed 0.1 mA within the patient environment (according to EN 60601-1-1). This must be ensured when installing the system.

4.9.2 PDMS connection

Warning

Risk for the patient as a result of corrupted data

➢ Data transferred to a patient data management system (PDMS) must not be used as a basis for diagnosis and/or therapy-related decisions.

Warning

Risk for the patient as a result of ignored alarm signals

The reliability of alarm signal transmissions to external alarm systems cannot be guaranteed, meaning that alarms can fail to be indicated externally.

➢ Stay close enough to the device to be able to notice any alarms it emits at all times.

A shielded Cat 5 patch cable (3 metres long) is included with the multiFiltratePRO for the connection to the data network of a patient data management system. Further cables can be ordered in different lengths if required.

5 Alarm processing

5.1 Repeated confirmation of a message

For the safety systems, the relevant alarm limits and alarm conditions described in chapter 12 "Specifications", under "Balancing/dialysate circuit and safety systems" and "Extracorporeal blood circuit and safety systems", also apply.

Alarm processing changes can be made in the Setup.

Operators must stay close enough to the device to be able to notice any emitted visual or audible alarms at all times.

Warning

Risk for the patient as a result of repeated message confirmation

➢ Always correct the problem that caused the message before confirming it.

Note

When alarms and warnings occur, follow the information given in the messages, as well as any explanations given in the Help function (**?**).

If the following alarms and warnings are repeatedly confirmed without being corrected, this can endanger the patient as follows:

Alarms / warnings	Possible patient hazard
Pressure drop in the return line Access pressure and return pressure alarms	External blood leak Bleeding into tissue Haemolysis, through kinks in the tubing system
Anticoagulation alarms (e.g., heparin pump alarms)	Loss of blood through blood-clotting in the extracorporeal blood circuit Wrong dosage of anticoagulation medium
Blood leak alarms	Loss of blood into filtrate/plasma
Isolated citrate dosage with balancing switched off	Citrate accumulation/disruption of acid-base balance
Low temperature warnings	Hypothermia

5.2 Alarm schemes

Note

The alarm scheme used must be specified by the responsible organisation, and its suitability for the place of operation and the prevailing environmental conditions must be assessed.

Warning

Risk for the patient as a result of ignored alarm signals

If different alarm schemes are set for different devices, the same alarm condition can generate a different alarm response, depending on the device in use. This can lead to misinterpretation.

➢ Use the same alarm scheme for all devices.

The device features two alarm schemes. The chosen scheme is configured in the **System Parameters** menu.

Any switching between schemes must be authorised and performed by – or on behalf of – the organisation responsible for the use of the device.

The alarm scheme defines the information, warnings and alarms provided to the operator in the event of malfunctions, according to the alarm conditions.

An alarm always comprises a visual indication and an audible tone. The required information or cause of the alarm is also displayed as text on the screen.

All visual signalling of an alarm condition and priority is displayed using the operating status indicator (traffic light). This displays the appropriate colour (red, yellow, green) in a specific flashing pattern.

The audible signals generated by alarm conditions are correlated with the visual status indications. They also use a range of tone sequences and patterns of repetition to inform the operator about the priority and the relevance of the alarm condition.

Alarm scheme "one" displays a state-oriented system of alarms and corresponds to the former alarm schemes provided by the Fresenius Medical Care range of devices.

Alarm scheme "two" displays the potential danger presented by an alarm condition. It assigns a priority to every alarm and is based on the alarm standard EN 60601-1-8 for medical devices used in intensive medical care.

5.2.1 Alarm scheme one

This alarm scheme defines an absolutely unambiguous relationship between the alarm condition, device response and alarm signalling.

Basic assignment:

Alarm condition stops the blood and balancing circuits:
The operating status indicator (traffic light) is red and the device emits an audible tone.

Alarm condition stops the balancing circuit:
The operating status indicator (traffic light) is yellow and the system emits an audible tone.

In addition, this scheme also provides an operator information function: Isolated audible tone without signalling the alarm condition via the operating status indicator (traffic light).

The alarm conditions are prioritised internally. A more urgent alarm will be displayed over a less urgent alarm on the screen.

5.2.2 Alarm scheme two

This scheme is based on assigning priority levels to alarm conditions. Priorities correspond to the danger level at hand and the time before a potential hazard occurs, according to the following table:

Possible result of failing to respond to the cause of the alarm condition	Start of potential injury		
	Instant	Soon	Delayed
Death or irreversible injury	High priority	High priority	Medium priority
Reversible injury	High priority	Medium priority	Low priority
Minor injury or discomfort	Medium priority	Low priority	Low priority or no signal

The signals and tone sequences corresponding to the various priorities are assigned uniformly within medical device groups: as a result, all devices for extracorporeal blood treatment will, as a rule, have a uniform set of alarm signals.

Basic assignment:

The assignment of alarm priority to device response is as follows:

High priority:
Red flashing operating status indicator (traffic light) and repeated tone sequence of 10 beeps.

Medium priority:
Yellow flashing operating status indicator (traffic light) and repeated tone sequence of 3 beeps.

Low priority:
Yellow steady operating status indicator (traffic light) and repeated tone sequence of 2 beeps.

In addition, this scheme also provides an operator information function: Green flashing operating status indicator (traffic light) and repeated single tone.

In this way, each alarm condition is assigned a priority that defines the alarm response of the device.

5.3 High-priority alarm conditions

Since critical alarm conditions always place the device into safe mode (treatment or blood flow is stopped), high-priority alarms of this kind occur only in exceptional cases where a subsequent patient hazard remains possible despite the automatic device response.

In alarm scheme two, the following error conditions meet the requirements of a high-priority alarm:

– **Low return pressure alarm** message:
  Here, there is a possibility that the patient may have become disconnected from the device accidentally, but could still be losing blood through his or her vascular access site.
– **High access pressure alarm** message:
  Here, there is a possibility that the patient may have become disconnected from the device accidentally, but could still be losing blood through his or her vascular access site.
– Failure of the Ci-Ca pumps to detect the tubing system positioner:
  Here, there is a possibility the patient may suffer air infusion or blood loss via the Ci-Ca tubing system (line occlusion cannot be detected).

In addition, the following conditions have an elevated risk and require intensive observation and monitoring:

– Device condition following an air alarm
– Bypass condition following a blood leak alarm

Warning

Risk of blood loss as a result of clotting

If the operator fails to react properly in the event of a blood pump standstill, this can lead to clotting and the loss of the patient's blood contained in the extracorporeal circuit at the time.

➢ Correct problems that cause an alarm condition with a blood pump standstill and start the blood pump again as fast as possible.

5.4 Alarm system

Pressure monitoring

To avoid unnecessary false alarms, the alarm limit window of a pressure can be temporarily extended, disabled, or repositioned around the current pressure, following changes to relevant parameters, after pressure alarms, or stopping/starting the pumps. Such conditions are only permitted for short times, and the current pressure monitoring status is always shown by the appropriate alarm limit window colour (yellow=active, grey=inactive). The monitoring of the maximum and minimum possible pressure limits remains unaffected.

Note

The pressure alarm limits used must be evaluated to ensure they are suitable for the patient and the selected treatment option.

In doing so, special attention must be paid to any alarm settings that could limit the effectiveness of the alarm system.

Lower return pressure limit

In the event of a low return pressure alarm, the lower limit of the return pressure can be extended from +10 mmHg (default value) to -100 mmHg as necessary, depending on the setting in the Service setup. This allows treatment to be performed with very low or even negative return pressures, if necessary.
(Factory setting: extending lower return pressure limit is deactivated)

Warning

Risk of blood loss as a result of an undetectable dislocation

Setting the lower limit of the return pressure to -100 mmHg restricts the possibilities for detecting a possible dislocation of the return line.

➢ This option should be configured only in exceptional cases that are medically necessary and performed with care and under close supervision.

Warning

Risk of blood loss as a result of connection sites not closed correctly

To protect the patient from dangerous blood loss, return pressure monitoring of the extracorporeal blood circuit is used as a safety system against external blood leaks. However, pressure monitoring cannot detect an external blood leak in all cases. Particularly critical occurrences are dislocations of the connections to the catheters or small leaks in the high pressure components of the extracorporeal blood circuit.

➢ The extracorporeal blood circuit must be checked regularly for leaks while treatment is in progress, paying particular attention to all the joints of the tubing system and the return line.

Air infusion

To ensure that the stringent limit values for detecting air infusion are always maintained, you may need to restrict the maximum blood flow for low-weight patients (see chapter 12.11 on page 12-12).

Note

Air infusion limit values are dependent on blood flow and patient weight. Full sensitivity at maximum blood flow is achieved with patients weighing upwards of 45 kg.

Alarm priorities

In an alarm state, subsequent alarms of the same priority or of a lower priority are not separately signalled by the device. Subsequent alarms of a higher priority are signalled.

5.5 Response of the alarm system

- **When starting treatment or resuming treatment after an alarm**

After confirming certain error messages, the activation of new error messages from the following components is delayed, or the alarm limits are reset, while the treatment is being resumed:

Air bubble detector

Warning

Risk of air embolism as a result of air in the tubing system

➢ While bypassing the pressure monitoring system, the operator is responsible for the patient's safety.

– After starting active removal of air: 5 ml
– After the "Microbubbles detected" message: 2 minutes

The message **Microbubbles detected downstream of bubble catcher** can be overridden no more than 3 times in the course of a treatment. The next time the alarm occurs, **air removal** procedures must be performed.

Pressure displays

– The alarm limit windows of the pressures shown in the display are reactivated with a delay of up to 10 seconds.
– For the purpose of resuming treatment after pressure alarms, the alarm limit windows can be repositioned if this is cleared first.
– After a parameter change (e.g. stopping and starting the blood pump), the alarm limit windows are automatically deactivated for up to 10 seconds. In order to avoid repeat alarms, the alarm limit value is then either repositioned around the current pressure value, or kept as it is and reactivated, depending on the cause of the alarm.

- **Bypassing an alarm (temporarily deactivating an alarm)**

Warning

Risk for the patient due to haemolysis or blood loss / risk of blood loss due to bypassed blood leak detector

When the blood leak safety system is bypassed, monitoring for haemolysis or blood loss is deactivated temporarily or for the entire treatment.

➢ In this case, the operator is responsible for the patient's safety.

➢ Especially when treating permanently haemolytic plasma, look for additional dark colouration in the plasma circuit in the event of a blood leak.

Note

If the message **Blood leak detected** is pending, the treatment option TPE allows you to deactivate the safety system. This means that monitoring for haemolysis and blood leaks is cancelled for the duration of the current treatment. The safety system is reactivated when the device is switched on again (see chapter 4.6.15 on page 4-103).

The **Bypass** button allows the following active alarms to be bypassed (deactivated) for a defined period:

Alarm	Bypass time
Massive blood leak	Maximum 1 minute
Haemolysis / blood leak	Maximum 2 minutes

- **Suppressing the alarm tone (Audio paused)**

The **Audio paused** button allows the operator to pause (deactivate) the audible tone of a signalled alarm for a certain time. This is only possible for active alarms and is indicated by the LED of the **Audio paused** button.

The **Audio paused** function cannot be cancelled before time. If a new alarm occurs during this time, the audible alarm tone of the new alarm is signalled regardless.

Name	Suppress time
Audio paused (SOUND OFF)	2 minutes

5.6 Messages

Note

Each message window has a colour-coded frame. The visual and audible signalling of the messages can differ, depending on the alarm scheme used.

The **?** button can be used to access the Help function. This provides operators with further information on the possible cause as well as possible remedies.

Warning

Risk for the patient as a result of ignored alarm signals

If the sound volume of an alarm signal is set too low, background noises can prevent the operator from hearing the alarm tones.

➢ Set the sound volume so that alarm tones can be heard above any background noises.



Depending on the alarm scheme used, the messages have different window frame colours and different tones according to their priority. The sound volume of the audible alarm tone can be set in the **System Parameters** menu.

Each message window contains a short description of the problem and information on how to correct it. In some cases, problems are described with the aid of illustrations.

Each display message is identified by a number in the lower left-hand corner. If a problem cannot be corrected, this number will enable service support to provide faster assistance.

5.7 Messages during the functional test

Note

If the functional test repeatedly fails to complete successfully, the available treatment options may be restricted until the error can be corrected. Always contact service support in this case.

If the battery test is failed, no treatment will be permitted by the device.

If the battery test detects an incompletely charged battery, the device will allow a treatment to be performed. However, in the event of a mains power failure, emergency operation may be even more restricted than usual.

If the test of the **Ambient temperature sensor** is failed and treatment is started regardless, the heater performance can be significantly diminished, as only default values can be used. Additional, external heating and heat monitoring measures must be taken in this case.

If the heparin pump test fails, the heparin pump can be deactivated for the entire treatment if this can be managed without heparin anticoagulation.

5.8 UF/BF message

Note

High filtrate rates in combination with low blood flow rates may lead to an inadequate concentration of blood in the haemofilter (massive increase of the TMP). To a great extent, the blood concentration required depends on the individual filter. For this reason, there is a general risk of clotting in the capillaries.

To avoid this reaction, it is advisable to keep the UF rate for postdilution to no more than 20 % of the blood flow rate.

If an inadvisable UF/BF ratio of over 20 % is set, the UF/BF ratio display changes from green to red.



If this message is simply confirmed with the **Confirm** button, this indicates that the operator accepts this imbalance, along with the possible resultant clotting in the filter and tubing system.

It is advisable to correct this imbalance by changing the parameters.

5.9 Ratio of calcium flow to filtrate flow

The Ca flow is calculated by the system as a function of the filtrate flow (sum of the dialysate flow, substituate flow, net UF rate, citrate flow and Ca flow), or “filtrate” for short, the set Ca dose, and the concentration set in the Setup for the Ca solution being used. The calcium flow is limited by the control range of the calcium pump.

Control range of the Ca pump: 1–100 ml/h.

If the settings of the various different flow rates in combination with the required calcium dose result in a calcium flow rate that is outside the pump control range, a message will be displayed.

In this case, the operator must adjust the filtrate flow accordingly, by modifying the dialysate and/or substituate flow and, if necessary, altering the calcium dose.

Note

If the modifications performed are inadequate for bringing the calcium flow rate back within the control range of the calcium pump, the message will be repeated after some seconds.

If a calcium flow rate message is ignored and simply confirmed, the calcium pump will be operated at the maximum or minimum possible rate, depending on whether the calcium flow is too high or too low.

The message will then be repeated after no more than 2 minutes.

5.10 Ratio of citrate flow to blood flow

The citrate flow rate is calculated by the system depending on the set citrate dose, the set blood flow, and the concentration of the citrate solution used (defined in the Setup), and is limited by the control range of the citrate pump.

Control range of the citrate pump: 10–600 ml/h

If the initial settings result in a citrate flow outside the pump control range, a message will be displayed.

In this case, the operator must adjust the blood flow or, if necessary, alter the citrate dose to continue treatment.

Note

If the modifications performed are inadequate for bringing the citrate flow rate back within the control range of the citrate pump, the message will be repeated after some seconds.

If a citrate flow rate message is ignored and simply confirmed, the citrate pump will be operated at the maximum or minimum possible rate, depending on whether the citrate flow is too high or too low.

The message will then be repeated after no more than 2 minutes.

5.11 Ratio of plasma rate to blood flow

Note

High plasma rates in combination with low blood flow rates may lead to an inadequate concentration of blood in the haemofilter (massive increase of the TMP). This concentration of the blood depends on the respective filter used. For this reason, there is a general risk of haemolysis and clotting in the capillaries.

To avoid this reaction, the plasma rate can only be set to a maximum of 30 % of the blood flow.

5.12 Pressure deviation messages

5.12.1 Resetting the alarm limit windows



The actual pressure value lies outside the alarm limit window.

An audible tone is emitted.
The system is stopped.

➢ Press **Confirm** to continue with the treatment.



➢ Press **OK** to reset all the alarm limit windows.

The size and position of the limit value windows will be applied.
If the alarm limit windows are not reset, this message will erase itself, and the previous alarm limit windows will be kept as they were.

5.12.2 Reducing the access pressure



If a low access pressure alarm occurs due to an occlusion of the catheter or needle (suction to the vessel wall), the access pressure can be relieved automatically.

➢ Press the **Reduce** key to start the pressure reduction.

If the pressure has already been equalised due to the blood pump stopping, the **Confirm** button can be pressed to continue treatment.



➢ After making sure the access line is free of air, start the pressure reduction by pressing the **Confirm** button.

Press **Cancel** to cancel the process.



Treatment is resumed when the pressure reduction has been completed.

The process can be cancelled at any time by pressing **Cancel**.

5.13 Message "Air detected downstream of the bubble catcher"

5.13.1 Before beginning deaeration procedures

Warning

Risk of air embolism as a result of air in the tubing system

If deaeration procedures are not performed properly, this can lead to air infusion.

➢ Deaeration procedures must always be carried out in accordance with the instructions displayed by the device. The operator is responsible for following the instructions correctly.

➢ In addition, observe the following when performing deaeration procedures:
- Read the detailed descriptions of the messages by pressing the **?** button in each case.
- If the return pressure exceeds 40 mmHg, the pressure must first be reduced at the bubble catcher with the aid of a syringe until the device displays the next message with further instructions.
- While deaeration procedures are in progress, the blood flow rate is automatically lowered to 50 ml/min. To speed up the process of purging air pockets and microbubbles from the tubes, the blood flow rate can be raised as necessary.

5.13.2 Air detected

If air is detected in the return line downstream of the bubble catcher, this is indicated by an audible tone and a screen message.

Balancing is switched off.
The blood pump is stopped.

➢ Press **Confirm** to confirm that you have followed the instructions in the message.

5.13.3 Deaeration procedures

➢ Press **Confirm** in the confirmation prompt.



This message appears if the return pressure exceeds 40 mmHg.

➢ Follow the instructions.

The next message appears automatically as soon as the return pressure has fallen below 40 mmHg.



➢ Press **Start** to push the air out into the NaCl solution.

The blood pump is running at 50 ml/min.



Blood pump stops automatically after 100 ml.

The blood pump can also be stopped before reaching the 100 ml by pressing the **Stop** button, if the operator can no longer see any air in the system.



➢ Press **Yes** to confirm that the system is free of air.

Or

➢ Press **No** to continue removing any remaining air bubbles.

The previous message is automatically displayed.



➢ Connect the patient.

➢ Press the **Continue** button to resume the treatment.

The blood pump will run at the rate set previously.

➢ Check the blood pump rate and adjust it as necessary.

5.14 Message "Microbubbles detected downstream of bubble catcher"

5.14.1 Before removing the microbubbles

Warning

Risk of air embolism as a result of air in the tubing system

➢ While bypassing the pressure monitoring system, the operator is responsible for the patient's safety.

Warning

Risk of air embolism as a result of air in the tubing system

If deaeration procedures are not performed properly, this can lead to air infusion.

➢ Deaeration procedures must always be carried out in accordance with the instructions displayed by the device. The operator is responsible for following the instructions correctly.

➢ In addition, observe the following when performing deaeration procedures:
- Read the detailed descriptions of the messages by pressing the **?** button in each case.
- If the return pressure exceeds 40 mmHg, the pressure must first be reduced at the bubble catcher with the aid of a syringe until the device displays the next message with further instructions.
- While deaeration procedures are in progress, the blood flow rate is automatically lowered to 50 ml/min. To speed up the process of purging air pockets and microbubbles from the tubes, the blood flow rate can be raised as necessary.

5.14.2 Microbubbles detected

Note

The message can be bypassed up to 3 times in the course of a treatment, by pressing **Continue**. If microbubbles continue to be detected, deaeration procedures must be performed.



If microbubbles are detected in the return line downstream of the bubble catcher, this is indicated by an audible tone and a screen message.

➢ If there are **no microbubbles** to be seen, press the **Continue** button.

Or

➢ If there are microbubbles, follow the instructions and press **Confirm** when you have finished.

➢ Perform deaeration procedures (see chapter 5.13.3 on page 5-15).

5.15 Blood leak

Warning

Risk for the patient due to haemolysis or blood loss / risk of blood loss due to bypassed blood leak detector

When the blood leak safety system is bypassed, monitoring for haemolysis or blood loss is deactivated temporarily or for the entire treatment.

➢ In this case, the operator is responsible for the patient's safety.

➢ Especially when treating permanently haemolytic plasma, look for additional dark colouration in the plasma circuit in the event of a blood leak.

Note

If the message **Blood leak detected** is pending, the treatment option TPE allows you to deactivate the safety system. This means that monitoring for haemolysis and blood leaks is cancelled for the duration of the current treatment. The safety system is reactivated when the device is switched on again (see chapter 4.6.15 on page 4-103).



If the blood leak detector (yellow) detects blood in the filtrate line, this is indicated by an audible tone and a screen message.

Balancing is switched off.
All pumps are stopped.

➢ Press the **Bypass** button to continue treatment.

The bypass time for the blood leak detector message is 2 minutes.
1 minute, in the case of a massive blood leak.

➢ Read the help text and follow the instructions. Terminate the treatment if necessary.

5.16 Power failure (mains power failure)

5.16.1 During preparation

- **Tubing system not yet mounted**

  If a power failure occurs before the tubing system has been mounted, the device will shut down without delay.

- **Tubing system is mounted**

  The **Mains power failure** message will be displayed.
  The system is stopped completely.

  When power is restored, the message **Continue preparation** must be confirmed by pressing the **Confirm** button.

5.16.2 During treatment

Note

If the battery test detected an incompletely charged battery, emergency operation following a power failure may be even more restricted than usual.

The **Mains power failure** message will be displayed.
An audible tone is emitted (without delay).
Balancing is switched off.
The blood pump is running.
Anticoagulation is switched on.
The heater is switched off.

If the blood pump is running, emergency operation is possible for a maximum of 15 minutes.

The message is repeated every 2 minutes and must be confirmed by pressing the **Confirm** button.

When power is restored, the system will start automatically.

When the 15 minutes have expired, or if the battery has less than minimum power remaining, the blood pump is stopped and cannot be started again until power is restored.

After a further 5 minutes, or if the minimum battery power is depleted even further, the device will shut down.

In this case, terminate the treatment with manual blood reinfusion, if necessary (see chapter 5.18 on page 5-22).

5.17 Display failure

Screen goes dark or menu buttons no longer respond.

Warning

Risk for the patient as a result of a device malfunction

Treatment cannot be performed safely in the event of a display failure, as the device cannot be operated any longer.

➢ Press the **Stop Pumps** button (red).
The pumps will be stopped.

➢ Perform a manual blood reinfusion (see chapter 5.18 on page 5-22).

5.18 Manual blood reinfusion

Warning

Risk of air embolism as a result of air in the tubing system

If the manual blood reinfusion is not performed properly, this can lead to air infusion.

➢ The following must be observed when performing a manual blood reinfusion:

– Turn the emergency operation hand crank of the blood pump only in the direction indicated by the arrow, to avoid the risk of air infusion via the access line.

– Visually check that return line is free of air, to avoid the risk of air infusion.

Warning

Risk of blood loss and risk of air embolism as a result of manual blood reinfusion

➢ The instructions for performing a manual blood reinfusion must be strictly followed.

➢ Disconnect the access line from the patient and connect it to the NaCl solution. Break the cone, if necessary.

➢ Remove the access and return lines from their respective line occlusion clamps.

➢ To return the blood to the patient, use the hand crank integrated in the pump rotor.

Turn only clockwise, as shown on the rotor.

➢ Keep visually checking that the tube is free of air.

5.19 Manually opening the pressure measurement units

Warning

Risk of blood loss as a result of damaged tubing systems

➢ Before manually opening the pressure measurement units, the pressure in the tubing system will need to be reduced at the bubble catcher, with the aid of an empty syringe.

The pressure measurement units will need to be manually opened to remove the tubing system in the following situations:

– Power failure and empty battery
– Defective pneumatics

In this case, terminate the treatment with manual blood reinfusion, if necessary (see chapter 5.18 on page 5-22).

Requirements

– Syringe
– Emergency venting set
  Adapter
  Check valve

➢ Use the adapter to connect an empty syringe to the Luer lock connector on the rear of the device.

➢ Repeatedly build up pressure with the aid of the syringe, until the pressure measurement units open.

6 Cleaning / disinfection

Warning

Risk of cross-contamination as a result of insufficient disinfection

Risk of contamination as a result of insufficient disinfection

There is a risk of spreading germs.

➢ A surface disinfection must always be performed after each treatment.

➢ Disinfections of the device must be performed according to the instructions in the Instructions for Use. If unsuitable procedures are followed, effective disinfection or cleaning is not possible.

➢ Only the disinfectants and cleaning agents listed in chapter 6 must be used.

6.1 Surface cleaning / surface disinfection

Switch the device off and disconnect it from any external power sources before cleaning and disinfection. A surface disinfection must always be performed after each treatment. Make sure that the area around sensors and actuators is clean to avoid an impairment of the functions.

Dirt, for example, blood and filtrate, must be removed immediately with a disposable paper towel dampened with disinfectant. The surface must then be disinfected a second time by wiping or spray disinfection. Do not use any sharp objects for cleaning.

6.1.1 Cleaning the display



➢ Press the **monitor symbol** on the **Preparation** button for approximately 3 seconds.

This "deactivates" the display.

➢ Clean the display.

Note

The "deactivated" display will automatically become active once more as soon as a message is displayed.



➢ Press the **monitor symbol** on the **Preparation** button for approximately 1 second.

This "reactivates" the display.

6.1.2 Detachable device components

The following device components can be detached for easier cleaning:
– Pump rotors (blood pump, dialysate pump, substituate pump, filtrate pump)
– Scale trays

6.2 Disinfectants and cleaning agents

The following disinfectants have been tested for use on the device. The recommended applied concentrations correspond to the specifications of the manufacturers of the disinfectants at the time of publishing these Instructions for Use. Always check the application concentration against the current product information of the disinfectants.

Incidin Extra N

Active substance base: aldehyde-free preparation
Disinfection type: wipe disinfection
Applied concentration: 1 % in water
Acting time: 15 min

ClearSurf

Active substance base: cationic surfactants
Disinfection type: wipe disinfection
Applied concentration: 0.5 % in water
Acting time: 60 min
Applied concentration: 1 % in water
Acting time: 15 min

ClearSurf Wipes

Ready-to-use wipes
Active substance base: cationic surfactants
Disinfection type: wipe disinfection
Applied concentration: 1 % in water
Acting time: 15 min

Freka-NOL

Active substance base: ethanol
Disinfection type: wipe disinfection
Applied concentration: undiluted
Acting time: 1 min
Recommended use: Freka-WIPES disposable cloths soaked with Freka-NOL in their dispenser.

7 Functional description

7.1 Device functions

Extracorporeal blood circuit

The device features a pump-controlled extracorporeal blood circuit. The extracorporeal blood circuit is monitored during treatment.

Balancing

Roller pumps are used to convey the filtrate, substituate, dialysate, plasma, and rinsing solutions, depending on the procedure. The balancing is gravity-controlled using integrated scales with which each of the fluids necessary for a treatment are weighed. The two integrated heaters reliably control the set treatment temperature, even at high flow rates.

Handling

The operating concept with its clear menu structure allows for easy operation. Treatment parameters and menu buttons are displayed on a large screen. The device is operated with a touchscreen, e.g., for selecting fields displayed on the screen.

Functional test

As soon as it is switched on, the device performs an automatic functional test of all operating, display, monitoring, and alarm functions to ensure their proper operation. Some of these tests are repeated at intervals during treatment.

Regional citrate anticoagulation

The integrated citrate pump permits a continuous regional anticoagulation of the patient's blood in the extracorporeal blood circuit by infusing a citrate solution into the access line.

During a Ci-Ca treatment a corresponding amount of calcium is removed from the patient's blood. For this reason, a calcium substituate is infused into the return line by the integrated calcium pump.

7.2 Description of therapies

7.2.1 Continuous renal replacement therapy

Indication

The different continuous renal replacement therapies (CRRT) can be indicated whenever the removal of urinary excreted substances is required in addition to volume removal. This also applies if electrolyte imbalances or disorders of the acid-base balance are to be corrected.

Vascular access

The CRRT therapies use a veno-venous vascular access, i.e., blood is both removed from and, after treatment, reinfused into a vein of the patient. Usually a large-bore central venous double-lumen catheter is used for the vascular access.

CRRT types

Continuous haemofiltration (CVVH) can be performed as predilution CVVH (Pre CVVH for short) or as postdilution CVVH (Post CVVH for short). In addition, the device also supports CVVH with both pre-filter and post-filter dilution (Pre-Post CVVH for short).

Continuous veno-venous haemodialysis (CVVHD) is a further option.

Finally, the device offers the possibility of a combined haemofiltration and haemodialysis procedure (CVVHDF). Depending on where the substituate is infused into the extracorporeal circuit, there are two types of CVVHDF procedure (Pre CVVHDF and Post CVVHDF for short).

The type of CRRT procedure and the patient-specific parameters are individually prescribed by the attending physician in each case.

Effectiveness of CRRT therapies

As for intermittent dialysis procedures, the effectiveness of a CRRT therapy depends on the molecular weight of the solutes that need to be removed. The prescription parameters are specific to each treatment procedure, and directly influence the effectiveness of the treatment. Solute clearance must result from the diffusion or convection mechanisms applied, or a combination of both.

The main prescription parameters for a CRRT treatment are as follows:
- Blood flow
- Dialysate flow
- Ultrafiltration goal or continuous net UF rate
- Substituate flows, for haemofiltration or haemodiafiltration
- Dialyser attributes (e.g., the effective surface area and the dialyser mass transfer coefficient, among other attributes)

Clotting risk in CRRT therapies

The risk of clotting in the extracorporeal blood circuit differs according to the individual CRRT procedures. With a diafiltration procedure using postdilution, there is a haemoconcentration of the blood at the filter outlet, depending on the ratio of the filtrate flow to the blood flow and on the patient's haematocrit. This is assumed to be the reason for the shorter service lives of the filters in Post-CVVH compared to Pre-CVVH.

7.2.1.1 CVVH

Post CVVH

Postdilution means that the "substituate" or replacement fluid is not infused into the extracorporeal blood circuit until after the filter, i.e., after the ultrafiltrate has been removed. As a consequence, the blood at the filter outlet has a higher haemoconcentration (higher concentration of cells and proteins). This can increase the risk of clotting in the extracorporeal blood circuit. To avoid a critical haemoconcentration, the filtration fraction should not be set at more than 30 %, relative to the blood flow rate and taking the treatment parameters determined by the physician into account. A filtration fraction > 20 % is always displayed on the device.

Pre CVVH

Predilution means that the substituate is infused into the extracorporeal blood circuit before the blood reaches the filter, thus reducing the risk of a critical haemoconcentration. However, the disadvantage of this procedure is that the blood in the filter is diluted, which leads to a lower clearance of toxins per litre of ultrafiltrate than with Post-CVVH. If the same volume of substituate is used predilution is less effective than postdilution. The disadvantage caused by this dilution can be reduced by increasing the blood flow rate. Alternatively, It is always possible to select a different CRRT therapy.

Pre-Post CVVH

Pre CVVH + Post CVVH => Pre Post CVVH

This reduces the disadvantages and combines the advantages of the separate procedures. Depending on the application conditions, the treatment can thus be optimised.

Fig.: Flow diagram of the different CVVH procedures



Legend

1 Line occlusion clamp (red)
2 Blood pump

3 Filter
4 Fill level detector
5 Optical detector
6 Air bubble detector
7 Line occlusion clamp (blue)
8 Scale
9 Filtrate
10 Filtrate pump
11 Blood leak detector (yellow)
12 Substituate pump
13 Heater (white)
14 Substituate
15 Scale
16 Postdilution port
17 Predilution port

Treatment data

CVVH	Min.	Max.	Resolution	Unit
Blood flow	0	500	10	ml/min
Net UF rate	Off / 10	990	10	ml/h
Continuous heparin administration	Off / 0.5	25	0.1	ml/h
Anticoagulation bolus	Off / 0.1	5	0.1	ml
Substituate	600	4800	10	ml/h
Temperature	Off / 35	39	0.5	°C

Fig.: Pre-Post CVVH flow diagram



Legend

1	Line occlusion clamp (red)
2	Blood pump
3	Filter
4	Fill level detector
5	Optical detector
6	Air bubble detector
7	Line occlusion clamp (blue)
8	Scale
9	Filtrate
10	Filtrate pump
11	Blood leak detector (yellow)
12	Postdilution substituate pump
13	Heater (white)
14	Substituate
15	Scale
16	Predilution substituate pump
17	Heater (green)
18	Postdilution port
19	Predilution port

Treatment data

Pre-Post CVVH	Min.	Max.	Resolution	Unit
Blood flow	0	500	10	ml/min
Net UF rate	Off / 10	990	10	ml/h
Continuous heparin administration	Off / 0.5	25	0.1	ml/h
Anticoagulation bolus	Off / 0.1	5	0.1	ml
Predilution substituate	600	4800	10	ml/h
Postdilution substituate	600	4800	10	ml/h
Temperature	Off / 35	39	0.5	°C

7.2.1.2 CVVHD

With CVVHD, the blood is purified mainly through dialysis. In addition to solute clearance through diffusion, which is the main process for removing toxins in this case, a certain amount of clearance through convection also takes place within the filter, by volume removal. Under typical CRRT conditions, where the blood flow is considerably higher than the dialysate flow, an almost complete saturation of the dialysate with toxins of a low molecular weight, such as urea and creatinine, can normally be expected. The efficiency of a CVVHD procedure is therefore comparable with that of a Post CVVH procedure. As the speed of diffusion is relative to the molecular weight, the full saturation of the dialysate with larger, so-called middle-molecular weight solutes may not be achieved, depending on the blood and dialysate flow rates set. The clearance rate achieved for these substances is thus lower than with Post CVVH (if the same dialysate and substituate quantities are used). This disadvantage of CVVHD can be compensated at least partially through the use of filters with a large active surface and High-Flux membranes. The advantage of CVVHD lies in the possibility of setting a lower blood flow than in Pre-CVVH and Post-CVVH.

Fig.: CVVHD flow diagram



Legend

1 Line occlusion clamp (red)
2 Blood pump
3 Filter
4 Fill level detector
5 Optical detector
6 Air bubble detector
7 Line occlusion clamp (blue)
8 Scale
9 Filtrate
10 Filtrate pump
11 Blood leak detector (yellow)
12 Heater (green)
13 Dialysate pump
14 Dialysate
15 Scale

Treatment data

CVVHD	Min.	Max.	Resolution	Unit
Blood flow with heparinisation	0	500	10	ml/min
Net UF rate	Off / 10	990	10	ml/h
Blood flow with Ci-Ca anticoagulation	0	200	10	ml/min
Citrate dose	2	6	0.1	mmol/l
Calcium dose	0	3	0.1	mmol/l
Continuous heparin administration	Off / 0.5	25	0.1	ml/h
Anticoagulation bolus	Off / 0.1	5	0.1	ml
Dialysate	600	4800	10	ml/h
Temperature	Off / 35	39	0.5	°C

7.2.1.3 CVVHDF

Combination of the basic therapies

These basic therapies can be combined in pairs:

Pre CVVH + CVVHD => Pre CVVHDF

Post CVVH + CVVHD => Post CVVHDF

This reduces the disadvantages and combines the advantages of the separate procedures. Depending on the application conditions, the treatment can thus be optimised. For example, Post CVVHDF makes it possible to select the highest possible filtrate flow relative to the achievable blood flow and still keep haemoconcentration in the filter to within acceptable limits. The dialysis component of a Post CVVHDF procedure further increases the treatment efficiency, without additional blood flow requirements, as the filtration fraction is not affected by this.

Fig.: Post CVVHDF (Ci-Ca) flow diagram



Legend

1 Line occlusion clamp (red)
2 Blood pump
3 Filter
4 Fill level detector
5 Optical detector
6 Air bubble detector
7 Line occlusion clamp (blue)
8 Scale
9 Filtrate
10 Filtrate pump
11 Blood leak detector (yellow)
12 Substituate pump
13 Heater (white)
14 Substituate
15 Scale
16 Dialysate pump
17 Heater (green)
18 Dialysate
19 Scale
20 Postdilution port

Fig.: Flow diagram of the different CVVHDF procedures



Legend

1 Line occlusion clamp (red)
2 Blood pump
3 Filter
4 Fill level detector
5 Optical detector
6 Air bubble detector
7 Line occlusion clamp (blue)
8 Scale
9 Filtrate
10 Filtrate pump
11 Blood leak detector (yellow)
12 Substituate pump
13 Heater (white)
14 Substituate / dialysate
15 Scale
16 Dialysate pump
17 Heater (green)
18 Postdilution port
19 Predilution port

Treatment data

CVVHDF	Min.	Max.	Resolution	Unit
Blood flow with heparinisation	0	500	10	ml/min
Net UF rate	Off / 10	990	10	ml/h
Blood flow with Ci-Ca anticoagulation	0	200	10	ml/min
Citrate dose	2	6	0.1	mmol/l
Calcium dose	0.1	3	0.1	mmol/l
Continuous heparin administration	Off / 0.5	25	0.1	ml/h
Anticoagulation bolus	Off / 0.1	5	0.1	ml
Substituate	600	4800	10	ml/h
Substituate with Ci-Ca anticoagulation	600	2400	10	ml/h
Dialysate	600	4800	10	ml/h
Temperature	Off / 35	39	0.5	°C

7.2.2 Therapeutic plasma exchange

Indication

Therapeutic plasma exchange (TPE) is used when pathogenic plasma components can only be removed with the highly permeable membranes of special plasma filters due to their size or specific binding to large plasma proteins, such as albumin.

Autoimmune diseases, such as Guillain-Barré syndrome, are an example of the group of diseases for which the removal of autoantibodies by TPE is an accepted therapeutic option.

In some cases, it is also attempted to supply normal plasma components with the infused replacement solution.

Types of TPE

A TPE can be performed by centrifugation or by membrane plasma separation. The device system supports implementation in the form of membrane plasma separation.

Extracorporeal blood circuit and balancing

The extracorporeal blood circuit in TPE differs only slightly from that in CRRT. The balancing circuit is basically structured the same as for Post CVVH. However, to ensure gentle warming of the replacement solution, which may be donor plasma, there are two heater bags connected in series to minimise risks due to local overheating of the plasma.

Plasma filters

In TPE, filters with a particularly permeable membrane are used that are permeable for all plasma components, but not the cellular components of the blood and are therefore known as plasma filters.
In TPE, the plasma including the components to be removed is filtered off and a suitable replacement solution is infused using gravimetric balancing.

Replacement solution

Because the removed plasma contains colloido-osmotically active proteins such as albumin,
usually iso-oncotic colloidal replacement solutions are used.

Frequently, an iso-oncotic human albumin solution is used. A lack of coagulation factors or other essential plasma components occurring as a result of the plasma exchange or occurring independently can be counteracted by using Fresh Frozen Plasma (FFP) in whole or in part (then preferably towards the end of treatment) as a replacement solution.

In some cases, such as thrombotic thrombocytopaenic purpura (TTP, also referred to as Moschkowitz syndrome), in addition to the removal of pathological plasma components, the infusion of normal plasma components with the replacement solution is essential. In such cases, FFP is generally recommended as a replacement solution, or alternatively cryoprecipitated plasma.

Efficacy

In TPE, typically 1 to 2 times the plasma volume of the patient is exchanged.

Because of the decrease in the plasma concentration of the substances to be removed in the course of the TPE treatment, TPE is terminated after the prescribed plasma exchange. If and as long as clinically necessary, further TPE treatments will be administered on one of the following days.

Fig.: TPE flow diagram



Legend

1	Line occlusion clamp (red)
2	Blood pump
3	Filter
4	Fill level detector
5	Optical detector
6	Air bubble detector
7	Line occlusion clamp (blue)
8	Scale
9	Filtrate
10	Filtrate pump
11	Blood leak detector (yellow)
12	Substituate pump
13	Heater (white) and heater (green)
14	Plasma
15	Scale

Treatment data

TPE	Min.	Max.	Resolution	Unit
Blood flow	10	300	10	ml/min
Ratio of plasma rate to blood flow	0	30	1	%
Plasma	Off / 10	50	1	ml/min
Continuous heparin administration	Off / 0.5	25	0.1	ml/h
Anticoagulation bolus	Off / 0.1	5	0.1	ml
Target volume	Off / 10	39990	10	ml
Temperature	Off	On	-	-

Warning

Risk for the patient due to heat loss via the extracorporeal blood circuit if the temperature of the plasma replacement solution is too low

Haemodynamic instability due to the reduction in core body temperature

- ➢ Preheat plasma replacement solution to at least 20 °C before treatment.
- ➢ Conduct treatment at a room temperature of at least 20 °C.
- ➢ Switch on heater.
- ➢ Avoid drafts during treatment.
- ➢ Regular monitoring of patient temperature.
- ➢ If necessary, take measures to maintain patient temperature, such as use of electric blankets.

Note

In order to avoid damage to the proteins in donor plasma, the heating power in TPE treatments has been reduced. The temperature at the insertion site depends among other things on the ambient temperature (see chapter 12on page 12-1).

7.3 Anticoagulation

Requirement for anticoagulation

When performing extracorporeal blood treatments, anticoagulation of the blood is generally required. It prevents blood-clotting in the extracorporeal blood circuit and ensures an adequate operating life of the filters used.

7.3.1 Systemic anticoagulation

Systemic anticoagulants

Different substances can be used for anticoagulation. The decision to employ unfractionated or fractionated heparin, heparinoids, direct thrombin inhibitors, or pentsaccharides is made by the attending physician on a case basis.

Integrated heparin pump for anticoagulation

A heparin pump for the continuous infusion of anticoagulants is integrated in the device. This pump can also be used to administer a bolus when required. An infusion line for anticoagulants is included in the tubing system.

Fig.: Schematic of systemic anticoagulation



Legend

1 Line occlusion clamp (red)
2 Blood pump
3 Filter
4 Fill level detector
5 Optical detector
6 Air bubble detector
7 Line occlusion clamp (blue)
8 Heparin pump

7.3.2 Regional citrate anticoagulation

Warning

Risk of contamination as a result of unsuitable infusion solutions

➢ For the treatment modes CVVHDF and CVVH, only solutions that are suitable for infusion must be used.

Warning

Risk for the patient as a result of a disorder of the electrolyte balance

There is a risk of hypocalcaemia or hypercalcaemia.

➢ The post-filter calcium concentration must be checked 5 minutes after switching on the Ci-Ca anticoagulation and at regular intervals afterwards.

Warning

Risk for the patient as a result of incorrect Ci-Ca anticoagulation and changes in the patient's acid-base balance

Risk for the patient as a result of a disorder of the electrolyte balance

➢ Observe the instructions for taking a sample in chapter 7.

➢ In the event of widely varying measurement values of the electrolytes and the acid-base balance, consult a physician.

Warning

Risk for the patient as a result of incorrect Ci-Ca anticoagulation and changes in the patient's acid-base balance

Risk for the patient as a result of a disorder of the electrolyte balance

➢ Check that the citrate and calcium solutions used correspond to the types selected in the Setup and shown on the screen.

Warning

Risk for the patient as a result of a disorder of the electrolyte balance

With citrate anticoagulation, if balancing is stopped for long periods of time or interrupted too frequently, this can result in an undesirable citrate accumulation if citrate anticoagulation is continued unchanged, as the calcium flow and the filtrate flow are linked and calcium substitution is therefore also interrupted whenever the filtrate flow is interrupted.

➢ Keep balancing interruptions to a minimum if citrate flow continues.

7.3.2.1 Basic information on citrate anticoagulation

Regional citrate anticoagulation

In conjunction with calcium-free dialysate, exogenous citrate for regional (localised) anticoagulation can be infused into the extracorporeal blood circuit only.

Effect of the citrate

The citrate binds the ionised calcium that is present in the blood and forms a calcium-citrate complex. The resulting reduction of the ionised calcium concentration inhibits several steps in the coagulation cascade and the activation of complements. The quantity of citrate which is inevitably infused into the body is quickly metabolised by most patients.

Limits of citrate anticoagulation

Citrate anticoagulation does not prevent blood-clotting in the extracorporeal blood circuit in all cases. The fundamental causes are complex and even divergent, depending on the underlying disease and comorbid conditions.

For patients with systemic blood clot activation, e.g., HIT or antiphospholipid antibody syndrome, a systemic anticoagulation can therefore be indicated in addition to the citrate anticoagulation.

Mutually compatible solutions in citrate anticoagulation

The different continuous renal replacement therapies with regional citrate anticoagulation described in the literature can differ considerably, also with regard to the adaption of the treatment to the specific patient.

Regional citrate anticoagulation requires mutually compatible solutions (solutions with citrate, other CRRT solutions depending on the procedure, solutions with calcium). These solutions must also be used with matching flows to minimise the risk of electrolyte balance and acid-base balance disorders.

Use only approved combinations of mutually compatible solutions for regional citrate anticoagulation.

The following is a specific description of the treatment therapies Ci-Ca CVVHD and Ci-Ca Post-CVVHDF of the device.

Differences Ci-Ca CVVHD and Ci-Ca postCVVHDF

Differing from Ci-Ca CVVHD, an additional calcium-containing, bicarbonate-buffered substituate is infused in postdilution when performing a Ci-Ca postCVVHDF treatment. The haemoconcentration at the filter outlet should, if possible, not exceed 20 %. The substituate flow can, for example, be selected as 1/6 of the blood flow (16.7 ml/min = 1000 ml/h with a blood flow of 100 ml/min). With regard to the values set on the display, this corresponds to a ratio of "10:1".

If the haemoconcentration at the filter outlet exceeds 20 % due to the required Ca flow and a clinically required ultrafiltration, the substituate flow can be reduced so that this limit is not exceeded.

As a result of the substituate flow, there are differences between Ci-Ca CVVHD and Ci-Ca postCVVHDF regarding the control of the acid-base balance and selecting the appropriate citrate dose.

Laboratory tests during citrate anticoagulation

Note

It is absolutely necessary to ensure that the two measurements of the ionised calcium are not mistaken for each other.

Electrolyte checks (sodium, potassium, calcium, magnesium, phosphate, acid-base balance) must be supplemented by close monitoring of the concentration of the systemic ionised calcium concentration and the systemic acid-base balance. Usually the same systemic blood sample can be used to determine these values.

In addition, appropriate citrate anticoagulation must be checked by determining the ionised calcium in the extracorporeal blood circuit. When performing a Ci-Ca treatment, this is checked downstream of the filter.

Immediate availability of the measurement of the systemic ionised calcium and of the acid-base balance

Note

During the treatment, the analyser for determining the acid-base balance and the concentrations of ionised calcium must be located in the immediate vicinity of the device, so that results are directly available.

For example in intensive care units, this can be done with an automatic blood gas analyser, which can also measure ionised calcium.

Sample collection / systemic blood sample

If the patient has an arterial access (e.g., for collecting blood samples from artificially ventilated patients or for invasive blood pressure measurement), the blood sample to check the systemic ionised calcium and the systemic acid-base balance should be taken there. Values which may have been measured for the control of a mechanical respiration can be used.

Alternatively, the sample can be collected on the venous side, if the patient does not have an arterial access. This must be taken into account in the interpretation of the acid-base values. Here a collection site separate from the extracorporeal blood circuit is recommended.

Alternatively, the blood sample can be taken slowly from the sampling site (red) of the access line while the blood pump is running.

Note

If the sampling site on the access line is used, it must be ensured that the blood pump is running while the sample is collected and that the blood sample is aspirated slowly to prevent citrate from being admixed by the citrate infusion.

In case of recirculation in the area of the catheter, blood which has just been returned and with it some citrate will enter into the aspirated blood. This addition of citrate leads to incorrect measurement values for the systemic ionised calcium.

Note

In situations presenting an increased risk for recirculation, e.g., reverse catheter connection or femoral catheter position, the sampling site on the access line should not be used. Unexpectedly low measurement values of the systemic ionised calcium of samples collected at this site should always be checked by measuring a separately collected systemic sample.

Sample collection / extracorporeal blood circuit

For a check of the ionised calcium in the extracorporeal blood circuit, the blood sample is collected from the sampling site (blue) of the return line downstream of the filter.

Frequency of laboratory tests

The systemic acid-base balance and systemic ionised calcium should be checked prior to the treatment. If there is no other clinical indication, a hypocalcaemia should be corrected before the start of the Ci-Ca treatment.

The ionised calcium downstream of the filter should be checked approximately 5 minutes after the start of the treatment to verify correct connection.

Note

If no significant reduction of the post-filter ionised calcium is detected during the first measurement performed 5 minutes after the start of the treatment, the treatment must be stopped immediately. This may be indicative of an incorrect connection, it must especially be checked that the citrate and calcium solution have not been reversed.

All three laboratory parameters must be regularly checked during the Ci-Ca treatment. The intervals necessary for these regular determinations depend on the patient's clinical situation.

Note

Whenever a situation is not clear and is possibly associated with an abnormal concentration of systemic ionised calcium or with a disturbed acid-base balance, these parameters should be checked immediately.

Magnesium

Since citrate forms a complex not only with calcium but also with magnesium, there is also a shift of protein-bound magnesium towards magnesium-citrate complexes. Compared with CRRT solutions commonly used for systemic anticoagulation, the use of a slightly higher magnesium concentration in the dialysate used or an additional infusion of magnesium may be indicated.

Sodium

Cases of hypernatraemia have been observed in connection with some variants of citrate anticoagulation. These were caused by excessive sodium concentrations in the citrate solution used, in combination with failing to adjust the sodium concentration in the HF solution / dialysate. For this reason, the Na concentration of Ci-Ca dialysates K2 and Ci-Ca dialysates K4 has been adjusted to 133 mmol/l.

Fig.: Schematic of regional anticoagulation



Legend

1 Line occlusion clamp (red)
2 Blood pump
3 Filter
4 Fill level detector
5 Optical detector
6 Air bubble detector
7 Line occlusion clamp (blue)
8 Citrate drip counter (green)/citrate fill level detector (green)
9 Citrate pump (green)
10 Calcium pump (white)
11 Calcium drip counter (white)/calcium fill level detector (white)

7.3.2.2 Adequate anticoagulation in the extracorporeal blood circuit

Required citrate dose

The citrate dose is defined as the volume of citrate ions (in mmol) that is infused per litre of processed blood, for which reason its unit is that of a concentration. The citrate dose can be set within a range from 2 to 6 mmol/l.

In many patients, the required regional anticoagulation for a Ci-Ca CVVHD is achieved with a citrate dose of 3.5 to 4.5 mmol/l.

With Ci-Ca postCVVHDF, the use of a higher citrate dose is recommended: here, a starting value of 5.0 mmol/l citrate dose is appropriate. This change, in comparison to Ci-Ca CVVHD, compensates for the effects of the haemofiltration component of Ci-Ca postCVVHDF on the acid-base balance and inhibits a premature increase in the concentration of ionised calcium following infusion of the calcium-containing substituate at the postdilution stage.

The citrate ion concentration of the citrate solution used is required for the calculation of the applied citrate flow from the blood flow and the set citrate dose.

Adequate citrate anticoagulation in the extracorporeal blood circuit

The efficiency of the citrate anticoagulation is typically checked by determining the ionised calcium in the extracorporeal blood circuit. Lowering values to below 0.35 mmol/l of ionised calcium in the extracorporeal blood circuit (downstream of the filter) is associated with only a minor risk of clotting in the extracorporeal blood circuit. For Ci-Ca postCVVHDF, lowering values slightly more has the benefit of inhibiting a premature increase in the concentration of ionised calcium following infusion of the calcium-containing substituate at the postdilution stage.

Adjusting the citrate dose

If the ionised calcium measured in the extracorporeal blood circuit is lower than the desired value, the citrate dose should be reduced. Accordingly, the citrate dose should be increased if the ionised calcium in the extracorporeal blood circuit is reduced insufficiently.

The citrate dose can be set in increments of 0.1 mmol/l. This increment serves for fine adjustment in case of a very small deviation from the target range.

After the citrate dose has been readjusted, the new setting can be checked only a few minutes later and readjusted if necessary. The extracorporeal fill volume should be completely exchanged at least once, and the required time therefore depends on the set blood flow. All kits for Ci-Ca treatments permit a representative check after 5 minutes even in case of a low blood flow of 80 ml/min.

7.3.2.3 Control of systemic ionised calcium

Necessity of calcium substitution

During the treatment, a part of the calcium-citrate complexes as well as a part of the ionised calcium passes from the patient’s blood into the filtrate and is thus removed from the patient.

To compensate for this calcium loss, calcium solution is infused into the extracorporeal blood circuit. This is done with the calcium pump which is integrated in the device system.

Avoiding hypocalcemia and hypercalcemia

The substitution of calcium must be adapted to the patient's needs to avoid hypocalcemia or hypercalcemia.

Verification of the calcium substitution

Adequate calcium substitution is determined by regular checks of the systemic ionised calcium.

For the collection of the blood sample to check the systemic ionised calcium, observe the instructions for taking a sample/systemic blood sample (see chapter on page 7-18).

Unless clinically contraindicated, the systemic ionised calcium values should be within the normal range.

Required calcium dose

The calcium dose is defined as the volume of calcium ions (in mmol) infused per litre of filtrate produced. The Ca dose (in the display: calcium/filtrate ratio) can be adjusted for Ci-Ca CVVHD within a range of 0.0 to 3.0 mmol/l. With Ci-Ca postCVVHDF, the calcium dose equals the overall calcium infusion, i.e., the sum of calcium infused with the calcium solution and the calcium in the substituate, in relation to the filtrate flow. Unlike with Ci-Ca CVVHD, very small values for the calcium dose cannot be set for Ci-Ca postCVVHDF, since it is essential that calcium is infused with the substituate. In particular, a calcium dose of 0.0 mmol/l can never be set for Ci-Ca postCVVHDF. The upper configuration threshold is identical, at 3.0 mmol/l.

Based on theoretical estimations and empirical experience, an average calcium dose of approximately 1.7 mmol/l is required to maintain the systemic ionised calcium within the normal range or within the target range prescribed by the physician. This value can, however, vary from patient to patient, and even fluctuate for the same patient during the course of treatment. Accordingly, it is necessary to verify the effect by measuring systemic ionised calcium and then adjust the calcium dose as required.

The direct coupling of the calcium dose to the filtrate flow has the effect that the calcium substitution is automatically adjusted to the efficiency of the treatment, which means, for example, that in case of an elevated calcium removal, caused by an increase of the dialysate flow, the calcium substitution is automatically increased.

In this case, steps should be taken to correct this situation manually after the appropriate control measurements. For more information on citrate accumulation (see chapter 7.3.2.5 on page 7-25).

In Ci-Ca CVVHD and Ci-Ca postCVVHDF, the concentration of the calcium solution is a major parameter when calculating the infused calcium flow from the filtrate flow and the set calcium dose. In Ci-Ca postCVVHDF, the calcium concentration of the substituate infused in postdilution is also considered in the calculation.

Adjusting the calcium dose if measured values are outside the target range

If the systemic ionised calcium measured is undesirably low, the calcium dose should be increased. Accordingly, the calcium dose should be reduced in case of elevated systemic ionised calcium values. Even if the calcium dose can be adjusted in increments of 0.1 mmol/l, the effect of such a change is so low that double increments, i.e. of 0.2 mmol/l, can also be used for fine adjustment. In the event of major deviations of the measured systemic ionised calcium concentration, the calcium dose should be readjusted in even greater increments, if necessary.

Delayed effect in case of changed calcium dose

Note

Unlike changes to the citrate dose, the effect of a change to the calcium dose can be assessed only after some time has passed.

This is caused by the fact that the systemic distribution volume must first develop a new balance. Depending on the efficiency of the CRRT treatment and the height of the patient (or his/her distribution volume for calcium), first effects can already be seen after a few hours. The full effect can, however, only be assessed after approximately one day.

This must be particularly taken into account if several equivalent changes are made within short intervals because, in this case, there may be an excessive response (e.g., hypercalcemia if the calcium dose is increased repeatedly at short intervals).

High calcium dose: possible citrate accumulation

If the calcium dose necessary for stabilising the systemic ionised calcium is higher than 2.1 mmol/l, this might be indicative of a citrate accumulation. The device alerts the operator to this fact when setting the respective calcium doses and suggests a measurement of the total calcium. For more information on citrate accumulation (see chapter 7.3.2.5 on page 7-25).

Low calcium dose: possible evidence of a clogged membrane

If a calcium dose of less than 1.3 mmol/l is sufficient for the stabilisation of the systemic ionised calcium, this may be indicative of a clogged membrane with reduced permeability for calcium-citrate complexes. Apart from the reduced elimination of calcium and a correspondingly lower requirement for calcium substitution, an increased systemic infusion of citrate and, after metabolism, an alkalosis are to be expected. A combination of low requirements for calcium substitution and metabolic alkalosis can also be indicative of a clogged membrane. A clogged membrane has severely restricted functionality and must be replaced (restart treatment following replacement of the kit).

7.3.2.4 Control of the systemic acid-base balance

Differences of the various citrate procedures

The corrective measures which can be employed to obtain a normal acid-base balance can differ considerably between the different citrate anticoagulation methods. The following describes the procedure within the Ci-Ca CVVHD and the Ci-Ca postCVVHDF treatments.

Background on the resulting acid-base balance when using citrate anticoagulation

The citrate volume that is unavoidably infused systemically is metabolised: here, for each citrate ion that is fully metabolised to carbon dioxide and water (or other non-charged substances), three protons are also metabolised in the process. This results in the production of three bicarbonate ions. If not compensated, a metabolic alkalosis would develop.

Therefore an adapted dialysate with 20 mmol/l bicarbonate is used in Ci-Ca CVVHD and Ci-Ca postCVVHDF. This concentration is lower than that of other common CRRT solutions. Dialysis to 20 mmol/l bicarbonate leads to the removal of citrate in the filter and, to a certain extent, of bicarbonate from the blood. Viewed in isolation this removal of buffer bases would lead to metabolic acidosis.

The desired balance of buffer bases can be reached by balancing the addition of buffer bases as an effect of systemic citrate infusion and the removal of buffer bases as an effect of the dialysis against the adapted dialysate. In practice, the processes are balanced so that the systemic acid-base balance of the patient is maintained within the desired range.

The Ci-Ca postCVVHDF treatment is based on the Ci-Ca CVVHD. In Ci-Ca postCVVHDF, a calcium-containing bicarbonate-buffered haemofiltration solution is also infused in postdilution and filtration across the membrane is correspondingly increased. As the additional filtrate is formed from the citrate-containing blood, a buffer base concentration in the filtrate is typically to be expected which lies above the typical bicarbonate level (e.g. 35 mmol/l) in the substituate. (The buffer base concentration is to be understood here as the total bicarbonate concentration times a factor of 3 for the metabolism of weighted citrate concentration, and in the same way as the concentrations of other metabolisable anions, such as lactate, etc.) With this approach, the additional convective component results in more buffer bases being removed than infused – including citrate, among others. This can be compensated by increasing the citrate dose above the level required for anticoagulation in the filter, to approximately 5.0 mmol/l. Since part of the additionally infused citrate is systemically infused, this helps to equalise the buffer base balance. One positive extra effect of the increased citrate dose is that it inhibits a premature increase in the concentration of ionised calcium following infusion of the calcium-containing substituate at the postdilution stage.

Derived measures for adjusting the acid-base balance

If the patient shows signs of metabolic acidosis during the treatment, the administered citrate volume must be increased or the effective removal of buffer bases from the blood in the filter must be reduced. In Ci-Ca CVVHD and Ci-Ca postCVVHDF, this can be achieved by increasing the set blood flow (which automatically increases the citrate infusion) and/or by reducing the dialysate flow (which reduces the net removal of buffer bases from the blood). The latter approach will, however, also reduce the efficiency of the treatment. Alternatively, separate infusion of bicarbonate permits an additional administration of buffer bases without reducing the efficiency of the treatment or causing an additional citrate load on the metabolism.

With Ci-Ca CVVHD, by changing one of the two named flows by 20 %, one can theoretically expect an effect of approximately 4 mmol/l on the systemic bicarbonate concentration or base excess. Depending on the dimension of the effect intended, smaller or larger stepwise adjustments may be necessary. The proper adjusting method should be selected such that the necessary efficiency of the treatment is ensured and that the practically achievable blood flow range is taken into consideration.

For Ci-Ca postCVVHDF, almost the same applies as for Ci-Ca CVVHD. However, the additional infusion of the bicarbonate-buffered substituate has a stabilising effect on the resulting acid-base balance. For an effect on the acid-base balance, the ratio of blood to dialysate flow in Ci-Ca postCVVHDF must therefore be changed to a larger extent than in Ci-Ca CVVHD. By changing one of the two flows by 30 %, one can theoretically expect an effect of approximately 4 mmol/l on the systemic bicarbonate concentration or base excess.

Note

With Ci-Ca postCVVHDF, adjusting the blood flow – even to alter the acid-base balance – also requires adjustment of the substituate flow.

Delayed effect in case of changed blood to dialysate flow ratio

Note

Just as when changing the calcium dose, the effect of a changed blood to dialysate flow ratio can be assessed only some time after the change.

This is caused by the fact that the systemic distribution volume must first develop a new balance. Depending on the efficiency of the CRRT treatment and the height of the patient (or his/her distribution volume for buffer bases, or the essential systemic bicarbonate buffer base), first effects can already be seen after a few hours. The full effect can, however, only be assessed after approximately one day.

This must be particularly taken into account if several equivalent changes are made at short intervals, as these may cause an excessive response.

7.3.2.5 Citrate accumulation

Insufficient citrate metabolism and citrate accumulation

The systemically infused citrate is usually metabolised quickly. In patients who have, or develop, a metabolic disorder for citrate, the metabolism is slower. This results in an elevated systemic citrate concentration. As the systemic citrate concentration is only measured in exceptional cases in the hospital, it is assessed indirectly by its effects.

The systemically accumulated citrate also binds calcium. As a consequence the percentage of ionised calcium in the total calcium decreases.

Generally, the shift between systemic ionised calcium and total calcium is first indicated by a drop of the systemic ionised calcium concentration, which is properly corrected by increasing the calcium dose. A calcium dose above some 2.1 mmol/l (empirically determined) which is set on the device can be indicative of a possible citrate accumulation. The device will show an appropriate message.

Note

If doses of up to 3 mmol/l of calcium per litre of filtrate are not sufficient to stabilise the systemic ionised calcium concentration, citrate accumulation must be suspected. In this case, citrate anticoagulation must be stopped immediately.

After a stabilisation of the systemic ionised calcium by an appropriate calcium substitution, the shift in the concentration ratio of total calcium to systemic ionised calcium is shown by an increased total calcium. This increase is relative to the citrate accumulation, corresponding to the calcium-citrate complexes circulating in the blood.

An increase of the concentration ratio of total calcium to systemic ionised calcium above 2.5 is cited in the literature as a sign of citrate accumulation. However, this value should not be regarded a strict limit, but as an aid to orientation.

Citrate accumulation may also cause a mild metabolic acidosis. This can, however, also be a symptom of a variety of other causes and is therefore not specific for a metabolic citrate disorder.

Alkalosis / hypercalcemia after citrate anticoagulation

After completion of the treatment, the accumulated calcium-citrate complexes are metabolised by the patient. This may result in alkalosis and hypercalcemia.

If clinically indicated, these risks can be reduced by continuing the CRRT treatment without citrate anticoagulation.

7.3.3 Solutions for citrate anticoagulation

Preparation

Suitable NaCl solutions are used for filling the tubing system. The citrate and calcium lines are filled with the appropriate citrate and calcium solutions.

Warning

Risk of blood loss as a result of clotting

Risk for the patient as a result of a disorder of the electrolyte balance due to incorrect selection of dialysate

The use of calcium-containing dialysate for a Ci-Ca treatment can lead to blood clotting and/or hypercalcaemia.

➢ Only use calcium-free dialysate for treatments with citrate anticoagulation.

Warning

Risk for the patient as a result of a disorder of the electrolyte balance due to incorrect selection of substituate

The use of substituate with the wrong calcium level for a Ci-Ca treatment can lead to an electrolyte imbalance in the patient.

➢ Only use calcium-containing substituate for treatments with citrate anticoagulation.

➢ Check that the calcium solution used corresponds to the type selected in the Setup and shown on the screen.

Treatment

Warning

Risk for the patient as a result of a disorder of the electrolyte balance due to incorrect selection of dialysate and substituate

➢ After changing the treatment mode, change the solutions if necessary.

➢ Adjust the flow ratios of the solutions in relation to each other and in relation to the blood flow.

Warning

Risk for the patient as a result of a reduction in body temperature

If the temperature of the citrate and calcium solutions is too low, this can lead to hypothermia in the patient.

➢ The solutions must be at room temperature when used.

➢ Either select a suitable storage temperature or heat the bags to the required temperature before use.

Warning

Risk for the patient as a result of incorrect Ci-Ca anticoagulation and changes in the patient's acid-base balance

Risk for the patient as a result of a disorder of the electrolyte balance

➢ Check that the citrate and calcium solutions used correspond to the types selected in the Setup and shown on the screen.

Depending on the citrate and calcium solutions used locally, the concentration of the citrate and calcium ions in the respective solutions must be stored in the Service setup menu of the device (unit: mmol/l). This is done by Technical Service personnel. This also applies to the filling volume of the storage containers used.

The stored concentrations and volumes can be viewed in the **Ci-Ca bag change** menu. These values must be confirmed on selection of citrate anticoagulation and whenever the bag change menu is used.

Citrate and calcium solutions

For Ci-Ca CVVHD and Ci-Ca postCVVHDF, the sole approved citrate solution is 4 % Na_3 citrate in each case, containing 136 mmol/l of citrate ions.

The concentration of the calcium solution used may be basically within a range from 50 to 500 mmol/l. The recommended calcium solution is one with approximately 100 mmol/l. Higher calcium concentrations lead to lower calcium flows and can increase the risk of local clot formation due to the poorer quality of intermixing that occurs at the calcium infusion site.

The citrate and calcium solutions must be suitable for infusion.

Note

Despite citrate anticoagulation, localised clotting can occur in the tubing system during the treatment. Perform regular visual checks of the blood lines, especially in the area from the venous chamber to the connection of the return line to the vascular access. If clot formations become apparent ("white bands"), replace the cassette.

Ca-containing substituate

In addition to the solutions needed for Ci-Ca CVVHD, Ci-Ca postCVVHDF will also require a calcium-containing, bicarbonate-buffered substituate. The use of a substituate of this type with 1.5 mmol/l calcium and 35 mmol/l bicarbonate is recommended.

CRRT treatments	Citrate solution	HF solution / dialysate	Ca solution
Ci-Ca CVVHD	4 % Na_3 citrate (corresponding to 136 mmol/l citrate) 1.5 litre bag	Ci-Ca Dialysate K2, Ci-Ca Dialysate K4, Ci-Ca Dialysate K2 Plus, Ci-Ca Dialysate K4 Plus per 5 litre bag	$CaCl_2$ solution in the appropriate concentration (50 to 500 mmol/l calcium ions); preferably approx. 100 mmol/l
Ci-Ca postCVVHDF	4 % Na_3 citrate (corresponding to 136 mmol/l citrate) 1.5 litre bag	Ci-Ca Dialysate K2, Ci-Ca Dialysate K4, Ci-Ca Dialysate K2 Plus, Ci-Ca Dialysate K4 Plus per 5 litre bag Additionally, a calcium-containing, bicarbonate-buffered substituate	$CaCl_2$ solution in the appropriate concentration (50 to 500 mmol/l calcium ions); preferably approx. 100 mmol/l

8 Consumables, accessories, additional equipment

Warning

Chapter 8 (see chapter 8 on page 8-1) contains a list of consumables and accessories that are suitable for use with this device and can be used safely with it.

The manufacturer cannot guarantee that other consumables and accessories than those listed in this chapter are suitable for use with this device. The manufacturer cannot guarantee that the safety and performance of the device will remain unimpaired if consumables and accessories other than those listed in this chapter are used.

If other consumables and accessories are used, their suitability must be verified beforehand. This can be done with the aid of the information in the instructions accompanying such consumables and accessories.

The manufacturer accepts no liability for damage to the device resulting from the use of unsuitable consumables or accessories.

Warning

Risk for the patient as a result of improper use of consumables

Treatment cannot be performed properly and safely if consumables are used incorrectly.

➢ Follow the instructions that come with the consumables used.

The local service support organisation will provide information on further accessories, consumables and other additional equipment on request.

Symbols on consumables:

When using consumables, it is important to take note of the following symbols:

Single-use article
Identified by the symbol:

Do not re-use.

Use-by date
Identified by the symbol:

Use by

Long-term operation
Identified by the symbol:

Indication of max. operating time and max. delivery volume

8.1 Consumables

8.1.1 multiFiltratePRO Treatment kits

Product	Part number	Information
multiFiltratePRO Kit Ci-Ca® HD EMiC®2	F00 000 462	multiFiltratePRO Ci-Ca® HD treatment cassette with Ultraflux® EMiC®2
multiFiltratePRO Kit Ci-Ca® HD 1000	F00 000 463	multiFiltratePRO Ci-Ca® HD treatment cassette with Ultraflux® AV 1000 S
multiFiltratePRO Kit Ci-Ca® HDF 1000	F00 005 329	multiFiltratePRO Ci-Ca® HDF treatment cassette with Ultraflux® AV 1000 S
multiFiltratePRO Kit HDF 1000	F00 000 461	multiFiltratePRO treatment cassette for HDF, HD, HF with Ultraflux® AV 1000 S
multiFiltratePRO Kit HDF 600	F00 000 460	multiFiltratePRO treatment cassette for HDF, HD, HF with Ultraflux® AV 600 S
multiFiltratePRO-Kit TPE P1 dry	F00 006 441	multiFiltratePRO treatment cassette for TPE with Plasmaflux® P1 dry
multiFiltratePRO-Kit TPE P2 dry	F00 006 443	multiFiltratePRO treatment cassette for TPE with Plasmaflux® P2 dry

8.1.2 Haemofilters/plasma filters

- **Haemofilters**

Product	Part number	Information
Ultraflux® AV 600 S	500 736 1	Ultraflux® haemofilter, steam-sterilised, 1.4 m^2 surface, Fresenius Polysulfone® membrane, blood fill volume 100 ml
Ultraflux® AV 1000 S	500 898 1	Ultraflux® haemofilter, steam-sterilised, 1.8 m^2 surface, Fresenius Polysulfone® membrane, blood fill volume 130 ml

- **Plasma filters**

Product	Part number	Description
plasmaFlux® P1 *dry*	500 802 1	Plasma filter (dry on delivery), steam sterilised, 0.3 m^2 surface, blood fill volume 35 ml, Fresenius Polysulfone® membrane
plasmaFlux® P2 *dry*	500 803 1	Plasma filter (dry on delivery), steam sterilised, 0.6 m^2 surface, blood fill volume 67 ml, Fresenius Polysulfone® membrane

8.1.3 Isotonic NaCl solutions

Suitable NaCl solutions must be used.

8.1.4 Dialysate and haemofiltration solutions

Product	Part number	Information
Ci-Ca® Dialysate K2	968 920 1	Calcium-free dialysate for regional citrate anticoagulation. 5 l double-chamber bag containing 2 mmol/l potassium
Ci-Ca® Dialysate K4	F00 000 431	Calcium-free dialysate for regional citrate anticoagulation. 5 l double-chamber bag containing 4 mmol/l potassium
Ci-Ca® Dialysate K2 ***Plus***	F00 001 624	Calcium-free dialysate for regional citrate anticoagulation, 5 l double-chamber bag containing 2 mmol/l potassium and 1.25 mmol/l inorganic phosphate
Ci-Ca® Dialysate K4 ***Plus***	F00 001 625	Calcium-free dialysate for regional citrate anticoagulation, 5 l double-chamber bag containing 4 mmol/l potassium and 1.25 mmol/l inorganic phosphate
multi***Plus*** K^+ 2 mmol/l	968 820 1	Phosphate-containing bicarbonate-buffered dialysate, 5-l double-chamber bag containing 2 mmol/l potassium and 1 mmol/l inorganic phosphate

8.1.5 Citrate solution

Product	Part number	Information
4 % citrate solution	E2012	Trisodium citrate solution for regional citrate anticoagulation, 1.5 l bag

8.1.6 Disposable syringes

Product	Part number	Information
Fresenius Medical Care 30 ml	5030321	Internal diameter: 22.00 mm
Fresenius Injectomat 50 ml	9000711	Internal diameter: 28.84 mm
B. Braun Perfusor 50 ml	8728844F	Internal diameter: 27.79 mm

Note

The measurements below were taken from a number of sample items.

Fresenius Medical Care cannot be held responsible for possible changes to the syringe measurements.

Product	Part number	Information
B. Braun Omnifix 30 ml	4617304F	Internal diameter: 22.04 mm
B. Braun Omnifix 50 ml	4617509F	Internal diameter: 27.79 mm
BD Perfusion 50 ml	300137	Internal diameter: 27.79 mm
BD Plastipak 50 ml	300865	Internal diameter: 26.47 mm

8.1.7 Other single-use items

Product	Part number	Information
CAVH/D – CVVH/D dialysate connector	501 491 1	Adapter for connecting substituate system (with male connector) to haemofilter, e.g. for change of treatment mode
2 x HF female / 4 x HF male adapter	504 613 1	For connecting 4 solution bags to one substituate or dialysate system
HF female / Luer lock female PF adapter	501 474 1	Adapter for connecting infusion equipment to HF tubing systems
HF female / Luer lock male adapter	501 689 1	For connecting solution bags to the substituate system
HF female / spike adapter	501 635 1	For connecting solution bags with septum to substituate systems
Hansen male / Luer lock male adapter	501 688 1	For setting up a Pre-Post CVVH treatment
Spike connector	501 592 1	Spike connector / Luer lock female
Spike connector vented	F00 000 520	Spike connector vented / Luer lock female
Luer lock SN adapter	502 785 1	When using two filtrate bags

Product	Part number	Information
Y-adapter for filtrate bags, 2x female Luer lock / 1x male Luer lock	F00005539	When using two filtrate bags
Luer Lock female adapter	501 480 1	For connecting 2 male Luer lock connectors
Luer lock male adapter	501 477 1	For connecting 2 female Luer lock connectors
Collection bag, 2000 ml	501 509 1	2000 ml collection bag with female Luer lock connector
10 litre filtrate bag	502 901 1	Filtrate collection bag with drain valve, male Luer lock connector
10 litre single-use filtrate bag	502 903 1	Single-use filtrate collection bag with male Luer lock
Pressure line	501 463 1	Complete pressure line with filter, male Luer lock connector, 30 cm, blue
Forceps	284 524 1	For closing off lines
Freka-Flex transfer system	288 901 1	Infusion system with roller clamps and drip chamber
75-cm extension	703 001 1	Tube extension male / female Luer lock
Recirculation connector	501 597 1	Tube adapter with 2 female Luer lock connectors and grommet

8.2 Additional equipment

Product	Part number	Information
Equipotential bonding cable	M90 113 1	Original Fresenius accessories
Staff call cord	M55 510 1	Original Fresenius accessories
Accessory bag without contents	M41 115 1	Original Fresenius accessories
Ethernet cable	M28 074 1	Shielding: CAT5 or better Length: 3 m
Plasma bag holder	F40002822	Original Fresenius accessories

9 Installation

9.1 Connection requirements

9.1.1 Environment

The following considerations need to be taken into account for the operating environment:
- No splash water area
- Ceilings, walls, floors: smooth, liquid-tight, scrub-resistant, suitable for wet disinfection
- Ensure adequate load-carrying capacity of the floors
- Space requirements of each device approx. 1 m^2
- Emergency lighting (for at least 1 hour in case of power failure)
- Distances to areas such as MRI scanner rooms

9.1.2 Power supply network

Power supply network requirements:
- The requirements specified by IEC 60364-7-710 for Group 1 rooms must be met.
- Power failures < 20 ms
- A grounding system must be installed as prescribed.
- A power socket with a protective earth connection is required.
- The line cross-section and the line lengths to the wall outlet must ensure that the voltage tolerance and the function of the protective devices is always guaranteed. Recommended line cross-section to the power socket: at least 3 x 1.5 mm^2 copper core for 220 V – 240 V and at least 3 x 2.5 mm^2 copper core for voltages of less than 220 V.
- Each electric circuit is protected from damage through fault conditions with an automatic, fast-acting circuit-breaker (recommended: 16 A at 220 V – 240 V and 20 A for voltages < 220 V).
- No more than 1 device per wall outlet and electric circuit.
- The use of power strips and extension cables is prohibited.
- Residual-current devices (RCDs) which protect against dangerous shock currents in the event of fault conditions. One residual-current device (RCD less than 30 mA) for each device or electric circuit.
- Overvoltage / lightning protection in the main and emergency power supply networks.
- An equipment bonding connection must be available for an additional equipotential bonding conductor.

9.1.3 Electrical installation

Warning

Risk of injury as a result of an electric shock

Without a protective earth connection, there is a risk of electric shock.

➢ Always connect the device to a power supply network with a protective earth.

Power supply connection	The national standards and regulations must be observed when connecting the device to the power supply network.
Electromagnetic compatibility (EMC)	Observe during installation and start-up: (see chapter 12.5 on page 12-3)
Protective earth	For safety class I devices, the quality of the protective earth conductor of the installation is of particular importance.
Power supply cord	If the power supply cord needs to be replaced, use only the power supply cord approved by the manufacturer and listed in the spare parts catalogue. The use of additional power strips and extension cables is prohibited.
Equipotential bonding	Connect the equipotential bonding conductor to the rear of the device using accessories approved by the manufacturer if this is required by law at the place of installation.
Leakage currents	If additional equipment not listed in the Accessories chapter is connected to the device, there is a danger that the permitted leakage currents will be exceeded.

9.2 Installation / initial start-up requirements

Note

In order to minimise the risk of using incorrect citrate or calcium containers, it is advisable to have only one container of each type (one size and one concentration in each case) available throughout the entire hospital or dialysis centre. The same citrate and calcium container settings must be made in the Setup of all the devices in the same hospital or dialysis centre.

After bringing the device from a cooler room into a warmer room, allow approximately 2 hours for the system to adjust to the ambient temperature before turning it on.

Charging the built-in battery

On receipt of the device, charge the battery as follows:
– Use the power supply cord to connect the device to the power supply.
– Switch the power switch of the device to "on".
– Leave the power switch of the device on for 10 hours.

9.3 Important information on initial start-up

For initial start-up only

The following information is only intended for the initial start-up. This information does not apply to recommissioning devices that have been taken out of service even temporarily.

Environmental conditions

Variations in temperature during transport may cause water condensation on electrical parts. In the event of major variations in temperature, allow sufficient time for the device to adjust to the ambient temperature before start-up.

Qualification requirements of testers

The initial start-up must only be performed by the manufacturer's service support organisation or a person authorised by it.

The initial start-up must only be performed by personnel qualified to perform the required procedures correctly based on their education, training, knowledge and experience. Furthermore, the persons performing the checks must be permitted to do so independently and without outside interference.

Specifications

The information contained in the Specifications chapter must be observed.

Documentation

The initial start-up report and detailed explanations of how to perform the procedures are described in the Service Manual.

Reports are available upon request.

The completion of the initial start-up must be entered in the Medical Device Register.

10 Transport / storage

Warning

Risk of injury from a tilting device

Tilt hazard when pushing the device or leaning against it or if maximum inclination of 5° is exceeded

Lateral force exerted on the device, or if the maximum angle of inclination of 5° is exceeded, can result in the device tilting or slipping.

➢ Make sure you follow the instructions for relocation and transport.

➢ Ensure that the device is standing in a stable position.

Note

Never pull or push the device while holding onto the scales.

For moving the device, always use the push handles at the front and back.

The device must not be carried. Use a lift, ramp or similar to overcome level differences.

10.1 Relocation

After the initial start-up, a device must only be relocated inside the same building or ward.

Moving the device

The device rests on a trolley and can therefore be moved to different locations without any problems. The trolley features 4 wheels, each of which has a locking brake. The rear wheels can also be locked for pushing.

Using the handles at the front and back, the device can be turned, pushed and pulled in any direction.

Directional stability

After locking the rear wheels into position, use the front handle to push the device before you. Look out for obstacles in your path.

Uneven surfaces

Level differences up to 1 cm.

To avoid damaging or overturning the device, observe the following:

➢ Using the front handle, push the device slowly before you until the obstacle is reached.

➢ Gently push the device over the obstacle, placing one foot on the trolley bar of the device for extra support.

Locking the brakes

Once the device has been moved to its final position for treatment, the brakes on all 4 wheels must be locked.

● **If preparation has already been started, observe the following**

Requirements for relocation

– The functional test has been completed.
– The tubing systems (cassette) have been mounted, filled and rinsed.
– The treatment data has been entered.
– The device is in "Circulation" mode.
– Fold the filter holder forward.
– Swivel and tilt the monitor back against the device.
– The weights carried by the IV poles and the scales must not exceed the following values. The rear hooks on the IV poles should be used.

Left IV pole	5.5 kg
Substituate / dialysate scale, each	12 kg
Right IV pole	5.5 kg

Interrupting the power supply

The device can be disconnected from the power supply by pulling out the power plug. The device indicates a power failure. Press the **Audio paused** button to suppress the audible alarm signal for 2 minutes. The device must be relocated as fast as possible, as battery operation is only possible for a limited time.

Checks after relocation

Particular attention should be paid to the information in chapter 4.1 "Application principles".

Warning

Risk of air embolism as a result of air in the tubing system

Risk of blood loss as a result of connection sites not closed correctly

➢ Check the following after relocation:

– Make sure all screw-lock joints are properly tightened.
– Ensure that the filtrate bag hangs freely and does not touch any other objects.
– Visually check that the tubing systems (cassette) and the solution bags are not damaged or leaking and that they are properly mounted.

10.2 Transport

The device must never be transported with mounted tubing systems or with any load on the scales.

If the device needs to be transported to a location that is not within the immediate vicinity of its current location, then the relocation goes beyond the scope of the previous section. In this case, the full initial start-up procedure must be performed again at the destination.

Always transport the device in the original packaging. A device transport must only be performed by the manufacturer, or by a person authorised by the manufacturer for this purpose.

10.3 Storage

Note

To ensure that the internal battery is always charged and ready for use, the device must be connected to the power supply and the power switch must be set to "on".

The device must be stored upright in a well-ventilated room with low variations in temperature.

Maintenance of the built-in battery

On receipt of the device, charge the battery as follows:
– Use the power supply cord to connect the device to the power supply.
– Switch the power switch of the device to "on".
– Leave the power switch of the device on for 10 hours.

If the device is not used, repeat this procedure every six months.

- **Storage conditions**

Temperature	-20 °C to +60 °C
Relative humidity	30 % to 75 %, temporarily 95 %
Atmospheric pressure	500 hPa to 1060 hPa

10.4 Environmental compatibility / disposal

Within the EU member-states, the device must be disposed of in accordance with the "Directive on waste electrical and electronic equipment" (WEEE Directive). Also observe the applicable local regulations.

Before the device is sent off for disposal, the responsible organisation must ensure that all consumables attached to the device are removed and the device is disinfected as specified by the manufacturer (see chapter 6 on page 6-1).

Moreover, the responsible organisation must ensure that the waste disposal company is informed of the following facts before the dismantling process is begun:

– The device could still be contaminated when it is returned. Suitable safety measures must be in place for dismantling the device, including the use of personal protective equipment.

– For information on the batteries and other materials used, consult these Instructions for Use (see chapter 12.12 on page 12-17).

– Batteries must be properly disposed of in accordance with the applicable national regulations.

– The device includes electronic circuit boards and an LCD screen.

– More information will be made available by the manufacturer to waste disposal services on request.

11 Technical Safety Checks / maintenance procedures

11.1 Important information on the Technical Safety Checks / maintenance procedures

Technical Safety Checks (TSC)

The first TSC are required before the end of the 24th month following initial start-up after delivery from the factory. All further TSC are required before the end of the 24th month following the last TSC performed.

Maintenance procedures (MA)

The maintenance procedures (MA) are a recommendation of the manufacturer. The maintenance procedures help ensure trouble-free operation, and must be carried out for the first time before the end of the 24th month following initial start-up after delivery from the factory. All further MA should be performed before the end of the 24th month following the last MA performed.

Qualification requirements of testers

The checks must be performed by the manufacturer's service support organisation or a person authorised by it.

The specified checks may only be performed by personnel qualified to perform them correctly based on their education, training, knowledge and experience. Furthermore, the persons performing the checks must be permitted to do so independently and without outside interference.

Specifications

The information contained in the Specifications chapter must be observed.

Documentation

The TSC, MA and detailed explanations of how to perform them are described in the Service Manual.

Reports are available upon request.

The completion of the TSC must be entered in the Medical Device Register.

12 Specifications

12.1 Dimensions and weight

Dimensions	Height: approx. 167 cm Width: approx. 65 cm Depth: approx. 69 cm (not counting filter holder)
Weight	Weight: approx. 95 kg Safe working load: 45 kg Maximum total weight: approx. 140 kg

12.2 Electrical safety

	Classification according to EN 60601-1, IEC 60601-1
Degree of protection against electric shock	Protection class I
Applied part	Depending on the treatment procedure, the applied part comprises the extracorporeal blood circuit, the dialysate, substituate, and plasma circuits, and all components with a permanent, conductive connection to these circuits.
Applied part type (degree of protection for the patient)	200 to 230 V AC, 50 Hz: type CF applies 100 to 127 V AC, 50 Hz: type CF applies 100 to 127 V AC, 60 Hz: type CF applies 240 V AC, 50 Hz: type BF applies 200 to 240 V AC, 60 Hz: type BF applies
Defibrillator-proof applied part	The applied part is defibrillator-proof, irrespective of the single-use items used.
Degree of protection against ingress of liquids	Drip-proof
Leakage currents	according to EN 60601-1

12.3 Electric power supply

Line voltage	100 to 240 V AC, 50 to 60 Hz (Always go by the line voltage, frequency and current consumption information specified on the identification label attached to the device itself.)

Power supply connection	16 A at 230 V, determined according to VDE 0100 Part 710
Operating current	Max. 4.4 A, (at 240 V AC) Max. 12 A, (at 100 V AC)
Power supply (internal)	+24 V DC ± 5 %, 35 A short-circuit-proof 800 W total output power
Power switch	All-pole, simultaneous disconnection
Battery	Lead-acid battery (maintenance-free) 2 x 12 V, 7.2 Ah

12.4 Identification label (device marking)

12.4.1 Identification label of the device

The identification label shown is only an example. Always go by the information shown on the identification label affixed to the device itself.



Legend

1 Type identification
2 Serial number
3 Maximum total weight
4 Manufacturer and year of manufacture
5 Symbol for the marking of electrical and electronic equipment (Do not dispose of the device with household waste.)
6 CE mark
7 Equipment code (EC)
8 Protection rating IP 21
2: Protection against touch and foreign bodies with a diameter greater than 12.5 mm
1: Protection against ingress of liquids: Drip-proof

12.4.2 Power label

The power label shown is only an example. Always go by the information shown on the power label affixed to the device itself.



Legend

1 Power supply rating
2 Operating current
3 Applied part type (degree of protection for the patient)

12.5 Information on electromagnetic compatibility (IEC 60601-1-2:2014)

Specifications refer to the requirements of IEC 60601-1-2:2014.

12.5.1 Minimum distances between radiation source and medical electrical equipment

Medical electrical devices are subject to special protective measures with regard to electromagnetic compatibility (EMC).

Warning

Risk for the patient as a result of a device malfunction

Portable RF communications equipment (radio equipment including its accessories such as antenna cables and external antennas) should not be used at a distance less than 30 cm (12 inches) from the device parts and cables designated by the manufacturer. Non-compliance may result in impairment in the performance of the device.

➢ Always maintain a distance of at least 30 cm between portable and mobile RF communication devices and the device.

Portable and mobile RF communication devices can include the following sources of radiation (example devices):
mobile phone, smartphone, tablet PC, cordless phone, notebook/laptop, wireless keyboard, wireless mouse, wireless speaker, wireless remote control (The device-specific wireless remote control provided by the manufacturer is not affected.)

Warning

Risk for the patient as a result of a device malfunction

The use of electrical accessories and cables other than those specified in the Instructions for Use can lead to an increase in electromagnetic emissions or a reduction in electromagnetic immunity of the device.

➢ Only use the accessories and cables approved by the manufacturer.

Warning

Risk for the patient as a result of electromagnetic incompatibility between devices

Electromagnetic interference from other devices can cause device malfunctions.

➢ Do not operate the device in the immediate vicinity of other devices.

If operation in the immediate vicinity of other devices cannot be avoided:

➢ Monitor the device to verify that it is working properly.

12.5.2 Guidance and manufacturer's declaration on EMC

- **Electromagnetic emissions**

Guidance and manufacturer's declaration – electromagnetic emissions		
The multiFiltratePRO device is intended for use in the electromagnetic environment specified below. The customer or the user of the multiFiltratePRO device should assure that it is used in such an environment.		
Emissions test	**Compliance**	**Electromagnetic environment – guidance**
RF emissions CISPR 11	Group 1, Class A	The multiFiltratePRO device uses RF energy only for its internal function. Therefore, its RF emissions are very low and are not likely to cause any interference in nearby electronic equipment. The multiFiltratePRO device is suitable for use in all establishments other than domestic and those directly connected to the public low-voltage power supply network that supplies buildings used for domestic purposes. The emissions characteristics of this equipment make it suitable for use in industrial areas and hospitals. If it is used in a residential environment this equipment might not offer adequate protection to radio-frequency communication services. The user might need to take mitigation measures, such as relocating or re-orienting the equipment.
Harmonic emissions IEC 61000-3-2	Class A	
Voltage fluctuations/flicker emissions IEC 61000-3-3	Complies	

- **Electromagnetic immunity**

Guidance and manufacturer's declaration – electromagnetic immunity			
The multiFiltratePRO device is intended for use in the electromagnetic environment specified below. The customer or the user of the multiFiltratePRO device should assure that it is used in such an environment.			
Immunity test	**IEC 60601 test level**	**Compliance level**	**Electromagnetic environment – guidance**
Electrostatic discharge (ESD) IEC 61000-4-2	±8 kV contact ±15 kV air	±8 kV contact ±15 kV air	Floors should be wood, concrete or ceramic tile. If floors are covered with synthetic material, the relative humidity should be at least 30 %.
Electrical fast transient/burst IEC 61000-4-4	±2 kV for power supply lines ±1 kV for input / output lines	±2 kV for power supply lines ±1 kV for input / output lines	Mains power quality should be that of a typical commercial or hospital environment.
Surge IEC 61000-4-5	±1 kV line(s) to line(s) ±2 kV line(s) to earth	±1 kV line(s) to line(s) ±2 kV line(s) to earth	Mains power quality should be that of a typical commercial or hospital environment.
Voltage dips, short interruptions and voltage variations on power supply input lines IEC 61000-4-11	0 % U_T for 0.5 cycle at 0, 45, 90, 135, 180, 225, 270 and 315 degrees 0 % U_T for 1 cycle 70 % U_T for 25 cycles 0 % U_T for 250 cycles (5 s)	0 % U_T for 0.5 cycle at 0, 45, 90, 135, 180, 225, 270 and 315 degrees 0 % U_T for 1 cycle 70 % U_T for 25 cycles 0 % U_T for 250 cycles (5 s)	In the event of power supply interruptions, the rechargeable battery of the multiFiltratePRO device temporarily takes over the supply for parts of the system without delay. Mains power quality should be that of a typical commercial or hospital environment.
Power frequency (50/60 Hz) magnetic field IEC 61000-4-8	30 A/m	30 A/m	Power frequency magnetic fields should be at levels characteristic of a typical location in a typical commercial or hospital environment.
Note: U_T is the a.c. mains voltage prior to application of the test level			
Conducted RF IEC 61000-4-6	3 V_{rms} 150 kHz to 80 MHz 6 V_{rms} in ISM bands between 150 kHz and 80 MHz	3 V_{rms} 6 V_{rms} in ISM bands	
Radiated RF IEC 61000-4-3	3 V/m 80 MHz to 2.7 GHz	3 V/m	
Note: These guidelines may not apply in all situations. Electromagnetic propagation is affected by absorption and reflection from structures, objects and people.			

12.6 Operating conditions

Operating temperature range	+15 to +35 °C
Atmospheric pressure	700 to 1060 hPa
Relative humidity	30 % to 75 %, temporarily 95 %
Operating altitude	Maximum operating altitude up to 3000 m The operating altitude depends on the atmospheric pressure and can vary accordingly. A lower atmospheric pressure than the minimum value specified can restrict the functions of the device and cause delays in opening the pressure measurement units.
Inclination during operation	Maximum angle of inclination during operation: 5°
IV pole load-bearing capacity	Maximum: 5.5 kg Maximum load per hook: 5.5 kg
Scale load capacity	Maximum: 12 kg each for scales 1 and 2 Maximum: 24 kg total for scales 3 and 4
Plasma bag holder load-bearing capacity	Maximum: 8 plasma bags with a volume of 320 ml each Maximum load per hook: 2 plasma bags with a volume of 320 ml each

12.7 Storage conditions

Temperature	-20 °C to +60 °C
Relative humidity	30 % to 75 %, temporarily 95 %
Atmospheric pressure	500 hPa to 1060 hPa

12.8 External connection options

Warning

Risk of injury as a result of an electric shock

There is a risk of electric shock if the patient comes into contact with the pins or contacts of the device's connectors, whether directly or indirectly through the operator.

➢ Avoid touching connector pins or contacts during treatment.

Other, additional equipment connected to this device must verifiably comply with the applicable IEC or ISO standards (e.g., IEC 60 950-1 for information technology equipment).

Furthermore, all device configurations must comply with the requirements for medical electrical systems (see EN 60601-1:2006 section 16 and annex I).

Connecting the device to an IT network that contains components not installed and validated by the manufacturer can introduce unknown risks for patients, operators or third parties. These risks must be identified, analysed, evaluated and checked by the responsible organisation. For assistance, refer to IEC 80001-1:2010 and annexes H5 and H6 of EN 60601-1:2006.

Any modifications to an IT network that has been installed and validated by the device manufacturer can introduce new risks and therefore require a repeat analysis. Especially problematic activities include:

– Changes to the IT network configuration
– Connection of additional components and devices to the IT network
– Removal of components and devices from the IT network
– Updates or upgrades of components and devices in the IT network

Note that local laws take priority over the above-mentioned normative requirements. Please address any queries to the local service support organisation.

LAN port

Interface for data exchange.
Electrically isolated by transformer.
Port: RJ 45
Shielding: CAT5 or better

Length: 3 m

RS232 port

The serial port is deactivated during treatment in normal operation.
Electrically isolated by optocoupler.
Port: DSUB 9-pin
Length of a serial line: max. 3 m, shielded

Service / diagnostics port

Serial port for diagnostics equipment.
Only for use by service support.
Port: DSUB 15-pin

Alarm system port

For connecting an external alerting system, e.g. nurse call (potential-free alarm output, alternating contact maximum 24 V / 24 W).
Port: 5-pin diode plug via shielded line, shielding must be grounded at both ends.

Only accessories and cables approved by the manufacturer must be used.

Signal transmissions to external alerting systems are not monitored by the device. Connecting an external alerting system has no influence on the visual and audible alarms on the device itself.

Warning

Risk for the patient as a result of ignored alarm signals

The reliability of alarm signal transmissions to external alarm systems cannot be guaranteed, meaning that alarms can fail to be indicated externally.

➢ Stay close enough to the device to be able to notice any alarms it emits at all times.

12.9 Operating programs

Functional test	Automatic test of the operating and safety systems. The functional test is mandatory after power on (not following a power failure).
Preparation	Defined by the optical detector in the return line, below the bubble catcher. Preparation is terminated as soon as the optical detector senses blood in the tubing system.
Filling the tubing system	The tubing systems are automatically filled and deaerated. Filling is terminated automatically.
Rinsing	Rinse volume: 300 to 5000 ml, can be set in the System Parameters menu. UF rinse: 300 to 2000 ml, can be set in the System Parameters menu.
Circulation	After rinsing, the extracorporeal circuit can be kept in circulation until the patient is connected. This is also sometimes referred to as "short-circuiting".
Patient connection	Connecting the patient
Treatment	Treatment starts as soon as the optical detector senses blood in the tubing system.
Treatment pause	The Treatment pause function allows the patient to be disconnected from the device for a short time during treatment. – Treatment pause without blood reinfusion for short periods – Treatment pause with blood reinfusion
End of treatment / Blood reinfusion	Blood reinfusion continues until the optical detector no longer detects blood, and can be extended for short periods afterwards.
System Parameters	After the functional test has been completed and a treatment has been selected, the volume (loudness) of the audible alarm, screen brightness, key sounds, and the standard values for the selected treatment can be entered as required in the Setup.

12.10 Balancing/dialysate circuit and safety systems

Blood leak/haemolysis detector (yellow)	Optical absorption method (red/green ratio). Response threshold of ≤ 0.5 ml blood loss per minute, independent of the flow rate (including measurement tolerance). The response threshold is set to allow a maximum filtrate flow and haematocrit value of 32 %. This corresponds to a maximum possible blood loss of 0.5 ml per minute. Basic measuring accuracy ±0.1 ml/min.

Flow rates

Depending on the treatment option:

Blood flow*	0 / 10 to 500 ml/min ±10 %
Substituate flow*	0 / 10 to 80 ml/min
Dialysate flow*	0 / 10 to 80 ml/min
Citrate flow*	0 / 10 to 600 ml/h
Calcium flow*	0 / 1 to 100 ml/h
Ultrafiltration rate (UF rate)	0 / 10 to 180 ml/min
Filtrate flow	0 / 10 to 180 ml/min
Net UF rate	0 / 10 to 990 ml/h

Pump type: tube pumps with spring-loaded rollers, fully-occluding.

The delivery accuracy of the pumps is ± 10 %, unless regulated by the scales. If regulated (for treatment procedures with scale balancing), the individual delivery accuracy of each pump depends on the accuracy of the associated scale. In this case, the total delivery accuracy corresponds to the specified balancing accuracy.

Ultrafiltration* / net fluid removal

The overall ultrafiltration or UF rate is automatically determined by the set substituate flow, the net UF rate, and the anticoagulation flow.
The net fluid removal of the patient can be selected through the net UF rate: 0 to 990 ml/h (in increments of 10 ml)
The ratio of the UF rate to the effective blood flow (UF/BF ratio) is monitored during treatment to ensure that the maximum limit value is not exceeded. If a discrepancy occurs (risk of excessive haemoconcentration), a warning will be displayed after approximately 5 seconds.

Balancing/dialysate circuit

Volume deviation < 1 %, relative to the total delivery volume (depending on the treatment option), if device is standing level or with an angle of inclination of no more than 5°.
If standard treatment parameters are used, and under normal operating conditions, a maximum balancing deviation of 30 ml/h can be expected for HDF treatment types.

For Ci-Ca treatment types, further deviation is possible, depending on the relevant volumes administered (see page 12-12 for information on the delivery accuracy of the citrate and calcium pumps).

Maximum balancing error during treatment

500 g during the treatment of an adult

Once this maximum balancing error value is reached, either through the addition of individual, smaller deviations or through a single serious balance monitoring error, balancing is automatically deactivated.

In normal operation (scale balancing active and error-free), even a deviation of only a few grams (depending on the flow rate) from the target value will result in a balancing warning. In the event of an error condition (scale defective or minor leaks), greater deviations are possible.

– Maximum balancing deviation < 100 ml/h
– Greater deviations are detected within a total maximum volume deficit of 500 g (functional test of scales)
– Once the maximum balancing error value is reached, balancing is automatically deactivated.

Balancing error

$E = E_{UF} + E_{SUB} + E_{Anticoagulation}$
(see also under "Balancing/dialysate circuit")

E = balancing error
E_{UF} = Ultrafiltration error
E_{SUB} = Substitution error
$E_{Anticoagulation}$ = Heparin or Ci-Ca anticoagulation error

Scale system

Maximum load: 12 kg per scale
Weighing range: 0 to 12 kg
Resolution: 1 g
Maximum linear deviation: ≤ ±1 % or 1 g
(the higher value always applies)

Substituate/dialysate temperature*

Treatment options: all treatment modes with exception of TPE

– Adjustable range: off, 35 to 39 °C
– Resolution: 0.5 °C
– At ambient temperatures of ≥20 °C and when using solutions at ambient temperatures, the set temperature is reached in normal operation (active balancing / alarm-free state) with an accuracy of +1.5 °C / -3 °C.
– For ambient room temperatures < 20 °C, greater downward deviations are possible due to heat losses. Additional, external measures must be undertaken as needed in these cases.

There are two alarm threshold values. As soon as an inflow temperature of 42 °C is exceeded, this starts an override condition during which the alarm is not yet sounded. After 120 ml at this temperature, or if an inflow temperature of 46 °C is reached, the alarm is sounded and the fluid inflow is stopped, This must be confirmed by the operator. An automatic restart is not performed until the temperature has dropped below the temperature alarm threshold.

Donor plasma - temperature* (FFP)

Treatment option: TPE

At ambient temperatures of 20 °C to 35 °C, a temperature between 25 °C and 38 °C at the insertion site is achieved when substituate or plasma heaters (active balancing/alarm-free state) are switched on.

Ambient temperature sensor

This temperature sensor measures the ambient room temperature. The measured temperature is used for regulating the integrated heaters. External additional heaters are not regulated.
Accuracy: ±1 °C

Heater microswitch

The microswitch is used for detecting a distended or incorrectly inserted heater bag.

(* = essential features for IEC 60601-1)

12.11 Extracorporeal blood circuit and safety systems

Return line pressure measurement

The hydrophobic filter in the return line is determined to be fully wetted when the return pressure sensor (blue) fails to detect any pressure fluctuations over at least 4 consecutive blood pump cycles. Pressure monitoring is deactivated for blood flow rates of less than 50 ml/min.

Access pressure

Display range: -300 to +300 mmHg
Resolution: 5 mmHg
Accuracy: 10 mmHg

No blood detected:
Access pressure alarm window size: -300 to +300 mmHg

Blood detected:
Access pressure alarm window size: +40 to +200 mmHg

Default value adjustable in User setup,
Factory setting: +200 mmHg

If the access pressure drops below the lower limit, the access line clamp will remain open to allow the pressure in the system to disperse. In the event of any further pressure alarm, the clamp will close.

Return pressure (safety system against external blood leaks)

Display range: -100 to +500 mmHg
Resolution: 5 mmHg
Accuracy: 10 mmHg

No blood detected:
Return pressure alarm window size: -100 to +500 mmHg

Blood detected:
Return pressure alarm window size: +40 to +200 mmHg

Default value adjustable in User setup,
Factory setting: +100 mmHg
Alarm window position can be set over a range from +10 to +500 mmHg (switchover to between -100 and +500 mmHg possible in the event of an alarm, if extending low return pressure alarm is activated in Service setup)

Factory setting: extending lower return pressure limit is deactivated.

Pre-filter pressure

Display range: -50 to +750 mmHg
Resolution: 5 mmHg
Accuracy: 10 mmHg

No blood detected:
Pre-filter pressure alarm window size: -50 to +750 mmHg

Blood detected:
Pre-filter pressure alarm window size: +40 to +200 mmHg

Default value adjustable in User setup,
Factory setting: +200 mmHg

TMP (CRRT)

Display range: -300 to +500 mmHg
Lower alarm limit: -60 mmHg
Upper alarm limit: +520 mmHg
Accuracy: 20 mmHg
Displayed only in Pressure / alarm history tab of treatment screen.
The TMP is calculated and displayed according to the following formula:

$TMP = ((P_{ven} + P_{pre}F) / 2) – P_{fil} + Offset$

TMP = transmembrane pressure
P_{ven} = return pressure
$P_{pre}F$ = pre-filter pressure
P_{fil} = filtrate pressure
Offset = 20 mmHg (correction value to compensate for hydrostatic pressure differences)

TMP (TPE)

Display range: -60 to +270 mmHg
Pressure alarm windows
Lower alarm limit: -60 mmHg
Upper alarm limit: +50 mmHg to maximum upper alarm limit
Maximum upper alarm limit can be defined in User setup between +50 and +100 mmHg

Accuracy: 20 mmHg
The TMP is calculated and displayed according to the following formula:
$TMP = ((P_{ven} + P_{pre}F) / 2) – P_{fil} + Offset$
TMP = transmembrane pressure
P_{ven} = return pressure
$P_{pre}F$ = pre-filter pressure
P_{fil} = filtrate pressure
Offset = 20 mmHg (correction value to compensate for hydrostatic pressure differences)

Blood pump

Spring-loaded rollers, fully occluding, pressure-limited to 2 bar for standard line with pump segment 6.4 x 1.8 (when using the prescribed tubing systems).

Warning

Risk for the patient as a result of insufficient detoxification

If the access pressure before the blood pump reaches extreme negative values, the blood flow can be reduced, which will impair the effectiveness of the treatment.

➢ Take suitable steps to avoid an extreme negative access pressure.

Delivery rate:
CRRT: 10 to 500 ml/min
CRRT with citrate anticoagulation: 10 to 200 ml/min
TPE: 10 to 300 ml/min

Resolution: 10 ml/min

Flow accuracy over
Pressure range ≥ -300 mmHg ≤ 10 %
Standard line with pump segment 6.4 x 1.8 mm
System accuracy of the delivered blood volume: ±10 % considered over the entire treatment duration and valid in typical treatment situations.

Blood pump stop alarm:
time-based standstill monitoring as a safety system against blood loss through clotting.
Alarm delay when blood pump stops:
1 minute (during treatment)
3 minutes (while patient is being connected or disconnected)
Alarm repeat if blood pump standstill continues: every 60 s

Fill level detector

Method:
Capacitive measurement

Switching point 13 mm, ±4 mm from upper edge

Optical detector

Method: infrared transmission

Distinguishes between:
– No blood detected (NaCl solution or air in tubing)
– Blood detected (blood in tubing)

Air bubble detector

Method:
Ultrasound transmission measurement through tubing

Detects:
– Air bubbles
– Blood foam (air/blood mixture)
– Microbubbles

Air alarm in the following cases:
– Blood foam
– Microbubbles
– Blood flow rate < 100 ml/min:
  Air bubble: volume ≥ 20 µl
– Blood flow rate ≥ 100 ml/min:
  10 air bubbles with a bubble volume of < 50 µl each, or
  1 air bubble with a bubble volume of ≥ 50 µl, or
  blood foam

The above data is based on a worst-case assumption, at a blood flow rate of 0 to 500 ml/min using the prescribed tubing systems.

Full sensitivity at the maximum blood flow is achieved with patients weighing upwards of 45 kg.

In order to ensure a similar sensitivity with patients weighing less than 45 kg in a worst-case scenario (level in bubble catcher has dropped), select a lower maximum blood pump rate according to the following table.

General limit value: 0.03 (ml/min) per kg		
Patient weight	Max. infused air for lowest possible hazard	Limited max. blood flow (condition: wetted)
40 kg	1.2 ml/min	458 ml/min
From 45 kg	≥ 1.35 ml/min	≥ 500 ml/min

Heparin pump

Pump type: syringe pump
Delivery rate: 0.5 to 25 ml/h
Resolution: 0.1 ml/min
Accuracy: ±5 % for delivery rate 1 to 25 ml/h measured over 2 hours with up to 1.2 bar counterpressure. At delivery rates < 1.0 ml/h, the tolerance could exceed the specified ±5 %.
Bolus administration: 0.1 to 5 ml in increments of 0.1 ml (preset maximum bolus volume is 5 ml. This parameter can be set to a lower volume in the System Parameters).
Bolus rate: 30 ml/min

Audible tone

Sound pressure level settings of the audible alarm:
Volume range: 50 to 80 dB ±5 dB
Factory setting: ≥ 65 dB
High-priority alarm: 60 to 80 dB ±5 dB
Medium priority alarm: 60 to 80 dB ±5 dB

Ci-Ca drip counter

Measuring range: 0 to 5 drips per second (independently for citrate and calcium)
Measuring method: optical

To permit drips to be detected accurately, the fluid level must be within or below the markings.

Citrate pump

Pump type: roller pump
Delivery accuracy: ±10 %
Delivery rate: 10 to 600 ml/h, depending on citrate/blood ratio.

Dose can be set.
Concentration of citrate per litre of delivered blood: 2 to 6 mmol/l in 0.1 mmol/l increments
Default value: 4.0 mmol/l

Calcium pump

Pump type: roller pump
Delivery accuracy: ±10 %, at delivery rates < 6 ml/h the deviation can be ±20 %
Delivery rate: off, 1 to 100 ml/h, depending on calcium/filtrate ratio.

Dose can be set.
Concentration of calcium per litre filtrate: 0 to 3 mmol/l in 0.1 mmol/l increments
Default value: 1.7 mmol/l

The Ci-Ca pumps run at a higher delivery rate (400 ml/h) while the Ci-Ca tube segments are being inserted/removed and the tubing system is being filled.

Ci-Ca fill level detector

Function: for detecting and differentiating between a full or empty Ci-Ca drip chamber (independently for citrate and calcium).
Measuring method: optical

To permit a filled drip chamber to be detected accurately, the fluid level must be within or above the markings.

Cassette detector

Differentiates between cassettes with and without a Ci-Ca system using a colour sensor and colour codes on the cassettes.

Cassette without Ci-Ca: blue marking

Ci-Ca cassette: yellow marking

12.12 Materials used

- **Plastics and cast resins**

Abbreviation	Material
ABS	PBT GF 20 UV stabilised, 6 mm (UL94 V0) PC GF8 (Romiloy 9035 UO UV cream)
Avery	Avery 420 matt, white, label "UL94 V0"
Duplobond	Duplobond 360.2 plus, polyethylene paper, pure acrylate, polyester film
Eastar	Eastar DN011
EPDM	EPDM Shore 70 A EPDM-XPP Shore 64 A
GV	Grivory GV-4H natural Grivory GV-5H natural
HY/EPDM medium resistance	Cellular rubber
Iglidur	Iglidur J Iglidur W300
Kapton film	MT50SK polyimide film
LD-PE	LD-PE (SK-03) polyethylene
Lupolen	Lupolen 1800 H, colourless
NBR	N7LM (70 Shore A)
PA6.6	PA6.6, natural PA6.6, black
PA6	PA6 GF15 PA6 GF10/GK20 (Frianyl) PA6 G, black
PA66	GF30 Ultramid A3EG6, black Ultramid A3K
PBT	Glass fiber-reinforced PBT composite
PEEK	Polyether ether ketone
PET	PET (P) natural, cream
PETG	Polyethylene terephthalate copolymer, cream

Abbreviation	Material
POM	Hostaform C 13021 Polyoxymethylene, natural Polyoxymethylene, cream RAL 9001 POM -C GF 25
PP	Hostacom G2UO2
Polyester	Polyester 100 %, Cu+Ni
PU	8052 white (similar to RAL 9001) MG 804 GR, black MG 804 GF, black GM959 white (similar to RAL 9001) PX 515, cream RAL 9001 SG95, transparent
PT	PT WN1452 VZ
PVC, hard	PVC, hard
PVC, soft	PVC, soft 65 +/- Shore A
PVC U	PVC U
Pocan	Pocan KU2-7125
Santoprene	Santoprene 271-80 R RAL 7038 agate grey Santoprene 271-73, 73 +-5 Shore A RAL 7038 agate grey
Elastosil silicone	LR 3003-50 45° Shore A, agate grey RAL 7038 LR 3003-70 Shore, natural, transparent LR 3003-70, agate grey RAL 7038 LR 3003-60 Shore A, cream RAL 9001 GL P60 (MVQ) WEHA-SI 5250 agate grey RAL 7038
Silicone	SIL (F163.900) fiberless insulating rubber bushing Silicone rubber bushing Silicone-coated paper
TPE	Alruna W50 RAL 9001 Alruna W60 RAL 9001
Nonwoven fabric	Nonwoven fabric, acrylic copolymer
Zytel	Zytel (nylon)

- **Metals, glass, graphite, ceramics**

Abbreviation	Material
Al	Aluminum Al Cu Mg Pb anodised E6 EV1, colourless Al Mg3 F25 DIN 1784 Al Mg Si 0.5 F22 Al Mg 1 F21 Al Mg 1 F21 coil-anodised E6 EV1 Al Mg 3 DIN EN ISO 9445 Al Mg 4.5 Mn Al Mg Si1 F28, RD EN 755-3 Al Mg Si1 W28
Bimetallic strip	Bimetallic strip
Cu	Copper
EP GC	Epoxy resin glass cloth EPGC 202 DIN 7735, type 2372.1, thickness 0.5 mm
Spring steel	Spring steel blank, DIN471 Form A
Float glass	Float glass
Brass 58	CuZn39Pb3
Brass	CuZn39Pb3 F44 Brass DIN 9021
Steel	Steel 8 zp. blue passivated, DIN 985 1.3541 (X47Cr14 DIN EN ISO 683-17) 1.0330 (ST12), sheet-steel DIN EN ISO 10131 1.0330 (ST12ZE), zinc electroplated zinc plated, chromated Steel blue annealed 5 µ, stamped Tempering class 5.8, gunmetal finish, case-hardened to 0.2 – 0.4 mm depth Steel 45H A2-2, DIN 914 Steel 9 S MnPb 28 K Steel 8.8, ISO 7380m zinc-plated Steel 8.8, zinc plated, DIN 7985
Stainless steel	1.4021 1.4037 (X65Cr13) 1.4122 1.4301 (V2A, X5CrNi18-10) 1.4305 1.4310 (X10CrNi18-8) 1.4401 (V4A) 1.4404 1.4568 (spring wire) A1, A2, A4 DIN 965-TX
Tin plate	1.0375

- **Electrical equipment**

Component	Material
Thermistor	Silicon
	Copper
	Silver
	PTFE
	Epoxy resin
Weighing cell platform	Aluminum, silicone rubber, PVC
Power switch	Thermoplastic case
	Copper
	Tin
	Bronze contacts
	Glass fiber-reinforced thermoplastic
Power supply unit	Aluminum
	FR-4 (PCB base material)
	Copper
	Tin
	Silicon
	Polyester
	Polyurethane
	Iron cores
	Ferrite cores
	PVC
Noise filter	Iron cores
	Ferrite cores
	Copper
	Tin
	PVC
	Polyester
Plug connectors	Copper + tin
	Glass fiber-reinforced thermoplastic
Cables	Copper

Component	Material
	PVC
	Teflon
Electronics	Electronic circuit boards
	LCD screen
	Glass fiber-reinforced thermoplastic
	Ferrite cores
	Copper
	Tin
	Silicon
	Lithium batteries
	Lead-acid rechargeable batteries
Drives	Ferrite rubber magnet
	Polyester / PTZTR (Avery Dennison)
	Micares X 1087 GY (Micafil)
	Delrin 500 (DuPont)
	RNF-100 (Raychem)
	Magnesol U-180 (Lacroix + Kress)
	PA Ultramid A3HG7nc (BASF)
	Glass-reinforced epoxy resin FR-4
	Polyester / PTWTR (Avery Dennison)
	Loctite 603
	Hardloc red 903686 (Denka)
	Hardloc green 906245 (Denka)
	PA66
Motor-gearbox combination	Polyamide, reinforced
	Steel
	Esters + polyolefin oil, lithium soap

Component	Material
	Brass
	Perfluorinated polyether, polytetrafluoroethylene (PTFE)
	Urethane methacrylate, butylcyclohexyl methacrylate, acrylic acid, butylene glycol dimethacrylate, hydroxypropyl methacrylate, acetylphenylhydrazine, octylphenoxy polyethoxy ethanol, cumene hydroperoxide

- **Auxiliary materials**

Auxiliary material group	Material
Felt	Wool, carbonised viscose
Gear lubricant	Molykote L-1122
Silicone sealant	DOW Corning 794F Aloxy Sealant
Silicone rubber	Material 70105070, Wacker Silicones E 41 transparent, 10-g tube, neutral
Double-sided adhesive tape	Adhesive: acrylate A 20, backing material: polyurethane foam (open-cell)
Adhesive	Araldite 2021, two-component toughened methacrylate adhesive system
Adhesive	Araldite 2029, two-component toughened methacrylate adhesive system
Adhesive	Araldite 2048, two-component toughened methacrylate adhesive system
Adhesive	Loctite 243 (acrylate, dimethacrylate ester)
Adhesive	Loctite 401
Adhesive	Loctite 406 (cyanoacrylate, ethyl cyanoacrylate)
Adhesive	Loctite 454 (cyanoacrylate, ethyl cyanoacrylate)
Adhesive	Cyanolit
Adhesive	Hysol 3421

Auxiliary material group	Material
Adhesive	Polysiloxane
Primer	Loctite 770 (polyolefin)
Lubricating oil	Paraliq P460: paraffin. Mineral oil, synthetic hydrocarbon oil, colourless – light yellow

- **Lacquers**

Auxiliary material group	Material
Wet coating, filler primer	Alexit 484 Alexit 342-67
Wet coating, top coat	Alexit 5300 Alexit 346-18 Freopox PB 10 13 A
Print colours, top coat	TP-218 / 65-HD NT TP-218 / 60 TP-218 / C-MIX 2000

13 Definitions

13.1 Terms

The terms used in this document correspond to the terminology defined in DIN 58352. Below is a selection of terms that may require further explanation.

Access pressure The access pressure is the pressure in the access system, between the patient's vascular access and the blood pump.

Access system The part of the extracorporeal blood circuit from the patient to the inlet of the filter.

Alarm function check The alarm function check is the verification of the proper function of the alarm equipment.

Alarm limit The alarm limit is a measured value which, if reached, will trigger an alarm.

Battery Internal emergency power supply capable of supporting emergency operation for a limited time in the event of power failures.

Blood leak detector The blood leak detector is a device that detects the presence of blood in the filtrate and plasma lines.

Blood pump The blood pump is the device that transports the blood in the extracorporeal circuit.

Calcium flow The calcium flow is the volume of calcium solution added to the patient’s blood per time unit.

Calcium pump The calcium pump is used for adding calcium solution to the patient’s blood in the extracorporeal circuit.

Card slot The card slot is for inserting the UserCard / ServiceCard.

Citrate dose The citrate dose is the volume of citrate solution added to the patient’s blood in relation to the blood flow. The dose is specified in mmol per litre of blood.

Citrate flow The citrate flow is the volume of citrate solution added to the patient’s blood per time unit.

Citrate pump The citrate pump is used for adding citrate solution to the patient’s blood in the extracorporeal circuit.

Convection Convection describes the transport of solutes by the bulk motion of the solvent (e.g. by advection, as in haemofiltration).

Dialysate	Dialysate is the term for the solution that removes water and waste from the blood in haemodialysis. In the dialyser, it flows around the blood in the opposite direction to it, separated only by the semipermeable membrane.
Diffusion	In haemodialysis, diffusion is the term used to describe the change in concentration of the solutes as they are transported in the solutions.
Exchange volume	The exchange volume is the amount of fluid filtered out of the blood and replaced with substituate on a 1:1 basis (flow rate specified as ml/h or ml/min). The effectiveness of the treatment is significantly proportional to the quantity of the exchange volume. The flow rate is the indicator of the speed at which the exchange is performed.
Extracorporeal blood circuit	The extracorporeal blood circuit is the blood circuit outside the body, e.g., in the haemodialysis device.
Filter life	The filter life is the parameter that is used to monitor how long blood has been flowing through the tubing system. This is basically the same as the treatment time, but will normally be higher, because, while the treatment time count is suspended when balancing is interrupted, the filter life count continues.
Filtrate / filtrate flow	Filtrate or filtrate flow is the sum total of the dialysate, substituate, net UF, heparin, citrate and calcium flow. The filtrate or filtrate flow forms the basis for the internal calculation of the calcium dose by the system.
Filtrate bag	The filtrate bag is the collection bag for the filtrate (ultrafiltrate), otherwise known as waste.
Filtration	Filtration describes the convective flow of solvents, e.g., water, through a membrane, in following a hydrostatic and/or osmotic pressure gradient. Dissolved particles are also carried along (convective transport) if they are not retained by the membrane.
Haemodialysis	Haemodialysis describes the diffusion and exchange process that takes place between the dialysate and the patient's blood in the extracorporeal blood circuit.
Haemofiltration	Haemofiltration is the ultrafiltration of plasma water and its solutes to eliminate endogenous and exogenous toxins and water while simultaneously replacing the ultrafiltrate with appropriate amounts of electrolyte solution.
Heparin pump (anticoagulant pump)	The heparin pump is used for adding the heparin anticoagulant to the patient’s blood in the extracorporeal circuit.
Hook-up test	The hook-up test is used for verifying that the pressure measurements via the pressure domes are working properly. It is also a test of the tubing system.

Insertion switch	Insertion switches are provided in the pump beds of the citrate and calcium pumps. The system uses the insertion switches to detect whether or not the respective Ci-Ca line pump segments have been correctly inserted.
Kit service life	This is a parameter that shows how long the tubing system has been in use. The kit service life is measured from the start of filling and generates a repeated alarm if the maximum time in operation and/or the maximum transported blood volume is exceeded. The kit should be replaced without delay in this case.
Net UF volume	This is the volume of fluid filtered out of the patient's blood that is not returned, i.e., is used to control the patient's body weight (the net UF rate is specified in ml/h).
Post-filter calcium concentration	The post-filter calcium concentration indicates the efficiency of the regional citrate anticoagulation and can be used as a control parameter.
Postdilution	Adding substituate downstream of the haemofilter.
Predilution	Adding substituate upstream of the haemofilter.
Preparation time	The preparation time begins when filling is started and ends when blood is detected while the patient is being connected. A single warning is displayed if the maximum preparation time is exceeded. Preparation can be continued after confirming the message. The preparation time also counts as part of the kit service life.
Return pressure	The return pressure is the pressure in the return line (e.g., in the bubble catcher).
Return system	The return system is the part of the extracorporeal blood circuit from the filter outlet back to the patient.
ServiceCard	Card for use by service engineers
Substituate	The substituate is the substitution fluid used in haemofiltration.
Systemic calcium concentration	This means the systemic, ionised calcium concentration in the patient. This measured value is used to verify and control calcium substitution.
Treatment time	This is the effective treatment duration so far, not including messages and periods during which balancing is switched off.
UserCard	Card for use by operators

13.2 Abbreviations

AC	Alternating current
BF	Blood flow
Ca	Calcium

Ci	Citrate
CRRT	Continuous renal replacement therapy
CVVH	Continuous venovenous haemofiltration
CVVHD	Continuous venovenous haemodialysis
CVVHDF	Continuous venovenous haemodiafiltration
DC	Direct current
Fig.	Figure
HD	Haemodialysis
HF	Haemofiltration
IEC	International Electrotechnical Commission
LED	Light-emitting diode
MA	Maintenance procedures
P	Pressure
Pre-Post CVVH	High-volume continuous venovenous haemofiltration
REACH	Registration, Evaluation, Authorisation and Restriction of Chemicals
SVHC	Substance of Very High Concern
TMP	Transmembrane pressure
TPE	Therapeutic plasma exchange
TSC	Technical Safety Checks
UF	Ultrafiltration

13.3 Symbols

	Follow instructions for use
	General warning
	Warning, do not overload (respect the maximum load)

	Warning, hot surface
	Warning, tilt hazard when pushing the device or leaning against it
IP21	Degree of protection against ingress of foreign bodies and liquids 2: Protection against touch and foreign bodies with a diameter greater than 12.5 mm 1: Protection against vertically falling water drops
	Applied part type (degree of protection for the patient): Type B
	Applied part type (degree of protection for the patient): Type BF
	Applied part type (degree of protection for the patient): Type CF
	Applied part type (degree of protection for the patient): Type BF, defibrillator-proof
	Applied part type (degree of protection for the patient): Type CF, defibrillator-proof
	Alternating current
	Protective earth
	Functional earth
	Equipotential bonding
	Dangerous electrical voltage
	Dangerous electrical voltage
I	ON
O	OFF
I/O	ON / OFF
	On / Off

LAN (local area network) network connection



Operating hours counter

Printer port



Scales

The CE mark documents compliance with the Medical Device Directive 93/42/EEC (MDD).
Notified body: TÜV PRODUCT SERVICE 0123

Symbol for the marking of electrical and electronic equipment
(Do not dispose of the device with household waste.)

Corrosive substance warning

Blood pump



Alarm system port

Alarm system port

RS 232 port

Service port

Non-ionising electromagnetic radiation

Max. operating time and max. delivery quantity

Direction of rotation, e.g., of a rotor

Audio paused

Manufacturer

Manufacturer and year of manufacture

Maximum total weight

Serial number

Scale 1 marker (green)

Scale 2 marker (white)

Wheel direction can be locked

Wheel can be swivelled

Wheel can be locked (brake function)

13.4 Symbols on consumables

Batch code

Date of manufacture

Permitted storage temperature range

Do not reuse

Sterilised with ethylene oxide

Use by

Part number

13.5 Certificates

The current versions of the EC certificates will be provided by your local service support organisation on request.

14 Options

14.1 Chapter without content

To facilitate the use of documents from Fresenius Medical Care, the organisation of the chapters has been standardised in all manuals. There may therefore be chapters within this document without any content.

15 Appendix

15.1 Instructions on the use of “free software”

Content

A. Haemodialysis system – “Free software”

B. Notice required according to German Medical Devices Act

C. Information and remarks on the free software contained in the haemodialysis system

I. GNU General Public License, version 2

II. GNU Lesser General Public License, version 2.1

III. Mozilla Public License, version 1.1

IV. Veillard License

V. Catharon License (Libft2lib)

A. Haemodialysis system – “Free software”

In addition to other software, the haemodialysis system contains what is called “free software”, which is subject to license conditions deviating from those of the proprietary software protected for Fresenius Medical Care and their licensors.

Some of the license conditions pertaining to such free software provide that Fresenius Medical Care is authorised to distribute the haemodialysis system only if the accompanying documentation contains special information and notices, supplies license conditions and/or provides the source code of such free software. Fresenius Medical Care meets these requirements by providing the copyright notices, remarks and license texts contained in section C below. Please note that, if such information is printed in two languages, the English version has priority.

However, the rights granted by copyright according to section C. and the license texts contained therein, which relate to such free software, do not include the right to make modifications to the haemodialysis system and subsequently continue use of the system with these modifications. On the contrary, the German Medical Devices Act (Medizinproduktegesetz; MPG) prohibits any further operation of the haemodialysis system once the software contained therein has been modified, because any medical device may only be operated in the form certified. For this reason, section B. contains an appropriate notice. In such a case, Fresenius Medical Care will stop any further technical support for the device involved. In addition, such modifications and/or manipulations may result in the voiding of warranty claims against Fresenius Medical Care or other vendors of the haemodialysis system in the event a claim has arisen or might arise in respect thereto. Any use of the free software contained in the haemodialysis system in a manner other than that required during proper operation of the device will solely be at your own risk.

Please also note that the authorities listed in section C apply only to the “free software” mentioned therein. Any other software contained in the haemodialysis system is protected by copyright for the benefit of Fresenius and their licensors and may be used only as intended for the haemodialysis system.

Both the GNU General Public License (GPL) and the GNU Lesser General Public License (LGPL) are supplied with this device. You can also download these license conditions from the internet.
For GPL, please refer to: http://www.gnu.org/copyleft/gpl.html
For LGPL, please refer to: http://www.gnu.org/copyleft/lesser.html

B. Notice required according to German Medical Devices Act

This medical device has been certified in conjunction with the operating system software Linux version 2.4.18. Any modification to the software contained in this medical device, including the operating system software, may result in the medical device losing its conformity with the regulations of the German Medical Devices Act (Medizinproduktegesetz; MPG) and in losing its right to bear the CE mark. Anyone operating a medical device without a valid CE mark according to the Medical Device Directive 93/42/EEC will be liable to prosecution. According to section 41 MPG, perpetrators may be sentenced to up to one year's imprisonment or may be fined. In addition, anyone modifying the software contained in this medical device, or allowing such a modification, will also be liable under product liability law to compensate injured third parties.

C. Information and remarks on the free software contained in the haemodialysis system

I. GNU General Public License, version 2

1. Copyright notice

The following copyright notice applies to the Linux operating system (Linux version 2.6.33.7), including the driver (DMFE.o) modified therein:

Copyright © Free Software Foundation, Inc., 59 Temple Place, Suite 330, Boston, MA 02111-1307, USA (Linux Version 2.4.18)

Copyright © Fresenius Medical Care (driver DMFE.o)

This program is free software; you can redistribute it and/or modify it under the terms of the GNU General Public License as published by the Free Software Foundation, Version 2.

This program is distributed in the hope that it will be useful but WITHOUT ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the GNU General Public License for more details.

You should have received a copy of the GNU General Public License along with this program; if not, write to the Free Software Foundation, Inc., 59 Temple Place, Suite 330, Boston, MA 02111-1307, USA.

2. License text of the GNU General Public License

GNU GENERAL PUBLIC LICENSE

Version 2, June 1991

Preamble

The licenses for most software are designed to take away your freedom to share and change it. By contrast, the GNU General Public License is intended to guarantee your freedom to share and change free software--to make sure the software is free for all its users. This General Public License applies to most of the Free Software Foundation's software and to any other program whose authors commit to using it. (Some other Free Software Foundation software is covered by the GNU Library General Public License instead.) You can apply it to your programs, too.

When we speak of free software, we are referring to freedom, not price. Our General Public Licenses are designed to make sure that you have the freedom to distribute copies of free software (and charge for this service if you wish), that you receive source code or can get it if you want it, that you can change the software or use pieces of it in new free programs; and that you know you can do these things.

To protect your rights, we need to make restrictions that forbid anyone to deny you these rights or to ask you to surrender the rights. These restrictions translate to certain responsibilities for you if you distribute copies of the software, or if you modify it.

For example, if you distribute copies of such a program, whether gratis or for a fee, you must give the recipients all the rights that you have. You must make sure that they, too, receive or can get the source code. And you must show them these terms so they know their rights.

We protect your rights with two steps: (1) copyright the software, and (2) offer you this license which gives you legal permission to copy, distribute and/or modify the software.

Also, for each author's protection and ours, we want to make certain that everyone understands that there is no warranty for this free software. If the software is modified by someone else and passed on, we want its recipients to know that what they have is not the original, so that any problems introduced by others will not reflect on the original authors' reputations.

Finally, any free program is threatened constantly by software patents. We wish to avoid the danger that redistributors of a free program will individually obtain patent licenses, in effect making the program proprietary. To prevent this, we have made it clear that any patent must be licensed for everyone's free use or not licensed at all.

The precise terms and conditions for copying, distribution and modification follow.

GNU GENERAL PUBLIC LICENSE
TERMS AND CONDITIONS FOR COPYING, DISTRIBUTION AND MODIFICATION

0. This License applies to any program or other work which contains a notice placed by the copyright holder saying it may be distributed under the terms of this General Public License. The "Program", below, refers to any such program or work, and a "work based on the Program" means either the Program or any derivative work under copyright law: that is to say, a work containing the Program or a portion of it, either verbatim or with modifications and/or translated into another language. (Hereinafter, translation is included without limitation in the term "modification".) Each licensee is addressed as "you".

Activities other than copying, distribution and modification are not covered by this License; they are outside its scope. The act of running the Program is not restricted, and the output from the Program is covered only if its contents constitute a work based on the Program (independent of having been made by running the Program). Whether that is true depends on what the Program does.

1. You may copy and distribute verbatim copies of the Program's source code as you receive it, in any medium, provided that you conspicuously and appropriately publish on each copy an appropriate copyright notice and disclaimer of warranty; keep intact all the notices that refer to this License and to the absence of any warranty; and give any other recipients of the Program a copy of this License along with the Program.

You may charge a fee for the physical act of transferring a copy, and you may at your option offer warranty protection in exchange for a fee.

2. You may modify your copy or copies of the Program or any portion of it, thus forming a work based on the Program, and copy and distribute such modifications or work under the terms of Section 1 above, provided that you also meet all of these conditions:

a) You must cause the modified files to carry prominent notices stating that you changed the files and the date of any change.

b) You must cause any work that you distribute or publish, that in whole or in part contains or is derived from the Program or any part thereof, to be licensed as a whole at no charge to all third parties under the terms of this License.

c) If the modified program normally reads commands interactively when run, you must cause it, when started running for such interactive use in the most ordinary way, to print or display an announcement including an appropriate copyright notice and a notice that there is no warranty (or else, saying that you provide a warranty) and that users may redistribute the program under these conditions, and telling the user how to view a copy of this License. (Exception: if the Program itself is interactive but does not normally print such an announcement, your work based on the Program is not required to print an announcement.)

These requirements apply to the modified work as a whole. If identifiable sections of that work are not derived from the Program, and can be reasonably considered independent and separate works in themselves, then this License, and its terms, do not apply to those sections when you distribute them as separate works. But when you distribute the same sections as part of a whole which is a work based on the Program, the distribution of the whole must be on the terms of this License, whose permissions for other licensees extend to the entire whole, and thus to each and every part regardless of who wrote it. Thus, it is not the intent of this section to claim rights or contest your rights to work written entirely by you; rather, the intent is to exercise the right to control the distribution of derivative or collective works based on the Program.

In addition, mere aggregation of another work not based on the Program with the Program (or with a work based on the Program) on a volume of a storage or distribution medium does not bring the other work under the scope of this License.

3. You may copy and distribute the Program (or a work based on it, under Section 2) in object code or executable form under the terms of Sections 1 and 2 above provided that you also do one of the following:

a) Accompany it with the complete corresponding machine-readable source code, which must be distributed under the terms of Sections 1 and 2 above on a medium customarily used for software interchange; or,

b) Accompany it with a written offer, valid for at least three years, to give any third party, for a charge no more than your cost of physically performing source distribution, a complete machine-readable copy of the corresponding source code, to be distributed under the terms of Sections 1 and 2 above on a medium customarily used for software interchange; or,

c) Accompany it with the information you received as to the offer to distribute corresponding source code. (This alternative is allowed only for noncommercial distribution and only if you received the program in object code or executable form with such an offer, in accord with Subsection b above.)

The source code for a work means the preferred form of the work for making modifications to it. For an executable work, complete source code means all the source code for all modules it contains, plus any associated interface definition files, plus the scripts used to control compilation and installation of the executable. However, as a special exception, the source code distributed need not include anything that is normally distributed (in either source or binary form) with the major components (compiler, kernel, and so on) of the operating system on which the executable runs, unless that component itself accompanies the executable.

If distribution of executable or object code is made by offering access to copy from a designated place, then offering equivalent access to copy the source code from the same place counts as distribution of the source code, even though third parties are not compelled to copy the source along with the object code.

4. You may not copy, modify, sublicense, or distribute the Program except as expressly provided under this License. Any attempt otherwise to copy, modify, sublicense or distribute the Program is void, and will automatically terminate your rights under this License. However, parties who have received copies, or rights, from you under this License will not have their licenses terminated so long as such parties remain in full compliance.

5. You are not required to accept this License, since you have not signed it. However, nothing else grants you permission to modify or distribute the Program or its derivative works. These actions are prohibited by law if you do not accept this License. Therefore, by modifying or distributing the Program (or any work based on the Program), you indicate your acceptance of this License to do so, and all its terms and conditions for copying, distributing or modifying the Program or works based on it.

6. Each time you redistribute the Program (or any work based on the Program), the recipient automatically receives a license from the original licensor to copy, distribute or modify the Program subject to these terms and conditions. You may not impose any further restrictions on the recipients' exercise of the rights granted herein. You are not responsible for enforcing compliance by third parties to this License.

7. If, as a consequence of a court judgment or allegation of patent infringement or for any other reason (not limited to patent issues), conditions are imposed on you (whether by court order, agreement or otherwise) that contradict the conditions of this License, they do not excuse you from the conditions of this License. If you cannot distribute so as to satisfy simultaneously your obligations under this License and any other pertinent obligations, then as a consequence you may not distribute the Program at all. For example, if a patent license would not permit royalty-free redistribution of the Program by all those who receive copies directly or indirectly through you, then the only way you could satisfy both it and this License would be to refrain entirely from distribution of the Program.

If any portion of this section is held invalid or unenforceable under any particular circumstance, the balance of the section is intended to apply and the section as a whole is intended to apply in other circumstances.

It is not the purpose of this section to induce you to infringe any patents or other property right claims or to contest validity of any such claims; this section has the sole purpose of protecting the integrity of the free software distribution system, which is implemented by public license practices. Many people have made generous contributions to the wide range of software distributed through that system in reliance on consistent application of that system; it is up to the author/donor to decide if he or she is willing to distribute software through any other system and a licensee cannot impose that choice.

This section is intended to make thoroughly clear what is believed to be a consequence of the rest of this License.

8. If the distribution and/or use of the Program is restricted in certain countries either by patents or by copyrighted interfaces, the original copyright holder who places the Program under this License may add an explicit geographical distribution limitation excluding those countries, so that distribution is permitted only in or among countries not thus excluded. In such case, this License incorporates the limitation as if written in the body of this License.

9. The Free Software Foundation may publish revised and/or new versions of the General Public License from time to time. Such new versions will be similar in spirit to the present version, but may differ in detail to address new problems or concerns.

Each version is given a distinguishing version number. If the Program specifies a version number of this License which applies to it and "any later version", you have the option of following the terms and conditions either of that version or of any later version published by the Free Software Foundation. If the Program does not specify a version number of this License, you may choose any version ever published by the Free Software Foundation.

10. If you wish to incorporate parts of the Program into other free programs whose distribution conditions are different, write to the author to ask for permission. For software which is copyrighted by the Free Software Foundation, write to the Free Software Foundation; we sometimes make exceptions for this. Our decision will be guided by the two goals of preserving the free status of all derivatives of our free software and of promoting the sharing and reuse of software generally.

NO WARRANTY

11. BECAUSE THE PROGRAM IS LICENSED FREE OF CHARGE, THERE IS NO WARRANTY FOR THE PROGRAM, TO THE EXTENT PERMITTED BY APPLICABLE LAW. EXCEPT WHEN OTHERWISE STATED IN WRITING THE COPYRIGHT HOLDERS AND/OR OTHER PARTIES PROVIDE THE PROGRAM "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE ENTIRE RISK AS TO THE QUALITY AND PERFORMANCE OF THE PROGRAM IS WITH YOU. SHOULD THE PROGRAM PROVE DEFECTIVE, YOU ASSUME THE COST OF ALL NECESSARY SERVICING, REPAIR OR CORRECTION.

12. IN NO EVENT UNLESS REQUIRED BY APPLICABLE LAW OR AGREED TO IN WRITING WILL ANY COPYRIGHT HOLDER, OR ANY OTHER PARTY WHO MAY MODIFY AND/OR REDISTRIBUTE THE PROGRAM AS PERMITTED ABOVE, BE LIABLE TO YOU FOR DAMAGES, INCLUDING ANY GENERAL, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THE USE OR INABILITY TO USE THE PROGRAM (INCLUDING BUT NOT LIMITED TO LOSS OF DATA OR DATA BEING RENDERED INACCURATE OR LOSSES SUSTAINED BY YOU OR THIRD PARTIES OR A FAILURE OF THE PROGRAM TO OPERATE WITH ANY OTHER PROGRAMS), EVEN IF SUCH HOLDER OR OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

END OF TERMS AND CONDITIONS

Offer

We should be pleased to provide you by mail with a CD containing a full machine-readable copy of the source text of the Linux kernel version 2.4.18, including the modified driver DMFE.o, for a period of three years starting at the time when this haemodialysis system was put into circulation (i.e., when the system was acquired). Only the usual copying and transfer costs will be charged. If you want us to send this CD to you, please inform us accordingly, by e-mail, telefax or mail, under the address given in the Operating Instructions. Please do not forget to specify the system type and the system number.

II. GNU Lesser General Public License, Version 2.1

1. Copyright notice

The following copyright notice applies to the glibc libraries version 2.2.5:

Copyright © Free Software Foundation, Inc., 59 Temple Place, Suite 330, Boston, MA 02111-1307, USA

This program is free software; you can redistribute it and/or modify it under the terms of the GNU General Public License as published by the Free Software Foundation, Version 2.1.

This program is distributed in the hope that it will be useful but WITHOUT ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the GNU Lesser General Public License for more details.

You should have received a copy of the GNU Lesser General Public License along with this library; if not, write to the Free Software Foundation, Inc., 59 Temple Place, Suite 330, Boston, MA 02111-1307, USA.

2. Advisory

The haemodialysis system contains the glibc libraries version 2.2.5, which are subject to the GNU Lesser General Public License version 2.1.

You are authorised to edit these libraries exclusively for your own use and to apply reverse engineering in order to eliminate any errors in such editing.

License text of the GNU Lesser General Public License

GNU LESSER GENERAL PUBLIC LICENSE

Version 2.1, February 1999

Copyright (C) 1991, 1999 Free Software Foundation, Inc.

51 Franklin Street, Fifth Floor, Boston, MA 02110-1301 USA

Everyone is permitted to copy and distribute verbatim copies of this license document, but changing it is not allowed.

[This is the first released version of the Lesser GPL. It also counts as the successor of the GNU Library Public License, version 2, hence the version number 2.1.]

Preamble

The licenses for most software are designed to take away your freedom to share and change it. By contrast, the GNU General Public Licenses are intended to guarantee your freedom to share and change free software--to make sure the software is free for all its users.

This license, the Lesser General Public License, applies to some specially designated software packages – typically libraries – of the Free Software Foundation and other authors who decide to use it. You can use it too, but we suggest you first think carefully about whether this license or the ordinary General Public License is the better strategy to use in any particular case, based on the explanations below.

When we speak of free software, we are referring to freedom of use, not price. Our General Public Licenses are designed to make sure that you have the freedom to distribute copies of free software (and charge for this service if you wish); that you receive source code or can get it if you want it; that you can change the software and use pieces of it in new free programs; and that you are informed that you can do these things.

To protect your rights, we need to make restrictions that forbid distributors to deny you these rights or to ask you to surrender these rights. These restrictions translate to certain responsibilities for you if you distribute copies of the library or if you modify it.

For example, if you distribute copies of the library, whether gratis or for a fee, you must give the recipients all the rights that we gave you. You must make sure that they, too, receive or can get the source code. If you link other code with the library, you must provide complete object files to the recipients, so that they can relink them with the library after making changes to the library and recompiling it. And you must show them these terms so they know their rights.

We protect your rights with a two-step method: (1) we copyright the library, and (2) we offer you this license, which gives you legal permission to copy, distribute and/or modify the library.

To protect each distributor, we want to make it very clear that there is no warranty for the free library. Also, if the library is modified by someone else and passed on, the recipients should know that what they have is not the original version, so that the original author's reputation will not be affected by problems that might be introduced by others.

Finally, software patents pose a constant threat to the existence of any free program. We wish to make sure that a company cannot effectively restrict the users of a free program by obtaining a restrictive license from a patent holder. Therefore, we insist that any patent license obtained for a version of the library must be consistent with the full freedom of use specified in this license.

Most GNU software, including some libraries, is covered by the ordinary GNU General Public License. This license, the GNU Lesser General Public License, applies to certain designated libraries, and is quite different from the ordinary General Public License. We use this license for certain libraries in order to permit linking those libraries into non-free programs.

When a program is linked with a library, whether statically or using a shared library, the combination of the two is legally speaking a combined work, a derivative of the original library. The ordinary General Public License therefore permits such linking only if the entire combination fits its criteria of freedom. The Lesser General Public License permits more lax criteria for linking other code with the library.

We call this license the "Lesser" General Public License because it does Less to protect the user's freedom than the ordinary General Public License. It also provides other free software developers Less of an advantage over competing non-free programs. These disadvantages are the reason we use the ordinary General Public License for many libraries. However, the Lesser license provides advantages in certain special circumstances.

For example, on rare occasions, there may be a special need to encourage the widest possible use of a certain library, so that it becomes a de-facto standard. To achieve this, non-free programs must be allowed to use the library. A more frequent case is that a free library does the same job as widely used non-free libraries. In this case, there is little to gain by limiting the free library to free software only, so we use the Lesser General Public License.

In other cases, permission to use a particular library in non-free programs enables a greater number of people to use a large body of free software. For example, permission to use the GNU C Library in non-free programs enables many more people to use the whole GNU operating system, as well as its variant, the GNU/Linux operating system.

Although the Lesser General Public License is Less protective of the users' freedom, it does ensure that the user of a program that is linked with the Library has the freedom and the wherewithal to run that program using a modified version of the Library.

The precise terms and conditions for copying, distribution and modification follow. Pay close attention to the difference between a "work based on the library" and a "work that uses the library". The former contains code derived from the library, whereas the latter must be combined with the library in order to run.

GNU LESSER GENERAL PUBLIC LICENSE
TERMS AND CONDITIONS FOR COPYING, DISTRIBUTION AND MODIFICATION

0. This License Agreement applies to any software library or other program which contains a notice placed by the copyright holder or other authorized party saying it may be distributed under the terms of this Lesser General Public License (also called "this License").Each licensee is addressed as "you".

A "library" means a collection of software functions and/or data prepared so as to be conveniently linked with application programs (which use some of those functions and data) to form executables.

The "Library", below, refers to any such software library or work which has been distributed under these terms. A "work based on the library" means either the Library or any derivative work under copyright law: that is to say, a work containing the Library or a portion of it, either verbatim or with modifications and/or translated straightforwardly into another language. (Hereinafter, translation is included without limitation in the term "modification".)

"Source code" for a work means the preferred form of the work for making modifications to it. For a library, complete source code means all the source code for all modules it contains, plus any associated interface definition files, plus the scripts used to control compilation and installation of the library.

Activities other than copying, distribution and modification are not covered by this License; they are outside its scope. The act of running a program using the Library is not restricted, and output from such a program is covered only if its contents constitute a work based on the Library (independent of the use of the Library in a tool for writing it). Whether that is true depends on what the Library does and what the program that uses the Library does.

1. You may copy and distribute verbatim copies of the Library's complete source code as you receive it, in any medium, provided that you conspicuously and appropriately publish on each copy an appropriate copyright notice and disclaimer of warranty; keep intact all the notices that refer to this License and to the absence of any warranty; and distribute a copy of this License along with the Library.

You may charge a fee for the physical act of transferring a copy, and you may at your option offer warranty protection in exchange for a fee.

2. You may modify your copy or copies of the Library or any portion of it, thus forming a work based on the Library, and copy and distribute such modifications or work under the terms of Section 1 above, provided that you also meet all of these conditions:

a) The modified work must itself be a software library.

b) You must cause the files modified to carry prominent notices stating that you changed the files and the date of any change.

c) You must cause the whole of the work to be licensed at no charge to all third parties under the terms of this License.

d) If a facility in the modified Library refers to a function or a table of data to be supplied by an application program that uses the facility, other than as an argument passed when the facility is invoked, then you must make a good faith effort to ensure that, in the event an application does not supply such function or table, the facility still operates, and performs whatever part of its purpose remains meaningful.
For example, a function in a library to compute square roots has a purpose that is entirely well-defined independent of the application. Therefore, Subsection 2d requires that any application-supplied function or table used by this function must be optional: if the application does not supply it, the square root function must still compute square roots.)

These requirements apply to the modified work as a whole. If identifiable sections of that work are not derived from the Library, and can be reasonably considered independent and separate works in themselves, then this License, and its terms, do not apply to those sections when you distribute them as separate works. But when you distribute the same sections as part of a whole which is a work based on the Library, the distribution of the whole must be on the terms of this License, whose permissions for other licensees extend to the entire whole, and thus to each and every part regardless of who wrote it.

Thus, it is not the intent of this section to claim rights or contest your rights to work written entirely by you; rather, the intent is to exercise the right to control the distribution of derivative or collective works based on the Library.

In addition, mere aggregation of another work not based on the Library with the Library (or with a work based on the Library) on a volume of a storage or distribution medium does not bring the other work under the scope of this License.

3. You may opt to apply the terms of the ordinary GNU General Public License instead of this License to a given copy of the Library. To do this, you must alter all the notices that refer to this License, so that they refer to the ordinary GNU General Public License, version 2, instead of to this License. (If a newer version than version 2 of the ordinary GNU General Public License has appeared, then you can specify that version instead if you wish.) Do not make any other change in these notices.

Once this change is made in a given copy, it is irreversible for that copy, so the ordinary GNU General Public License applies to all subsequent copies and derivative works made from that copy.

This option is useful when you wish to copy part of the code of the Library into a program that is not a library.

4. You may copy and distribute the Library (or a portion or derivative of it, under Section 2) in object code or executable form under the terms of Sections 1 and 2 above provided that you accompany it with the complete corresponding machine-readable source code, which must be distributed under the terms of Sections 1 and 2 above on a medium customarily used for software interchange.

If distribution of object code is made by offering access to copy from a designated place, then offering equivalent access to copy the source code from the same place satisfies the requirement to distribute the source code, even though third parties are not compelled to copy the source along with the object code.

5. A program that contains no derivative of any portion of the Library, but is designed to work with the Library by being compiled or linked with it, is called a "work that uses the Library". Such a work, in isolation, is not a derivative work of the Library, and therefore falls outside the scope of this License.

However, linking a "work that uses the Library" with the Library creates an executable that is a derivative of the Library (because it contains portions of the Library), rather than a "work that uses the library". The executable is therefore covered by this License. Section 6 states terms for distribution of such executables.

When a "work that uses the Library" uses material from a header file that is part of the Library, the object code for the work may be a derivative work of the Library even though the source code is not. Whether this is true is especially significant if the work can be linked without the Library, or if the work is itself a library. The threshold for this to be true is not precisely defined by law. If such an object file uses only numerical parameters, data structure layouts and accessors, and small macros and small inline functions (ten lines or less in length), then the use of the object file is unrestricted, regardless of whether it is legally a derivative work. (Executables containing this object code plus portions of the Library will still fall under Section 6.)

Otherwise, if the work is a derivative of the Library, you may distribute the object code for the work under the terms of Section 6. Any executables containing that work also fall under Section 6, whether or not they are linked directly with the Library itself.

6. As an exception to the Sections above, you may also combine or link a "work that uses the Library" with the Library to produce a work containing portions of the Library, and distribute that work under terms of your choice, provided that the terms permit modification of the work for the customer's own use and reverse engineering for debugging such modifications.

You must give prominent notice with each copy of the work that the Library is used in it and that the Library and its use are covered by this License. You must supply a copy of this License. If the work during execution displays copyright notices, you must include the copyright notice for the Library among them, as well as a reference directing the user to the copy of this License. Also, you must do one of these things:

a) Accompany the work with the complete corresponding machine-readable source code for the Library including whatever changes were used in the work (which must be distributed under Sections 1 and 2 above); and, if the work is an executable linked with the Library, with the complete machine-readable "work that uses the Library", as object code and/or source code, so that the user can modify the Library and then relink to produce a modified executable containing the modified Library. (It is understood that the user who changes the contents of definitions files in the Library will not necessarily be able to recompile the application to use the modified definitions.)

b) Use a suitable shared library mechanism for linking with the Library. A suitable mechanism is one that (1) uses at run time a copy of the library already present on the user's computer system, rather than copying library functions into the executable, and (2) will operate properly with a modified version of the library, if the user installs one, as long as the modified version is interface-compatible with the version that the work was made with.

c) Accompany the work with a written offer, valid for at least three years, to give the same user the materials specified in Subsection 6a, above, for a charge no more than the cost of performing this distribution.

d) If distribution of the work is made by offering access to copy from a designated place, offer equivalent access to copy the above specified materials from the same place.

e) Verify that the user has already received a copy of these materials or that you have already sent this user a copy.

For an executable, the required form of the "work that uses the Library" must include any data and utility programs needed for reproducing the executable from it. However, as a special exception,the materials to be distributed need not include anything that is normally distributed (in either source or binary form) with the major components (compiler, kernel, and so on) of the operating system on which the executable runs, unless that component itself accompanies the executable.

It may happen that this requirement contradicts the license restrictions of other proprietary libraries that do not normally accompany the operating system. Such a contradiction means you cannot use both them and the Library together in an executable that you distribute.

7. You may place library facilities that are a work based on the Library side-by-side in a single library together with other library facilities not covered by this License, and distribute such a combined library, provided that the separate distribution of the work based on the Library and of the other library facilities is otherwise permitted, and provided that you do these two things:

a) Accompany the combined library with a copy of the same work based on the Library, uncombined with any other library facilities. This must be distributed under the terms of the Sections above.

b) Give prominent notice with the combined library of the fact that part of it is a work based on the Library, and explaining where to find the accompanying uncombined form of the same work.

8. You may not copy, modify, sublicense, link with, or distribute the Library except as expressly provided under this License. Any attempt otherwise to copy, modify, sublicense, link with, or distribute the Library is void, and will automatically terminate your rights under this License. However, parties who have received copies, or rights, from you under this License will not have their licenses terminated so long as such parties remain in full compliance.

9. You are not required to accept this License, since you have not signed it. However, nothing else grants you permission to modify or distribute the Library or its derivative works. These actions are prohibited by law if you do not accept this License. Therefore, by modifying or distributing the Library (or any work based on the Library), you indicate your acceptance of this License to do so, and all its terms and conditions for copying, distributing or modifying the Library or works based on it.

10. Each time you redistribute the Library (or any work based on the Library), the recipient automatically receives a license from the original licensor to copy, distribute, link with or modify the Library subject to these terms and conditions. You may not impose any further restrictions on the recipients' exercise of the rights granted herein. You are not responsible for enforcing compliance by third parties with this License.

11. If, as a consequence of a court judgment or allegation of patent infringement or for any other reason (not limited to patent issues), conditions are imposed on you (whether by court order, agreement or otherwise) that contradict the conditions of this License, they do not excuse you from the conditions of this License. If you cannot distribute so as to satisfy simultaneously your obligations under this License and any other pertinent obligations, then as a consequence you may not distribute the Library at all. For example, if a patent license would not permit royalty-free redistribution of the Library by all those who receive copies directly or indirectly through you, then the only way you could satisfy both it and this License would be to refrain entirely from distribution of the Library.

If any portion of this section is held invalid or unenforceable under any particular circumstance, the balance of the section is intended to apply, and the section as a whole is intended to apply in other circumstances.

It is not the purpose of this section to induce you to infringe any patents or other property right claims or to contest validity of any such claims; this section has the sole purpose of protecting the integrity of the free software distribution system which is implemented by public license practices. Many people have made generous contributions to the wide range of software distributed through that system in reliance on consistent application of that system; it is up to the author/donor to decide if he or she is willing to distribute software through any other system and a licensee cannot impose that choice.

This section is intended to make thoroughly clear what is believed to be a consequence of the rest of this License.

12. If the distribution and/or use of the Library is restricted in certain countries either by patents or by copyrighted interfaces, the original copyright holder who places the Library under this License may add an explicit geographical distribution limitation excluding those countries, so that distribution is permitted only in or among countries not thus excluded. In such case, this License incorporates the limitation as if written in the body of this License.

13. The Free Software Foundation may publish revised and/or new versions of the Lesser General Public License from time to time. Such new versions will be similar in spirit to the present version, but may differ in detail to address new problems or concerns.

Each version is given a distinguishing version number. If the Library specifies a version number of this License which applies to it and "any later version", you have the option of following the terms and conditions either of that version or of any later version published by the Free Software Foundation. If the Library does not specify a license version number, you may choose any version ever published by the Free Software Foundation.

14. If you wish to incorporate parts of the Library into other free programs whose distribution conditions are incompatible with these, write to the author to ask for permission. For software which is copyrighted by the Free Software Foundation, write to the Free Software Foundation; we sometimes make exceptions for this. Our decision will be guided by the two goals of preserving the free status of all derivatives of our free software and of promoting the sharing and reuse of software generally.

NO WARRANTY

15. BECAUSE THE LIBRARY IS LICENSED FREE OF CHARGE, THERE IS NO WARRANTY FOR THE LIBRARY, TO THE EXTENT PERMITTED BY APPLICABLE LAW. EXCEPT WHEN OTHERWISE STATED IN WRITING THE COPYRIGHT HOLDERS AND/OR OTHER PARTIES PROVIDE THE LIBRARY "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE ENTIRE RISK AS TO THE QUALITY AND PERFORMANCE OF THE LIBRARY IS WITH YOU. SHOULD THE LIBRARY PROVE DEFECTIVE, YOU ASSUME THE COST OF ALL NECESSARY SERVICING, REPAIR OR CORRECTION.

16. IN NO EVENT UNLESS REQUIRED BY APPLICABLE LAW OR AGREED TO IN WRITING WILL ANY COPYRIGHT HOLDER, OR ANY OTHER PARTY WHO MAY MODIFY AND/OR REDISTRIBUTE THE LIBRARY AS PERMITTED ABOVE, BE LIABLE TO YOU FOR DAMAGES, INCLUDING ANY GENERAL, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THE USE OR INABILITY TO USE THE LIBRARY (INCLUDING BUT NOT LIMITED TO LOSS OF DATA OR DATA BEING RENDERED INACCURATE OR LOSSES SUSTAINED BY YOU OR THIRD PARTIES OR A FAILURE OF THE LIBRARY TO OPERATE WITH ANY OTHER SOFTWARE), EVEN IF SUCH HOLDER OR OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

END OF TERMS AND CONDITIONS

4. Source code

Offer

We should be pleased to provide you by mail with a CD containing a full machine-readable copy of the source text of the glibc libraries version 2.2.5, for a period of three years starting at the time when this haemodialysis system was put into circulation (i.e., when the system was acquired). Only the usual copying and transfer costs will be charged. If you want us to send this CD to you, please inform us accordingly, by e-mail, telefax or mail, under the address given in the Operating Instructions. Please do not forget to specify the system type and the system number.

III. Mozilla Public License, version 1.1

1. Copyright notice

The following copyright notice applies to the Nano-X server and the Libnano-X software:

The original code is Microwindows. The Initial Developer of the Original Code is Greg Haerr. Portions created by Greg Haerr are Copyright © 1999, 2000, 2001, 2002, 2003 Greg Haerr (greg@censoft.com). Portions are contributed by Koninklijke Philips Electronic N.V. These portions are Copyright 2002 Koninklijke Philips Electronic N.V.

2. Advisory

You can download the source code of the Nano-X server and the Libnano-X software from the following website: ftp://microwindows.org/pub/microwindows

IV. Veillard License

1. Copyright notice

The following copyright notice applies to the libXML library:

Copyright © 1998-2002 Daniel Veillard. All Rights Reserved.

2. Advisory

In addition, the following license conditions apply:

Permission is hereby granted, free of charge, to any person obtaining a copy of this software and associated documentation files (the „Software”) to deal in the Software without restriction, including without limitation of the rights to use, copy, modify, merge, publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons to whom the Software is furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all copies or substantial portions of the Software.

The Software is provided “as is”, without warranty of any kind, express or implied, including but not limited to the warranties of merchantability, fitness for a particular purpose and non-infringement. In no event shall the Daniel Veillard be liable for any claim, damage or other liability, whether in an action of contract, tort or otherwise, arising from, out of or in connection with the Software or the use or other dealings in the software.

Except as contained in this notice, the name of Daniel Veillard shall not be used in advertising or otherwise to promote the sale, use or other dealings in this Software without prior written authorization from him.

V. Catharon License (Libft2lib)

Part of this software is based on programmings made by Catharon Production, Inc.